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In the research reported in this dissertation, the concept of classic conjugate 
imaging, a non-tomographic nuclear medicine technique, is modified such that activity of 
a radiopharmaceutical distribution in the striata can be estimated.  A mathematical model 
is developed that extended the application of classic conjugate imaging to estimation of 
two distinct and aligned activity distributions. Error analysis of the mathematical model 
is performed to characterize the accuracy of the model and to benchmark the limitations 
of the model. Phantom experiments are performed to demonstrate the practical 
application of the model and to evaluate its’ accuracy. A Monte Carlo simulation model 
of conjugate imaging of activity uptake in the striata of a primate is developed to evaluate 
the accuracy of the modified conjugate imaging technique as applied in the use of a 
dedicate conjugate imaging system. In addition, the simulation model is used to 
determine and characterize the shielding design of the small field of view gamma 
cameras comprising the dedicated conjugate imaging system. The application of scatter 
correction is investigated to address the downscatter of high-energy photon emissions 
into the photopeak window and the inclusion of scattered primary photons in the 
photopeak window. 
In this dissertation, it is shown that the modified conjugate imaging technique 
developed can be used to estimate accurately activity uptake in each of two distinct and 
aligned activity distributions. The accuracy of the technique was shown to be comparable 
to that of clinical quantitative SPECT. The modified conjugate imaging technique used 
 xxvi
with the dedicated conjugate imaging system may, therefore, be a viable quantitative 
nuclear medicine technique for activity estimation of radiopharmaceutical uptake in the 
striata of Parkinsonian and schizophrenic patients. The portability and low cost relative to 
SPECT systems make the dedicated conjugate imaging system advantageous for clinics 









Parkinsonism is a term for progressive neurodegenerative disorders, which 
describes a variety of movement disorders pathologically characterized by the 
degeneration of dopaminergic neurons in the striatal dopaminergic system. Schizophrenia 
is a chronic neuropsychiatric disorder associated with the hyper-production of striatal 
dopamine.  During the last two decades nuclear medicine has been in the forefront of 
investigations of dopamine loss characteristic of Parkinsonism and dopamine hyper-
production associated with schizophrenia.  The striata, part of the basal ganglia, a 
collection of nuclei located deep in the cerebrum, are greatly responsible for controlling 
movements and maintaining postures by producing and transmitting dopamine.  Studies 
have suggested that nuclear medicine imaging can play a vital role in the clinical 
management of Parkinsonism and schizophrenia, specifically in the initial diagnosis, 
intermittent follow-ups, and drug efficacy investigations for clinical management of these 
diseases. 
The primary goal of the research presented in this dissertation is the development 
and characterization of conjugate imaging of two aligned activity distributions. The 
pursuit of this research is motivated by the study and evaluation of activity uptake in the 
striata of individuals with Parkinsonian or schizophrenic symptoms.  Of particular 
interest is the influence of radiopharmaceuticals. Most of the radiopharmaceuticals 
1 
presently available for striatal imaging are labeled with iodine-123 (123I) and technetium-
99m (99mTc). Differences in biodistribution and emission spectrums should be addressed 
to ensure accurate assessment of activity uptake in the striata.  
There are two main objectives for this study. The first objective is the 
development and assessment of a model describing conjugate imaging to the estimation 
of activities in each of two aligned sources. The second objective is the evaluation of the 
modified conjugate imaging technique as it applies to the estimation of activity uptake in 
the striata of a primate using a dedicated conjugate imaging system. Six specific tasks are 
completed to achieve the objectives. The first three tasks are related to the first main 
objective. The last three tasks are related to the second main objective.  
In task one, a mathematical model that extends the application of classic 
conjugate imaging to include the estimation of activity above background in each of two 
aligned source distributions is developed.  In task two, error analysis of the model is 
performed. In task three, phantom experiments are performed to evaluate the accuracy of 
the mathematical model and to demonstrate the practical applicability of the technique.  
Tasks four, five, and six utilize a Monte Carlo simulation model developed to 
simulate conjugate imaging of activity uptake in the striata of a primate using a dedicated 
conjugate imaging system. The Monte Carlo simulation model was developed using the 
Monte Carlo radiation transport code MCNP-4C. In task four, the Monte Carlo 
simulation model is used to design and characterize the shielding design of two small 
field of view (FOV) gamma cameras comprising the dedicated conjugate imaging system. 
In task five, the Monte Carlo simulation model is used to asses the accuracy of the 
estimations of activity uptake in the striata using the modified conjugate imaging 
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technique and dedicated conjugate imaging system. In task six, scatter correction is 
investigated. The application of the triple energy window (TEW) scatter correction 
technique to data generated from the Monte Carlo simulations using 123I and 99mTc 
radiopharmaceuticals is assessed.   
This dissertation has eight chapters. Chapter 2 provides background relevant to 
this research.  The work and results of this research are presented in Chapters 3-7.  
Chapter 8 summarizes the research and provides suggestions for future work. 
 3





During the last two decades, nuclear medicine has been used in investigations at 
the forefront of research of the abnormal dopamine function characteristic of 
Parkinsonian syndromes and schizophrenia (Booij, Tissingh et al. 1999). In these 
investigations the dopaminergic system in the striata is assessed in vivo through 
qualitative and semi-quantitative analyses. Qualitative imaging techniques have 
limitations, as radiopharmaceutical uptake assessment is based mainly on human eye 
discernment and physician experience. Quantitative nuclear medicine techniques rely less 
on the physician’s eye and more on the comparison of numerical values representing 
radiopharmaceutical uptake. Quantitative studies often result in more accurate assessment 
of disease development and drug therapy treatment. However, quantitative studies 
performed to date have focused on the relative activity ratio between the left and right 
striatum. The modified conjugate imaging technique introduced in this dissertation 
determines absolute activity estimates, in addition to relative activity estimates. The 
modified conjugate imaging technique is a single-photon emission technique that utilizes 
the geometry of the striata to estimate activity uptake in the striata.  
This chapter reviews the background topics relevant to the techniques adopted in 
this dissertation.  The subjects include single-photon emission imaging with specific 
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focus on classic conjugate imaging, striatal dopamine, Parkinsonism and Schizophrenia, 
and finally conjugate imaging of striata.  
 
2.1 Single-photon Emission Imaging 
This section provides a brief discussion on single-photon emission nuclear 
medicine including a description of standard techniques and equipment. The focus is 
single-photon emission imaging, qualitative and quantitative. An understanding of single-
photon emission imaging provides a foundation for understanding conjugate imaging. 
While planar emission imaging is the backbone of this work, single-photon emission 
computed tomography (SPECT) is also presented, as it is a standard nuclear medicine 
technique used in brain imaging, the primary clinical application relevant to this 
dissertation. Measurements from the modified conjugate imaging technique are compared 
to measurements from quantitative SPECT studies.  
Single-photon emission imaging is the form of nuclear medicine imaging that 
uses single photon emitting radiopharmaceuticals. There are two primary forms of single-
photon emission imaging, planar single-photon emission imaging and SPECT. Planar 
single-photon emission imaging generates two-dimensional (2-D) projections (images) of 
a distribution of a radiopharmaceutical.  SPECT generates three-dimensional (3-D) 
volume representations of a radiopharmaceutical distribution. Such 3-D volumes are 
generated through tomographic reconstruction of 2-D projections acquired from multiple 
angular positions about a body being imaged. Single-photon emission imaging uses 
gamma cameras to detect the photon emissions.  
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This section first discusses three aspects of single-photon emission image 
generation: photon interactions, radiopharmaceuticals, and gamma cameras. It then 
describes the difference between qualitative and quantitative images, and the 
mathematical basis of qualitative and quantitative planar and SPECT imaging. The 
section concludes with a brief discussion of the task of quantitative assessment of striata 
via the single-photon emission technique of conjugate imaging. 
 
2.1.1 Photon Interactions 
 Single-photon emission imaging exploits photon interactions in matter to generate 
in vivo images of the body and its physiological functions. The energy of photons used to 
generate single-photon emission images range from 80 keV to 800 keV.  These photons 
interact in matter primarily through photoelectric absorption and Compton scattering. The 
probability of each interaction occurring is dependent on the energy of photons and the 
material it is transversing. 
 
2.1.1.1 Photoelectric Absorption 
 In photoelectric absorption, an incident photon is absorbed by an atom. The 
energy of the photon is transferred to an inner shell electron, and the electron is ejected 
from the atom with kinetic energy equal to the incident photon energy minus the binding 
energy of the electron. Figure 2.1 is a sketch of the photoelectric process. Photoelectric 
absorption is a dominant process for low energy photons with energy 100 keV and below. 
The cross section of photoelectric absorption is proportional to Z3/hν3 where hν is the 











Figure 2.1. Photoelectric absorption. An incident photon of energy hν is absorbed by the 
atom and an inner shell electron is ejected. The electron is ejected at angle θ and has 





increases significantly in materials with high atomic numbers and decreases with an 
increase in photon energy. 
 
2.1.1.2 Compton Scattering 
 In Compton scattering, an incident photon collides with a loosely bound electron. 
The photon scatters off the electron at angle ϕ transferring some of its energy to the 
electron. The electron is scattered at angle θ with kinetic energy equal to the energy 
difference between the incident photon and the scattered photon. Figure 2.2 is a sketch of 











Figure 2.2. Compton scattering. An incident photon scatters off a loosely bound electron. 
The scattered photon scatters off at angle φ with energy of hν . The electron is ejected at 
angle θ and has energy T, which is equal to the difference between the energy of the 
























,  (2.1) 
where hν’ is the energy of the scattered photon; hν is the energy of the incident photon; 
moc2 is the rest mass of an electron; and φ is the scattering angle of the scattered photon. 
The kinetic energy of the scattered electron is  
 
    .    (2.2) 'υυ hhT −=
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Compton scattering is the dominant form of interaction for photons with energy ranging 
from about 100 keV to about 10 MeV making Compton scattering the dominant form of 
interaction in single-photon emission imaging. 
 
2.1.2 Radiopharmaceuticals 
Radiopharmaceuticals are pharmaceutical agents labeled with radioisotopes. They 
are designed to accumulate in a specific organ or volume of tissue through participation 
in a physiological function that is specific to that organ or volume of tissue. In this 
manner, a radiopharmaceutical transports a radioisotope to the target organ or volume. 
The radiopharmaceuticals used in imaging the striata participate in the process of 
neurotransmission of dopamine. 
Radiopharmaceuticals suitable for routine clinical single-photon imaging have 
several basic properties in common. The production of single-photon emission 
radiopharmaceutical is relatively inexpensive. The chemical combination of the 
pharmaceutical agent and the radioisotope does not change the chemical reactivity of the 
pharmaceutical agent as regards to its participation in a designated physiological 
function. In other words, the radiopharmaceutical participates in the function of interest 
without disrupting that function. A suitable clinical pharmaceutical has a high affinity for 
the target volume, and conversely, a low affinity for non-target organs or tissue, 
especially non-target organs in close proximity to the target volume. Affinity refers to the 
degree to which the radiopharmaceutical binds to the target. In addition to having high 
affinity for a target, the radiopharmaceutical has a low dissociation rate. The dissociation 
rate is the rate at which the radiopharmaceutical unbinds from the target site. Before 
9 
imaging can take place, the kinetics of the radiopharmaceutical must reach equilibrium. A 
pharmaceutical with a low dissociation rate remains bound to the target site long enough 
for equilibrium to be reached and the imaging study completed. Thus, it is important that 
the rate of dissociation be relatively small. In addition, the effective half-life of the 
radioisotope must be long enough to allow the completion of an imaging procedure and 
short enough to keep the radiation dose to the patient low. 
Once the radiopharmaceutical is administered, photons emitted from the 
radiopharmaceutical travel through the body. Many interact in the body through 
photoelectric absorption and Compton scattering. Some photons that exit the body, 
unscattered or scattered, are detected by a gamma camera. This detection is the first step 
in the image generation process.  
 
2.1.3 Gamma Camera 
2.1.3.1 Components 
 The gamma camera, also called the Anger Camera after its inventor, Hal Anger, is 
the most commonly used device in nuclear medicine (Anger 1958). The gamma camera 
consists of a collimator, scintillation crystal, lightguide, photomultiplier tubes (PMTs), 
preamplifiers, amplifiers, positioning circuitry, and pulse-height analyzers (PHAs). 
Figure 2.3 is an illustration of a gamma camera system, which includes a computer for 
image formation and display. The components of the gamma camera are encased in 
housing made of materials with high atomic numbers, for example lead or tungsten. This 
housing shields the camera from ambient radiation. The collimator is an array of holes 











Figure 2.3. Basic components of a gamma camera system. The photon emitted from the 
radioactivity distribution within the patient enters the gamma camera through the 
collimator. The photons interact in the scintillation crystal, which results in the emission 
of light photons. These light photons enter PMTs through the light guide. The PMTs 
convert light signal into an electric signal. The energy discrimination and positioning 
electronics use the electric signal to determine energy and position to generate images. 
The images are displayed on the computer. Figure courtesy of Larry Zeng, Ph.D., at the 










Figure 2.4. Collimators and cross section of a hexagonal collimator. The septa are made 
of a high atomic number and high-density material. The cross section resembles a 
honeycomb. Photons are emitted isotropically from activity distribution within the 
patient. Not all the photons are used to generate the image. A small percentage of photons 
that encounter the collimator are used to generate the image. Photons traveling through 
the collimator are usable. Photons traveling at an angle through the collimator have a 
high probability of being absorbed in the septa. These photons do not contribute to image 
formation. Figure courtesy of Larry Zeng, Ph.D., at the University of Utah. (Zeng 2003)
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shielding. The walls of the holes are called septa. Alloys of lead are the most common 
materials used as septa. Figure 2.4 includes an example of a cross section of a parallel-
hole collimator with hexagonal-shaped holes. The collimator allows photons traveling in 
the direction parallel to the collimator holes to pass through to the scintillation crystal and 
absorbs photons traveling in other directions. Photons passing through the collimator 
encounter the scintillation crystal. When a photon interacts with the atoms in the crystal, 
the crystal emits visible light photons approximately proportional to the amount of energy 
absorbed due to the photon interacting in the crystal. A light guide is an optical coupling 
compound that aids in the transmission of light photons from the scintillation crystal to 
the camera’s PMTs by minimizing reflection loss. A PMT is a vacuum tube that contains 
an anode, photocathode, and dynodes. A PMT generates an electric current (output 
signal) approximately proportional to the number of visible light photons that enter the 
PMT. The preampliers and amplifiers are electronics used to propagate and amplify PMT 
output signals prior to digitization, discrimination, and storage. The positioning circuitry 
estimates, from the output signals of the camera’s PMTs, the position of the gamma 
photon interaction in the crystal. The electronics of the PHA reject detected photons with 
energies not within a specified range. Data collected from the positioning circuitry and 
PHA are used to generate images. These images are digitally displayed on computer 
monitors. 
 
2.1.3.2 Gamma Camera Function 
 In a typical single-photon emission study, the radiopharmaceutical is 
administered to a patient orally or intravenously. The radiopharmaceutical is given time 
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to localize in the desired organ or volume in the patient. Gamma photons are emitted 
isotropically from the activity distribution. Many of these photons go undetected, as they 
never come in contact with the gamma camera. Photons with the potential to be detected 
are those that enter the gamma camera through its collimator or aperture. The collimator 
mechanically selects photons for possible detection. Photons that travel through the holes 
reach the scintillation crystal. Some interact with the crystal; some pass through it. 
Ideally, photons that impinge on the collimator at an angle are absorbed in the walls of 
the honeycomb-like structure of the septa. Figure 2.4 includes an illustration of 
collimation. Collimated photons that interact in the scintillation crystal transfer energy 
through Compton or photoelectric interactions to electrons in the scintillation crystal. 
These electrons, in turn, lose their energy by interacting with the crystal atoms through 
excitation and ionization. The excited atoms return to ground state by emission of visible 
photons. The number of visible photons emitted is proportional to the amount of energy 
transferred to the atom indirectly by the incident gamma photon. The light output of the 
crystal is transferred to the PMTs via the lightguide. A gamma camera usually has several 
PMTs. The exact number depends on the size of the scintillation crystal and the size of 
the PMTs. In a typical gamma camera, there are 37 to 93 PMTs in a hexagonal array. The 
lightguide distributes the light output from photon interactions in the crystal across 
several PMTs. The photocathode of each PMT converts the visible light photons into 
electrons. About four to six light photons must strike the photocathode to generate one 
electron. The electrons produced at the photocathode are then multiplied as they 
propagate through the dynodes. Dynodes are located along the PMT. Each dynode is held 
at a higher positive voltage than the previous dynode. When an electron strikes a dynode, 
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two or four new electrons are generated. These new electrons add to the number of 
electrons traveling through the tube to the anode. Although each PMT outputs electrons 
multiplicatively greater in number than the electrons released at its photocathode, the 
number of electrons needs to be further amplified. A preamplifier, attached to the PMT, 
enhances the electrical signal so the signal is sufficiently strong that it can pass through a 
cable to the main amplifier. The amplifier increases the signal by about three orders of 
magnitude. The positioning circuitry linked to the PMTs determines the position of the 
energy deposition of a photon in the crystal by summing weighted signals from the 
PMTs. The amount of light detected from each PMT is in direct relation to the PMT’s 
proximity to the location of the gamma-ray interaction in the scintillation crystal, i.e. the  
closer the PMT is to the event, the larger the PMT signal. As a result, the PMT signals 
are weighted in relation to their location to the event. The sum of the PMT output signals, 
known as the Z pulse, is proportional to the energy of the initial photon interacting in the 
crystal. The PHA accepts Z pulses within a specified energy range and rejects Z pulses 
outside the energy range. This range is referred to as an energy window. The detected 
photons within the photopeak window are the energy-window events used to generate 
images. The size of the energy window is dependent on the energy resolution of the 
gamma camera. The poorer the energy resolution, the wider the window. If the Z pulse is 
within a specified energy range, the Z pulse and the corresponding location are digitized 
and stored. 
 Typical nuclear medicine images are stored as n x n image matrices, where each 
image element is called a pixel. Each pixel corresponds to a small continuous range of (x, 
y) locations in real object space. The image matrix is similar to a counter; a count is 
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added to a pixel if the Z pulse occurred within the real object coordinate range 
represented by the pixel. Nuclear medicine images are usually stored as 64 x 64, 128 x 
128, 256 x 256, or 512 x 512 matrices. While the physical image size remains the same; 
the pixel size varies according to the number of total pixels. The pixels in a 64 x 64 
image matrix represent a larger range of spatial points in real object space than the pixels 
in a 512 x 512 image matrix. As a result, a 512 x 512 image records better spatial 
resolution, if the device hardware can accurately record such resolution. 
 
2.1.3.3 Gamma Camera Performance 
Not all gamma cameras are designed the same. As a result the performance of 
gamma cameras varies. The design of a gamma camera is largely dependent on the 
energy of photons to be imaged. The collimator and scintillation crystal thickness are 
selected to correspond with the energy of the photon to be imaged. The collimator and the 
scintillation crystal have great influence on the performance of a gamma camera. 
Collimators play a significant role in the performance of gamma cameras as they 
are the entry point into the gamma camera. While the performance of the gamma camera 
is influenced by several collimator characteristics, such as hole diameter and bore, septal 
wall thickness is of interest in this research. The selection of septal wall thickness is also 
dependent on the energy of the photon to be imaged. Imaging high-energy photons 
requires thick septal walls to minimize septal penetration – photons permeating the septal 
walls. Thinner septal walls are acceptable for imaging lower energy photons. However, 
the selection of an adequate collimator becomes more complicated, if the energy 
spectrum of the radiopharmaceutical has energy peaks higher than the principle energy 
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peak used for image generation. This is because higher energy gammas may downscatter 
into the photopeak of the spectrum. This is the case with 123I labeled 
radiopharmaceuticals.  In addition to the primary emission photon of 159 keV, 3% of 123I 
gamma photons are in the energy range of 248 keV - 784 keV. For 123I quantitative 
single-photon emission imaging studies of striatal dopamine neurotransmission, in which 
spatial resolution is important, a high-resolution collimator is needed. Typically, a low 
energy high-resolution parallel-hole collimator is used for such studies as imaging 
focuses on 123I’s primary gamma emission of 159 keV. However, the septal walls of such 
a collimator are too thin to absorb the energy of the high-energy gamma emissions of 123I. 
Thus, septal penetration occurs and the high-energy gamma emissions may interact in the 
scintillation crystal increasing image noise. 
Thickness of the scintillation crystal also influences the performance of a gamma 
camera, as it is the essential component for detection. A thicker crystal has higher 
detection efficiency than a thinner one of the same material. More photons are absorbed 
in a thicker crystal because photons that would have escaped a thinner crystal are now 
interacting in the crystal. A thicker crystal also decreases the spatial resolution of the 
gamma camera. Although more photons are absorbed in a thicker crystal, light photons 
leaving the crystal and entering the PMTs are spread out a larger area. In addition, many 
photons transfer energy through several Compton scatter events before escaping the 
crystal or eventually being absorbed by photoelectric interactions at distance from the 
location of the initial interaction. 
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2.1.4 Attenuation and Scatter 
Ideally, images generated from gamma cameras would be a true spatial and 
quantitative representations of the activity distributed throughout the target volume. 
However, in practice the images generated from gamma cameras are less-accurate 
representations due to attenuation and scatter. That is, the grayscale values of images 
generated from such data do not reflect absolutely the values of radioisotope uptakes in 
particular volumes of interest.  
Primary photons are photons emitted from a source of radioactivity that have not 
participated in an interaction. Primary photons that are absorbed in the scintillation 
crystal via the photoelectric effect provide useful spatial information about the activity 
distribution. Unfortunately, a large number of primary photons do not reach the camera 
due to Compton scattering or photoelectric absorption in the body. The loss of these 
photons is called attenuation. However, many photons are scattered in the body and are 
then detected by the gamma camera. Some photons exiting the body, unscattered or 
scattered, scatter in the camera before detection. The Z pulses of many of these scattered 
photons are often below the specified threshold and are therefore rejected by a PHA. Due 
to the finite energy resolution of the gamma camera, some Z pulses of scattered photons 
are not rejected. This is problematic because scattered photons are generally located a 
distance away from the Compton scatter event. The inclusion of scattered photons with 
approximately 159 keV energy degrades image quality as scattered photons do not 
provide accurate spatial information of the radiopharmaceutical distribution. In the case 
of radiopharmaceuticals that emit photons with energies higher that those of the primary 
photons, contributions from scattered higher-energy photons contaminant data from 
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primary photons. Such higher-energy photons are energetic enough to penetrate 
collimator septa and to deposit sufficient energy in the scintillation crystal that they 
contribute to the image. 123I is an example of a radioisotope that emits photons with a 
range of energies above the primary photon emission of 159 keV. 123I is an integral part 
of this dissertation and is discussed in more detail in section 2.4. 
Image data that lacks data from primary photons due to attenuation and includes 
scattered photon data are qualitative images. Even though qualitative images do not 
reflect fully the amount of activity distributed in volumes of interest, they do have 
clinical value. Qualitative single-photon emission images are a significant component of 
the management of patients in present nuclear medicine clinics. Although qualitative 
images can sometimes be sufficiently informative, quantitative images are at times 
necessary as they provide more definitive information, such as absolute quantities or 
ratios. For example, a longitudinal study of a disease documented only with sequential 
qualitative images may require that significant changes in the images exist before 
clinicians are able to discern any change. Use of only qualitative images proves to be 
problematic if a disease progresses slowly. Small changes are lost in qualitative images. 
Quantitative imaging provides a means of recognizing change and of measuring its 
amount. Quantitative imaging involves compensating for the effects of attenuation and 
scatter. Parkinsonism is an example of a disease that progresses slowly. Studies have 
suggested that quantitative imaging can be used to monitor successfully Parkinsonism 
and related drug therapies (Ichise and Ballinger 1996; Bourguignon, Pauwel et al. 1997; 
Messa, Volonte et al. 1998; Booij, Tissingh et al. 1999; Benamer, Patterson et al. 2000; 
Booij, Speelman et al. 2001; Costa 2001; Grosset 2001; Tatsch 2001; Tzen, Chin-Song et 
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al. 2001; Frey 2002; Pinborg, Videbaek et al. 2002; Poewe and Wenning 2002; Abella 
2003; Burn and O'Brien 2003; Catafau 2003; Jersild and Trevino 2003; Leenders 2003; 
Morrish 2003; Oertel, Gerstner et al. 2003; Piccini 2003; Pirker 2003; Seibyl 2003). 
Thus, of interest, are quantitative approaches to striatal uptake of relevant 
radiopharmaceuticals.  
 
2.1.5 Qualitative Single-photon Emission Imaging 
 Single-photon emission imaging, planar or tomographic, is based fundamentally 
on the attenuated Radon integral. The standard geometry and coordinate systems of 
patient and gamma camera set-up for single-photon emission imaging are illustrated in 
figure 2.5. Two coordinate systems, one based on the frame of reference of the patient 
and the other based on the frame of reference of the gamma camera, are depicted. The 
patient’s frame of reference is specified by the spatial coordinates x = (x,y,z) and is 
assumed to be stationary. The z coordinate is out of the page. The gamma camera’s frame 
of reference, specified by the spatial coordinates (xr yr, z), rotates about the z-axis with a 















,  (2.3) 
 
where E(xr, z) is the emission measurement, f(x) is the spatial distribution of the 
radiopharmaceutical, µ(x) is the distribution of attenuation coefficients, and dyr is the 
differential length along the line L in the yr direction. Equation 2.3 consists of two  
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Figure 2.5. Acquisition of emission data. The geometry and coordinate systems of patient 
and gamma camera set-up used to acquire an emission measurement. The patient is 
represented by the object. The detector in this illustration is acquiring an emission 
measurement from point x. The detector detects photons that are attenuated as they pass 
through the body from x to the detector. µ(x) is the distribution of attenuation coefficients 
within the object along the line segment L(x). The emission measurement is described by 
the attenuated Radon integral. The Radon integral sums the product of the radiotracer 
distribution f(x) and the fraction of transmitted photons from x along L, . Figure 



























integrals. The exponential integral is the summation of the attenuation coefficients along 
the line segment L’(x) as the tissue along L’(x) may not be homogenous. The integral of 
f(x) and the exponential term (the attenuation term) are the total radioactivity along the 
line segment L(x) as seen by the gamma camera. Depending on the image study the 
gamma camera or gamma cameras can be rotated about the zr axis through angle φ. At 
each angular location φ an emission measurement, an attenuated Radon integral, is 
acquired for each pixel of the image. Each measurement acquired by the camera in a 
specific angular location is a measurement of radiation traveling in the yr direction. 
 
2.1.6 Planar Emission Imaging 
 Planar emission imaging is the process by which images of single views of a 
radiopharmaceutical distribution are generated. An image of a single view of a 3D 
radiopharmaceutical distribution is called a planar projection. The gamma camera is 
placed at a fixed angular position φ and emission data are collected. The emission 
measurement in each pixel of a planar projection (planar image) is described 
approximately by the attenuated Radon integral, representing the sum of the activity 
along the line extending from a point within the distribution to the face of the gamma 
camera. Due to the integration of the activity along the line, the 3D distribution of the 
activity in the patient is depicted as a 2D image. One planar projection of the patient 
comprises the collection of attenuated Radon integrals in the yr direction.  
 Clinically, planar emission imaging is used to observe structure and function 
through static studies and dynamic studies. A static study is the acquisition of a single 
projection; a dynamic study, in this context, is the collection of a series of planar images 
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acquired intermittently over a specific time interval. A thyroid study is a common static 
study used to assess the function of a thyroid. Generally, three planar images are acquired 
– anterior, left anterior oblique, right anterior oblique. A common dynamic study is a 
renal study. A renal study is used to evaluate the function of a kidney by observing the 
kidney extracting the administered radiopharmaceutical from the blood and excreting it to 
the bladder. Usually, several sequential planar images are required for accurate 
assessment, as time-activity curves of total activity in the kidney or kidneys are needed.  
 
2.1.7 SPECT 
Single-photon emission computed tomography is the process of generating, from a 
collection of planar projections, cross-sectional views of a radioactivity distribution. 
These views can be combined to form a 3D representation of the distribution. SPECT is a 
two-step process: 1) image data acquisition and 2) image data reconstruction. The 
complete process of SPECT requires one or multiple gamma cameras, a means to display 
images, a gantry for camera rotation about the patient, and software to perform image 
reconstruction. For step one, a gamma camera or multiple gamma cameras are rotated 
about the patient (z-axis) through angle φ to acquire various projection views. The 
angular range is generally 180 or 360 degrees. The range depends on the organ imaged.  
Most commercial SPECT systems have two gamma cameras on a rotating gantry. Single 
and triple gamma camera systems are also available. Figure 2.6 is an illustration of a dual 
head gamma camera system acquiring projection data from different angles. Once the 





Figure 2.6. SPECT projection acquisition. Dual-head gamma camera system acquiring 
eight projections at different angles. A projection acquired for each gamma camera. 




transaxial cross-sectional images. In addition to transaxial slices, coronal and sagittal 
slices are often generated for SPECT studies by reslicing the volume of transaxial slices.  
The process of generating transaxial slices is called image reconstruction. Image 
reconstruction is an inverse problem that uses the measured data, the projections, to 
generate the transaxial slices of the activity distribution. Filtered backprojection is the 
most common reconstruction method applied in clinical settings (King and Farncombe, 
2003; Rosenthal, 1995; Tsui, 1996; Zeng, 2001). Iterative image reconstruction schemes 
are used in most research labs and their use is becoming more popular for clinical studies 
(Vandenberghe, D'Asseler et al. 2001; Zeng 2001). 
As stated previously, in section 2.2.4, a planar projection is described mathematically 
as a collection of attenuated Radon integrals. However, the attenuated Radon integral has 
proved too complex for practical use in clinical image reconstruction. Consequently, the 
attenuated Radon integral is often replaced with a Radon integral in the reconstruction 
process. If the attenuation coefficient distribution µ(x) in equation 2.3 is assumed to be 
zero, then equation 2.3 is the Radon integral of f(x). That is, equation 2.3 becomes 
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where f(x) is the spatial distribution of the activity and E(xr, z) is the emission 
measurement along the single line segment L measured at the single point (xr, z). 
Although the reconstruction calculation is less rigorous and less accurate with the use of 
the Radon integral than with the use of the attenuated Radon integral, the resulting 
SPECT images are clinically usable representations of the true activity distribution in the 
body. They are not quantitatively accurate and are sometimes misleading in the clinic 
setting, but nonetheless they are often diagnostically useful. 
 SPECT studies are used routinely in nuclear medicine departments. Often times, 
SPECT studies are performed when planar studies reveal abnormalities that require a 
better assessment. Bone SPECT studies are examples of studies performed in addition to 
corresponding planar bone studies. SPECT studies are also performed as primary 
diagnostic procedures. Such is the case for myocardial perfusion and brain perfusion 
assessment. Myocardial perfusion SPECT studies are the most common SPECT studies 
performed. They are used to assess a patient’s heart at rest and under stress. Brain 
perfusion SPECT is performed to identify clinical indications of cerebrovascular disease, 
dementia, and seizure. 
 
2.1.8 Quantitative Single-photon Emission Imaging 
Quantitative single-photon emission imaging incorporates correction techniques 
to estimate and correct for attenuation and scatter. Attenuation correction uses an 
attenuation map, usually now generated from transmission imaging, to account for counts 
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lost due to attenuation. Scatter correction estimates the fraction of scattered photons 
detected and subtracts that fraction from the total number of photons detected. 
Transmission imaging generates estimates of attenuation coefficients by using an 
external source. The external source is placed in such a position that the emissions of the 
source must pass through the patient to reach the detector. This configuration is 
illustrated in figure 2.7. The transmission measurement, T (xr, z), at a specific point (xr, z) 
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where µ(x) is the attenuation coefficient at x. Equation 2.5 is the Radon integral of µ(x) 
along the single line L measured at the single point (xr, z). The collection of Radon 
integrals in the yr direction is a transmission projection. Transmission tomography uses 
the collection of transmission projections in all yr directions for a fixed z to generate a 
transmission image of a transaxial slice of the body. A single transmission projection is 
used to correct attenuation in planar imaging studies. Transmission tomography is used to 
correct attenuation in SPECT studies.  
Classic conjugate imaging is a quantitative planar imaging technique that uses 
data acquired by two opposed gamma cameras to estimate the activity of a 
radiopharmaceutical distribution at an unknown depth (Barnes 1996; King and 
Farncombe 2003). Attenuation is corrected by using a measured effective attenuation 


















Figure 2.7. Acquisition of transmission data. Geometry and coordinate systems for 
patient and detector associated with a transmission projection. The patient is represented 
by the object with an attenuation coefficient µ(x). The patient is placed between the 
detector and source. The photons emitted from the source travel through the body. Some 
photons exiting the body are detected by the detector. The transmission measurement 
along L is described by the Radon integral in equation 2.5. Figure courtesy of Larry 
Zeng, Ph.D., at the University of Utah. (Zeng 2003)
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more detail in section 2.2 as it is the foundation for the modified conjugate imaging 
technique presented in this dissertation. Although transmission maps are used in SPECT 
studies, an attenuation constant has often been uniformly applied for volumes where the 
distribution of attenuation coefficients is relatively uniform (Tsui 1996; Catafau 2003). 
This is done, for example, in the reconstruction of brain studies. For volumes with a 
heterogeneous distribution of attenuation coefficients, an attenuation map is applied. 
Scatter contributes significantly to image data. Jaszczak estimated that about 40% 
of acquired image data are scattered radiation when 99m Tc radiopharmaceuticals are used 
(Jaszczak, Greer et al. 1984; Rosenthal, Cullom et al. 1995). This percentage can be 
larger for radiopharmaceuticals that also emit photons with higher energies than its 
primary photon emission, such as 123I (Gilland, Jaszczak et al. 1994; Dobbeleir, Hambye 
et al. 1999). These high-energy photons can downscatter into the photopeak window 
increasing the scatter fraction within that window. Although scatter-correction schemes 
have been developed and applied to SPECT studies, to date, scatter-correction techniques 
have yet to be implemented routinely in clinical settings.  
King and Farncombe classify scatter correction techniques into two main 
categories - scatter-estimate and reconstruction-based scatter compensation (RBSC) 
techniques (King and Farncombe 2003). Techniques that fall into the scatter-estimation 
group estimate scatter contribution using acquired emission data. RBSC techniques 
incorporate a modeled scatter response function into an iterative reconstruction scheme. 
RBSC techniques use principles of scatter interactions to estimate the scatter 
contribution. Since RBSC techniques are used with SPECT studies, these techniques will 
not be discussed further. 
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The scatter-estimation group can be sub-divided into energy-distribution and 
spatial-distribution methods. Energy-distribution methods estimate scatter contribution in 
the photopeak window using emission data in other energy-windows. This method is a 
pixel-based method, i.e. it is applied to each image pixel. Several energy-distribution 
methods have been used, but the Compton scatter window and triple-energy window 
(TEW) techniques are two of the most popular. Jaszczak et al. introduced the Compton 
scatter window technique in which emission data from an energy window below the 
photopeak window are used to correct for scatter (Jaszczak, Greer et al. 1984). Ogawa et 
al. introduced the TEW scatter technique that uses emission data acquired in two energy 
windows, one abutting the lower boundary of the photopeak window and the other 
abutting the upper boundary of the photopeak window (Ogawa, Harata et al. 1991). This 
technique, detailed in this work, is often applied to single-photon emission imaging 
studies using radiopharmaceuticals with high-energy photon emissions, in addition to 
their primary photon emission. In the spatial-distribution method, emission data acquired 
in the photopeak window is used to estimate the source distribution and to model the 
source contribution to the scatter distribution. In the convolution-subtraction method, an 
example of a spatial-distribution method, a model of the scatter distribution function is 
convolves with acquired emission data to obtain an estimate of the scatter distribution. 
This scatter distribution is subtracted from the emission data. 
Scatter contributions are not specifically addressed in the methodology of classic 
conjugate imaging. To account for scatter in classic conjugate imaging, one can modify 
the technique to include build-up factors or the projection data must be corrected using 
scatter-correction techniques (Wu and Siegel 1984; Barnes 1996; King and Farncombe 
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2003). The build-up factors can be calculated from empirical measurements or Monte 
Carlo computer simulations. However, the inclusion of build-up factors in the classic 
conjugate imaging technique increases the complexity of conjugate imaging. Although 
most scatter-correction techniques are applied primarily in SPECT studies, some can be 
modified for application to planar projection data.  
The image data generated in quantitative imaging more accurately reflect the true 
activity distribution than do data of qualitative techniques. The primary outcome sought 
in use of quantitative imaging, however, is not an image, but an estimate of the 
radioactivity in a radiopharmaceutical distribution. The estimation of activity can be 
presented as an absolute activity measurement or as one of a variety of other parameters 
such as binding potential (Karesh 1996). The binding potential is the ratio between 
specific binding and non-specific binding. It is the most common measurement made in 
quantitative imaging.  
 
2.2 Classic Conjugate Imaging 
Classic conjugate imaging is a non-tomographic nuclear medicine technique that 
uses gamma camera projection data from two diametrically opposed views to estimate the 
activity in a source embedded at an unknown depth in an attenuating medium. The 
technique can also be used to estimate the sum of activities in multiple sources embedded 
at unknown depths in an attenuating medium. The projection data can be acquired 
simultaneously by two gamma cameras or sequentially by one gamma camera, if the 
tracer dissociation rate is sufficiently slow. For the remainder of this dissertation, it is 
assumed two gamma cameras are used. Three sets of projection data – emission, 
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transmission, and flood - are acquired for each view. The flood data are used to determine 
the camera sensitivities for each camera. The transmission data are used to estimate the 
transmission factor for the imaged object. The emission data are geometrically averaged 
and used together with the calculated camera sensitivities and effective attenuation of the 
medium to estimate the activity of the source. 
 At the roots of conjugate imaging is conjugate counting introduced in 1937 by 
Robley Evans (Evans 1937). Evans used anterior and posterior count data collected by a 
Geiger counter to estimate the total activity of radium deposits in the bones of radium 
dial painters. For each measurement taken, the body of a radium dial painter was curved 
in an arc of 1 meter radius of curvature and the Geiger counter was positioned at the 
radius of curvature. The advent of imaging, rectilinear and planar, introduced new 
imaging geometries. Sorenson evaluated the influence of source-to-detector distance on 
the estimation of activity using conjugate imaging for different imaging set-up 
geometries including Evans arc geometry (Sorenson 1974). The geometry investigated by 
Sorenson that is most relevant to this work is a planar imaging geometry, i.e. parallel-
hole collimator imaging.  
The unique aspect of conjugate imaging is the one-dimensional treatment used to 
determine quantitative measurements. In ideal parallel-hole collimator imaging in which 
the detection of scattered photons and depth dependent blurring are considered negligible, 
the area circumscribed by each bore in the collimator can be treated as an individual 
detector. As such the counts in an image pixel can be determined by one-dimensional 
analysis in which the depth of activity is the only variable. The derivation of conjugate 
imaging presented in this chapter and my discussion of an extension in Chapter VI 
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assume an ideal parallel-hole collimator imaging geometry, which results a one-
dimensional treatment of the activity estimation problem and in pixel-by-pixel 
calculations. 
This section discusses the methodology and mathematics of classic conjugate 
imaging. The discussion includes conjugate imaging of planar and volume sources, 
applications of classic conjugate imaging, and modified conjugate imaging techniques 
based on classic conjugate imaging.  
 
2.2.1 The Planar Model 
 
We assume a planar source of radioactivity embedded in a medium with a 
thickness T as diagrammed in figure 2.8. The medium is uniformly attenuating with an 
effective linear attenuation coefficient µ. (That is the transmission factor at depth d is e-
µd.) The planar source A is at an unknown depth d. Emission data are acquired by placing 
the object between two opposed gamma cameras as shown in figure 2.8. The cameras in 
figure 2.8 are denoted as “Camera L” (left) and “Camera R” (right). This notation will be 
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Figure 2.8. Conjugate Imaging: Acquisition of emission data. Planar source with activity 
A is located at a depth d within a medium of thickness T. The medium is uniformly 
attenuating with an effective linear attenuation coefficient µ.The object is placed between 




The emission data can be expressed as 
 
( )dLL AeCE µ−=      (2.6) 
( )( )dTRR AeCE −−= µ ,    (2.7) 
 
where EL and ER are the emission data from the left and right cameras, respectively; CL 
and CR are the camera sensitivities of the left and right cameras, respectively; A is the 
source activity; T is the total object thickness; and d is the depth of the source as 
measured from the right surface of the medium. The units for the emission data are 
counts per second (cps). The camera sensitivity is expressed as counts per second divided 
by disintegrations per second (cps/dps). The activity is expressed as dps. Equations 2.6 















EEA µ .   (2.8) 
 
Since equation 2.8 is not dependent on the depth parameter d, conjugate imaging proves 
useful when a quantitative measurement of a source is desired but the depth of the source 
is unknown. Equation 2.8 cannot be solved without knowledge or measurements of the 
camera sensitivities, CL and CR, and the transmission factor, e-µT. Knowledge of these 
requires two additional sets of data, flood and transmission data.  
Flood data are acquired by placing a uniform flood source between and 
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Figure 2.9. Conjugate Imaging: Acquisition of flood data. A flood source with activity AF 
uniformly distributed is placed between camera L and camera R. The data acquired are 
used to determine the camera sensitivities. 
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activity AF. The flood data can be expressed as  
 
FLL ACF =     (2.9) 
FRR ACF = .    (2.10) 
 











C = .    (2.12) 
 
Transmission data are needed to compute the transmission factor of the medium, e-µT. 
Transmission data are obtained by each camera, as the data acquired by each camera are 
most likely different as the cameras likely have different sensitivities. When transmission 
data are collected by Camera L, the flood source is placed between Camera R and the 
object. When collected by Camera R, the flood source is placed between Camera L and 
the object. This is depicted in figure 2.10. In the absence of radioactivity in the object, the 
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Figure 2.10. Conjugate Imaging: Acquisition of transmission data. The object with planar 
source located at depth d is placed between camera L and camera R. The flood source is 
placed between camera L and the object to acquire transmission data for camera R. 
Transmission data from camera L are acquired with the transmission source between 




the geometric mean of the transmission data, TL and TR, and manipulating the resulting 









e 1=−µ .   (2.15) 
 
Although ideally, transmission data  would be acquired without the presence of 
radioactivity in the object, clinically this is usually not feasible. Accurate registration of 
transmission and emission data is necessary and accurate repositioning of the patient is 
difficult. As a result, the transmission data measured in most cases contain data from a 
source or sources together with data from the transmission source. The measured 
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where the superscript ‘ indicates a measured quantity. The emission data must then be 
subtracted from the measured transmssion data to obtain the true transmission data used 
in Equations 2.13-2.14. 
 
2.2.2 The Volume Model 
 In this section, the extension of the planar source model to the volume source 
model is discussed. Activity injected into an object will not accumulate in a planar or 
point distribution. The activity will gather in an organ or tumor with some thickness. Self 
attenuation is important in sources with a measureable thickness, as potential counts may 
be lost due to gamma interactions within the source. 
Consider activity A uniformly distributed throughout an attenuating medium of 
thickness t as seen in figure 2.11. The activity measured or seen by a gamma camea  is 
referred to as effective activity, Aeff . An infinitesimal slice of the source as seen by an 
ideal detector can be expressed as 
 
      xeff dAedA µ−= 0 x t≥ ≥ , (2.18) 
where     AdA dx
t
⎛ ⎞= ⎜ ⎟
⎝ ⎠
.    (2.19) 
 
In the above, dAeff  is the infinitesimal amount of effective activity in an infinitesimal 








Figure 2.11. Volume source with thickness t. Activity is distributed uniformly throughout 




transmission factor of activity in slice dx at depth x; A is the activity distributed 
throughout the source; and t is the source thickness. 
The effective activity of the source is obtained by integrating equation 2.18 over 
the thickness of the source. The result is 
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In the above, Aeff is the effective activity of the source; ft is a factor that modifies 
(increases) the e-µt/2 transmission factor for a source in the middle of thickness t; and A is 
the activity uniformly distributed throughout the source. The transmission factor e-µt/2 
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does not adequately represent the attenuation of activity distributed uniformly throughout 
thickness t. The factor ft is a correction factor that modifies e-µt/2 by accounting for effects 
of attenuation throughout t. The magnitude of ft is dependent on source thickness. The 
thicker the source, the larger the value of ft. For thinner sources, the self-attenuation 
factor has less significance. For example, assuming that 140 keV photons are distributed 
uniformly in a 3 cm thick slab of water and using an effective attenuation coefficient of 
0.140 cm-1, the self-attenuation factor ft of this source represents less than a 1% effect 
(Mintzer, Aarsvold et al. 2000). 
 If we replace the planar source in figure 2.8 with a volume source with a thickness 









Figure 2.12. A source with thickness t embedded in an object with thickness T. The 




Conjugate imaging of a volumetric source is based on the same acquisitions of emission, 
transmission, and flood data as used for conjugate imaging of a planar source. However, 
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it  is necessary to include the self-attenuation factor ft in models and computations. The 
following discussion presents the application of classic conjugate imaging to the 
quantification of the activity in a volume source. The emission data of a thick source can 
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= .    (2.24) 
 
Here, EL and ER are the emission data acquired from the left and right cameras, 
respectively; CL and CR are the camera sensitivities of the left and right cameras, 
respectively; Aeff is the effective source activity; and ft is the self-attenuation factor of the 
thick source. Substituting the value of Aeff (equation 2.24) into equations 2.22 and 2.23 
yields the following emission data expressions: 
 







ACE µ−= . (2.26) 
 











= .   (2.27) 
 
As mentioned previously, the self-attenuation factor of 140 keV photons distributed 
uniformly in a 3 cm thick slab of water with an attenuation coefficient of 0.140 cm-1 has 
less than a 1% affect on activity estimation. As a result, we assume the self-attenuation 
correction factor is one for sources less than or equal to 3 cm. Typically, the self-
attenuation correction factor ft is usually considered equal to one for source thickness less 
than half the object thickness, (Shung 1992). 
 The transmission data and flood data are measured using the same techniques 
discussed in the planar model section. 
 
2.2.3 Sum of Two Sources 
The sum of activity from two sources separated by a known distance, s, can be 
estimated by use of conjugate imaging (Sorenson 1974). We consider two sources of 
activity embedded in a uniformly attenuating object of thickness T. This is illustrated in 
figure 2.13. For this derivation, the sources are assumed to be thin enough relative to the 
attenuation coefficient that their thickness can be ignored, i.e. ft ≈ 1.  
The emission data acquired from the left and right cameras are expressed as 
 
( )( )sddLL eAeACE +−− += 11 21 µµ   (2.28) 









Figure 2.13. Two sources separated by a distance s in a uniformly attenuating object. The 
sources have activities A1 and A2. The object has a thickness T. The source with activity 




where EL and ER are the emission data; CL and CR are the camera sensitivities of the left 
and right cameras, respectively; and A1 and A2 represent the activities of the two planar 
sources in Figure 2.13. Taking the geometric mean of equations 2.28 and 2.29 and 





































RL µµ . (2.30) 
 
By comparing equations 2.30 with equation 2.8, one finds that the second factor in 
equation 2.30 is the correction factor for the use of classic conjugate imaging in the 
estimations of the sum of the activities in two distinct sources. The correction factor is 
dependent on the source activity ratio and the distance between the sources. Assuming 





















µ .  (2.31) 
 
This expression has a maximum value when r = 1. This implies the largest error in 
determining of the sum of two sources in this setting occurs when the source activities are 
approximately equal (i.e. r = 1).  When r = 1, the correction term is  
 












⎛ −+ sµ .   (2.32) 
 
Equation 2.32 can be used to determine the upper bound for error in estimating the total 
activity in two sources separated by a distance s. For 140 keV photons in water, a case in 
which the attenuation coefficient is 0.140 cm-1, the total activity of two sources separated 
by 2 cm is overestimated by 1%. However, for a separation of 6 cm, the total activity is 
overestimated by more than 10% (Mintzer, Aarsvold et al. 2000). 
Conjugate imaging may be applied to estimate the total activity of more than two 
sources (Evans 1937; Sorenson 1974). Evans found that if one assumed the activity from 
multiple sources was placed at a single mean depth, only a small error was introduced 
into the estimated activity. He estimated the error for radium dial painter studies to be 





 Robley Evans introduced conjugate counting in 1937 as a quantitative technique 
used in radium poisoning investigations. Evans used conjugate counting to estimate the 
amount of radium deposited in the bones of living people, specifically radium dial 
painters (Evans 1937). Since that time, classic conjugate imaging has been used to 
estimate the uptake of activity in tumors or normal organs for dosimetry calculations, 
therapy response estimations, and improved diagnostic assessment. However, with the 
advent of quantitative SPECT investigations, the employ of classic conjugate imaging has 
decreased such that its use is now limited.  
 Whole-body conjugate imaging is used to estimate biodistribution and dosimetry 
of radiopharmaceuticals (King and Farncombe 2003). Mozley used conjugate imaging to 
characterize the in vivo distribution of Tc-99m TRODAT (Mozley, Stubbs et al. 1998). 
 Several investigators have used conjugate imaging to estimate tumor uptake and 
uptake in normal surrounding tissues or organs. Thomas et. al. used conjugate imaging to 
estimate activity uptake in thyroid lesions to improve therapeutic treatment plans 
(Thomas, Maxon et al. 1976). Koral et al. applied conjugate imaging using pinhole 
collimators to the estimation of radiation dose to neck tumors (Koral, Adler et al. 1982). 
Hammond et al. presented conjugate imaging data on liver tumor uptake estimating error 
at less than 10% (Hammond, Moldofsky et al. 1984). Eary et al. used conjugate imaging 
to estimate the internal radiation dose to tumors and normal organs for radiolabeled 
antibody therapy (Eary, Appelbaum et al. 1989; Eary, Press et al. 1990). Eary et al. 
reported results with less than 6% error. Shulkin et al. used a modified conjugate imaging 
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technique to estimate the I-131 uptake in malignant pheochromocytomas; he reported less 
than 10% error (Shulkin, Sisson et al. 1988).  
 Sjogreen et al. used registered conjugate emission and transmission images to 
improve the quantitative measurements of organ uptake (Sjogreen, Ljungberg et al. 
2001).  Kojima et al. measured renal activity using conjugate imaging to evaluate the 
function of kidneys (Kojima, Ohyama et al. 2000). Yen et al. applied conjugate imaging 
to the determination of left ventricular volume, an important prognostic factor for patients 
with heart disease (Yen, Lim et al. 1994).  
 
2.2.5 Extension of Classic Conjugate Imaging 
 Classic conjugate imaging, as described in this work, is the use of conjugate 
emission views and transmission measurements in the estimation of activity in a single 
source or the sum of activities in multiple sources embedded in a uniformly attenuating 
medium. The uniformly attenuating medium is assumed to contain no activity. The 
clinical application of standard conjugate imaging is useful for estimation of activity 
uptake in a single organ or tumor, or in multiple organs or tumors in dosimetric studies. 
These studies are usually performed under the assumptions that the body is a uniformly 
attenuating medium and uptake of activity in the body excluding the tumors or targeted 
organs is negligible. The classic conjugate imaging formulation is not sufficient for 
clinical cases in which organ or tumor uptake is surrounded by non-uniformly attenuating 
tissue or tissue with activity uptake or for clinical cases in which the estimation of the 
individual activities within multiple sources is desirable. Appropriate extensions of 
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classic conjugate imaging are necessary, if conjugate imaging is to be successfully 
applied in more complex settings. 
 
2.2.5.1 Non-Uniformly Attenuating Medium 
 Sorenson and Thomas examined the estimation of activity in two overlapping 
sources embedded in a non-uniformly attenuating medium (Sorenson 1974; Thomas, 
Maxon et al. 1976). Figure 2.14 illustrates this geometry. Thomas designated one source 
to be the primary lesion and the other source to be the secondary lesion. In figure 2.14, 
the primary lesion is A2 and the secondary lesion is A4. The activity in each lesion was 
assumed to be uniformly distributed throughout the lesion thickness. Thomas derived a 
formula for the estimation of the activity in the primary lesion (Thomas, Maxon et al. 
1976). 
 If one assumes the two positions of acquisitions are left and right of an object, the 
activity in the primary lesion A2 is expressed as 
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46  





=α ,    (2.35) 
 
where EL and ER are the left and right emission data; e-µet is the transmission factor 
through the object with thickness t; f2 is the self-attenuation correction factor for the 
primary lesion 1; and C is the system calibration factor, e.g. the camera sensitivities. 
The term µe in equation 2.33 is the effective attenuation coefficient and is expressed as 
 







µµ ,    (2.36) 
 
where the index i represents the different regions of thickness ti with attenuation 
coefficient, µi. The term g(α) is a correction factor that is dependent on the source 
activities ratio α and the thicknesses and attenuation coefficients of regions 2, 3, and 4. 
 Thomas compared his theoretical formalism with experimental data. The 
correction provided by the correction factor g(α) increases significantly with increasing 
source activities ratio. For a source activities ratio of 0.01, g(α) provides a correction of 
less than 5%. However, for a source activities ratio of 0.3, g(α) corrects the estimation 
activity by more than 20%. Thomas also reported the influence of source thickness on the 
source self-attenuation correction term f. For 140-keV photons the self-attenuation 
correction is less than 5% for source distributions less than 6-cm thick with attenuation 
coefficients within the experimental range reported. However, for larger source 
distributions the correction factor could exceed 10% (Thomas, Maxon et al. 1976). 
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Figure 2.14. Two activity distributions embedded in a non-uniformly attenuating 
medium. Activities A2 and A4 are uniformly distributed throughout regions 2 and 4. 




2.2.5.2 Background Activity 
 Thomas et al. also examined estimation of activity of a single lesion surrounded 
by background activity in an attenuating medium (Thomas, Maxon et al. 1976). This is 
illustrated in figure 2.15. The primary lesion is region 3 and background activity is 
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Figure 2.15. A primary lesion surrounded by regions of background activity in a non-
uniformly attenuating medium. A3 is the primary lesion. A2 and A4 are the background 




Thomas expressed the activity of the primary lesion as 
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≡γ .    (2.41) 
 
In the equation 2.37, A3 is the activity of the primary lesion; A2 and A4 are the activities 
in the volumes adjoining A3; EA and EP are the anterior and posterior emission data, 
respectively; e-µet is the transmission factor through the object with thickness t; f3 is the 
self attenuation correction factor for primary source with thickness t3 and attenuation 
coefficient µ3; C is the system calibration factor, i.e. the camera sensitivity; and k(γ) is 
the correction factor. The effective attenuation coefficient of the object is expressed as 
 







µµ .    (2.42) 
 
In addition to the region thicknesses and attenuation coefficients, the source activity 
ratios of γ2 and γ4 must be known to yield the source activity.  
 Thomas compared his theoretical calculations with experimental data. The 
correction factor k(γ) significantly increases with increasing source activities ratio. For a 
ratio of 0.15, k(γ) is 20% or greater (Thomas, Maxon et al. 1976).  
 
2.2.5.3 Multiple Sources 
 In 1981, Tsui formulated a general conjugate imaging equation for m regions of 
activity embedded in a medium with n attenuating regions where m ≤ n. Each region has 
a uniform attenuation coefficient, µi, and a thickness, ti, where i = 1,2, . . ., n (Tsui, Chen 
et al. 1981). The activity in the m regions is expressed as 
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    )()()( kikiki tA ρ= ,   (2.43) 
 
where A i(k) is the activity in source layer i(k); ρ i(k) is the activity concentration in source 
layer i(k); and t i(k) is the thickness of source layer i(k); where k = 1, 2, …, m.  
 The emission data measured from the left and right cameras, EL and ER are 























































































where CL and CR are the camera sensitivities of the left and right cameras, respectively, 
and Fi(k) is the self-attenuation factor for source layer i(k).  
The geometric mean of the emission counts for m layers of activity embedded in n 
layers of attenuating medium is expressed as 
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where the indices k and k’ denote different source layers and index k’’ denotes a source 
layer between source layers k and k’.  
 For a single layer of radioactivity embedded in a medium with n attenuating 
regions, equation 2.47 simplifies to 
 













,  (2.47) 
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Equation 2.47 is classic conjugate imaging of a thick source. The activity in the single 
region can be calculated if the detector/camera sensitivities, the attenuation coefficients, 
and the source thickness are known.  
 In the case of two or more aligning layers of activities embedded in a medium, the 
activity in each source can only be determined if the ratio of activity per unit area in each 
source layer and a reference source is known.  The activity in the source layers can be 
determined through a system of simultaneous equations in terms of source activity per 
unit area, Ai.  
 The mathematical extensions provided by Thomas and Tsui require explicit 
knowledge of region thickness, attenuation coefficients, and activity ratios to determine 
individual activity distributions in an assembly of overlapping distributions. Clinically, 
knowledge of the activity ratios is usually not practical as such can generally be known 
only through use of invasive techniques.  
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2.3 Striatal Dopamine and Parkinsonism and Schizophrenia 
Early single-photon emission imaging studies of the striatal dopaminergic system 
indicated that assessment of radiopharmaceutical binding to dopamine transporters and 
D2 dopamine receptors in the striata provide a reasonable measure of dopamine 
production and transmission. As a result, single-photon emission imaging performed 
during the last two decades has been an integral part of in vivo studies investigating 
abnormal dopamine production and transmission in the striatal dopaminergic system. 
Parkinsonism, a collection of motor disorders, and schizophrenia, a neuropsychriatic 
disorder, are associated with abnormal dopamine production in the striatal dopaminergic 
system.  
Currently, diagnosis of Parkinsonism is primarily dependent on the expression of 
clinical symptoms and family history. Unfortunately, the various Parkinsonian disorders 
have very similar symptoms and the symptom presentations are usually in the later stages 
of the diseases. Parkinsonism imaging studies, especially Parkinson’s disease imaging 
studies, have demonstrated success in aiding in diagnosing the disease, studying the 
progression of the disease (i.e. longitudinal studies), and assessing drug therapy. These 
studies have been qualitative and quantitative. Quantitative studies are more accurate, 
especially in longitudinal studies, as disease progression can be relatively slow. 
Consequently, clinical quantitative nuclear medicine techniques are being developed to 
provide a more accurate assessment of dopamine production as it pertains to 
Parkinsonism.  
Single-photon emission studies of schizophrenia are performed to investigate the 
role of the striata in the pathology of the disorder as new hypotheses suggest that 
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excessive dopamine stimulation in the striata is not the primary reason for schizophrenia. 
Drug challenge imaging studies are also performed to evaluate the response of 
schizophrenic patients to neuroleptics. Many schizophrenia patients, who are clinically 
characterized to respond well to neuroleptics, do not do so. New neuroleptics are being 
produced to decrease side effects and increase symptom alleviation. Imaging studies are 
used to test and characterize these new drugs and their effects. 
The motivation of the development of the modified conjugate imaging technique is 
the quantitative assessment of radiopharmaceutical uptake in the striata with direct 
clinical application to pathology studies and care management research for Parkinsonism 
and schizophrenia. In the following section, the anatomy and function of the striata are 
presented as well as Parkinsonism and schizophrenia. The role of striatal dopamine in the 
manifestation of these disorders is also discussed briefly. 
 
2.3.1 Striata 
The striata are parts of the basal ganglia, a collection of nuclei in the cerebral 
cortex. The basal ganglia are anatomically symmetric. One set of nuclei in the basal 
ganglia is located in the left hemisphere and a second is located in the right hemisphere. 
Collectively, the left striatum and right striatum are referred to as striata. In transaxial and 
coronal views of the brain, the striata appear as two aligned structures. The striata are the 
input portal of the basal ganglia. A striatum consists of a putamen and a caudate nucleus. 
However, for the scope of this dissertation, neither the putamen nor the caudate nucleus is 
referred to individually; they are only referred to collectively as a striatum. In addition to 
the striata, the basal ganglia consist of the globus pallidus, substantia nigra, and 
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subthalamic nucleus. The substantia nigra are each divided into two sections – substantia 
nigra pars compacta and substantia nigra pars recticulata. Figure 2.16 is a detailed 
illustration of the physiological structure of the basal ganglia (The HOPES Brain Tutorial 
2003). The major tasks of the basal ganglia are to inhibit unwanted physical movement 
and to facilitate wanted physical movement. The basal ganglia receive input from the 
cerebral cortex and send information back to the cortex through the thalamus. There are 
two major pathways through the basal ganglia; one is direct, the other indirect. The direct 
and indirect pathways work together to legislate movement. The direct pathway 
facilitates movement and the indirect pathway inhibits movement. The amount of 
movement initiated is dependent on the activity in the direct and indirect pathways 
(Albin, Young et al. 1989; Mink 1996; Eidelberg 2003; Uhl 2003). Smooth movement is 
executed when the output from both pathways is in proper balance. 
Peripheral, but crucial, to these pathways is the nirgostriatal pathway. The 
nirgostriatal pathway aids in maintaining the balance between the direct and indirect 
pathways through the release of the neurotransmitter dopamine. Neurons project from the 
substantia nigra pars compacta to the neurons in the striata. The neurons originating in 
the substantia nigra pars compacta synthesize dopamine and store it in vesicles. In 
response to stimulation, dopamine is released into the synaptic cleft (Booij, Tissingh et al. 
1999). The dopamine crosses the synaptic cleft to bind with striatal dopamine receptors to 
stimulate the striatal neuron. The stimulated striatal neurons in turn send input to the 
direct and indirect pathways to modulate output from the basal ganglia (Albin, Young et 
al.; Mink). Figure 2.17 is a sketch of striatal neurons. 
The release and production of dopamine are facilitated by dopamine transporters 
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Figure 2.16. Illustration of the basal ganglia. The basal ganglia consist of the caudate 
nucleus, putamen, globus pallidus, subthalamic nucleus and substantia nigra. 
Anatomically, the basal ganglia only consist of the caudate nucleus, putamen, and the 
globus pallidus. The subthalamic nucleus and the substantia nigra are included because of 
their role in the function of the basal ganglia. The caudate nucleus and the putamen are 
collectively called the neostriatum; it is often called the striatum. Throughout the 
remainder of this dissertation striatum will be used to refer to the caudate nucleus and the 
putamen.  The substantia nigra is also divided into two components – the substantia nigra 
pars compacta (SNpc) and the substantia nigra recticulata (SNpr).(The HOPES Brain 
Tutorial 2003)
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Figure 2.17. Striatal neurons. The pre-synaptic terminal is the end of a dopaminergic 
neuron that projects from the substantia nigra pars compacta. The dopaminergic neuron 
produces dopamine and releases dopamine into the synaptic cleft in response to an action 
potential. The dopamine released into the synaptic cleft migrates and eventually binds to 
the D2 receptors located on the post-synaptic terminal of a striatal neuron. When enough 
dopamine has bound to the receptors, an action signal stimulates the striatal neuron. 
Dopamine left in the synaptic cleft is transported back to the pre-synaptic terminal of the 










transporter D2 receptor 
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(DAT) and dopamine receptors. Dopamine transporters are located on the ends of the 
neurons projecting from the substantia nigra pars compacta. This location is called the 
pre-synaptic terminal. Dopamine transporters aid in the release of dopamine into the 
synaptic cleft and are responsible for transporting the unused dopamine in the synaptic 
cleft back to the pre-synaptic terminal (Bourguignon, Pauwel et al. 1997; Uhl 2003). 
Dopamine receptors are located at the post-synaptic terminal of the striatal neurons. 
These receptors are the input portals of the striatal neurons. Dopamine binding to the 
receptors serves as a stimulus to the striatal neurons. Dopamine receptors have been 
categorized into at least five subtypes, which are classified into two classes, D1 and D2. 
Receptors in the D1 class are receptors D1 and D5. D2 class receptors are D2, D3, and D4.  
D1 and D2 receptors are the most abundant with their highest concentrations being in the 
striata (Bourguignon, Pauwel et al. 1997). D1 dopamine is released to stimulate the 
striatal neurons to send excitatory input to the direct pathway. D2 dopamine is released to 




Parkinsonism is a group of motor disorders associated with an abnormal loss of 
dopaminergic neurons in the nigrostriatal pathway. The group of motor disorders under 
the Parkinsonism moniker is often divided into four categories: primary Parkinsonism, 
secondary Parkinsonism, Parkinsonism-Plus syndromes, and heredodengerative 
disorders. Primary Parkinsonism is the most common form of Parkinsonism and is 
commonly referred to as Parkinson’s disease (PD). Until recently, the etiology of 
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Parkinson’s disease was unknown. But research in recent years suggests gene mutations 
might be the cause of Parkinson’s disease. Secondary Parkinsonism includes disorders 
with known causes. Examples of such disorders are vascular Parkinson’s disease and 
drug-induced Parkinson’s disease. Parkinsonism-Plus syndromes are disorders associated 
with other degenerative diseases, e.g., multiple system atrophy (MSA) and progressive 
supranuclear palsy (PSP). Heredodegenerative disorders are hereditary, e.g., Hunington’s 
disease.  
It is estimated that approximately 500,000 to 1.5 million people suffer from some 
form of Parkinsonism. Parkinsonism generally affects elderly people, but has been known 
to affect young and middle-aged adults. In an incidence study of Parkinsonism performed 
in Olmstead County, Minnesota, the average annual incidence rate of Parkinsonism is 
reported to be 114.4 per 100,000 people (Bower, Maraganore et al. 1999).  About 60-
85% of all cases of Parkinsonism are Parkinson’s disease. Secondary Parkinsonism 
accounts for about 8-10% of Parkinsonism; PSP and MSA are the next most common 
Parkinsonian syndromes (Albanese 2003; Mayo Clinic Staff). Pathological studies 
suggest that PSP represents 4.0-7.5% of all Parkinsonian disorders and MSA represents 
4-22% (Stacy and Jankovic 1992; Testa, Monza et al. 2001). Based on the same 
epidemiology study in Olmstead, Minnesota, the average annual incidence of PSP and 
MSA for ages 50-99 years is 5.3 and 3.0 per 100,000 people, respectively (Bower, 
Maraganore et al. 1999). 
Parkinsonism is the manifestation of the degeneration of dopaminergic neurons in 
the nigrostriatal pathway. Primary (Parkinson’s disease) and secondary Parkinsonism are 
characterized by the degeneration of the dopamine-producing neurons projecting from the 
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substantia nigra pars compacta. This results in the loss of dopamine and dopamine 
transporters; the transporters are located on the pre-synaptic terminal of these neurons. 
Parkinsonism-Plus syndromes are associated with the loss of striatal neurons, dopamine-
receiving neurons, as well as the dopamine-producing neurons in the substantia nigra pars 
compacta (Tatsch 2001; Seibyl 2003). 
Currently, clinical diagnosis of the specific forms of Parkinsonism is primarily 
predicated on the presentation of a combination of motor-deficient symptoms. These 
motor features are tremors at rest, bradykinesia (difficulty initiating movement), rigidity, 
postural instability, and a shuffling gait (freezing phenomenon) (Fahn 2003). Two or 
more of these symptoms must be present for a diagnosis of Parkinsonism and tremors at 
rest or bradykinesia must be one of the symptoms. Although the etiologies of the various 
forms of Parkinsonism are different, the presentation of symptoms is similar, especially 
in the early symptomatic stages. In addition, psuedoparkinsonism, motor disorders not 
associated with the degeneration of the nigrostriatal dopaminergic system, present with 
Parkinsonism-like symptoms. This overlapping of symptom presentation results in a 
moderate number of misdiagnosed cases.  
Pathological studies estimate that as many as 35 % of all PD cases clinically 
diagnosed have been erroneously characterized (Rajput, Rozdilsky et al. 1991; Seibyl 
2003). Early stages of PSP and MSA are commonly mistaken for PD.  It has been 
estimated that about 8% to 22% of clinically diagnosed PD cases are MSA cases (Schrag, 
Ben-Shlomo et al. 2002). Parkinson’s disease and essential tremor are frequently 
mistaken for one another. Some studies suggest that up to 25% of idiopathic Parkinson’s 
disease cases were actually essential tremor cases (Quinn 1994; Booij, Speelman et al. 
60  
2001). Conversely, patients in the early stages of idiopathic PD are often misdiagnosed 
with essential tremor, vascular PD, drug-induced PD, or Alzheimer’s disease (Seibyl 
2003). Misdiagnosis is an issue that has warranted concern due to the prognosis and 
treatment implications.  
Drug therapy has been used to mitigate the error of misdiagnosis between the 
various forms of Parkinsonism and other motor disorders. The response to the therapy is 
dependent on the motor disorder. Patients with early stage Parkinson’s disease respond 
well to the treatment. Patients with other forms of Parkinsonism or non-Parkinsonian 
motor disorders do not respond to the therapy. The most common drug therapy is 
levodopa, a dopamine-producing drug.  
 Due to the high incidence rate of Parkinson’s disease most treatment options for 
Parkinsonism are directed at the management and care of Parkinson’s disease. Patients 
with Parkinsonism-Plus syndromes have limited treatment options. The most common 
and widely clinically accepted Parkinson’s disease treatment is dopamine replacement 
using levodopa. Levodopa therapy decreases the symptoms of Parkinson’s disease. 
However, levodopa treatment is most beneficial in the early stages of Parkinson’s disease 
and provides on average five years of symptom relief. About 60% of patients using 
levodopa therapy experience sudden episodes of abnormal involuntary movements (Fahn 
2003). Dopamine agonists, drugs that readily bind to the dopamine receptors to simulate 
the neuron, have been used to manage Parkinson’s disease. Unfortunately, some of the 
side effects of dopamine agonists are hallucinations, confusion, and psychosis. The 
severity of these side effects increases with age. Neuroprotective treatments, techniques 
that protect the remaining dopaminergic neurons from degeneration, have been 
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researched but no technique developed thus far has been able to markedly stop 
progression of the disease.  
 
2.3.3 Schizophrenia 
Schizophrenia is a chronic neuropsychiatric disorder widely associated with 
hyper-production of dopamine. Clinically, schizophrenia is divided into five main types 
based on symptom expression. These schizophrenic types are hebephrenic type, catatonic 
type, paranoid type, undifferentiated type, and residual type. Hebephrenic schizophrenia, 
also referred to as disorganized schizophrenia, is characterized by hallucinations, 
delusions, incoherence, inappropriate laughter, and social withdrawal. Catatonic 
schizophrenia is characterized by motor disturbances that include alternating between 
immobility and wild excitement, decreased sensitivity to painful stimulus, and a decline 
in personal hygiene (Mental Health Channel 2004). Paranoid schizophrenia is 
characterized by delusions of persecution, anxiety, and violence. Undifferentiated 
schizophrenia is a schizophrenic type that is characterized by the expression of 
schizophrenic symptoms from more than one type of schizophrenia. Residual 
schizophrenia is characterized by the diminished expression of prominent schizophrenic 
symptoms. 
 Schizophrenia affects approximately 1% of the United States population. 
Typically, the onset of schizophrenia occurs in the late adolescent stage or early twenties. 
However, schizophrenia has been known to affect people 50 years old and below; 
occurrences in people above age 50 are rare. Full recovery is extremely rare. 
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Schizophrenic symptoms worsen after the onset of schizophrenia in approximately 75% 
of the people afflicted with schizophrenia (Mental Health Channel 2004).  
Clinically, schizophrenic symptoms are classified into two main groups - positive 
and negative. Positive symptoms are characterized as symptoms that generate distorted 
perceptions. Positive symptoms can be divided into the psychotic group and the 
disorganized group. Delusions and hallucinations make up the psychotic group. 
Disorganized thought and speech, inappropriate behavior and erratic behavior are 
examples of symptoms in the disorganized group (Andreasen 1995; Andreasen 1996). 
Negative symptoms are characterized by a reduction of normal function and behavioral 
deficits (Mental Health Channel 2004). Poor speech, lack of emotion, lack of energy, and 
a loss of interest are examples of negative symptoms. Schizophrenia is not defined by one 
symptom; schizophrenic symptoms are diverse and extensive. The World Health 
Organization and American Psychiatric Association compiled a symptomatic criterion-
based system for diagnosing schizophrenia (Andreasen 1995). If a patient exhibits two 
symptoms negative or positive, the patient can be diagnosed with schizophrenia. In the 
event that a patient exhibits a typical schizophrenic symptom, schizophrenia can be 
diagnosed. In either case, the symptom or symptoms must not be from another existing 
medical condition. 
 Although the causes of schizophrenia are unknown, several hypotheses have been 
proposed. The predominant hypothesis is the dopamine hypothesis (Carlsson and 
Lindqvist 1963; Creese, Burt et al. 1976; Sedvall and Farde 1995; Mann 1996; 
Frederickson 1998). The dopamine hypothesis suggests that schizophrenia is the 
manifestation of hyperactivity of dopaminergic function in the brain, specifically the 
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striata. Initial support of the dopamine hypothesis was indirect and based on the 
pharmacological studies of neuroleptic drugs. Neuroleptic drugs used to treat 
schizophrenia alleviate symptoms by blocking D2 dopamine receptors (Davis, Kahn et al. 
1991; Schwarz, Oertel et al. 1996; Harrison 2000; Depatie and Lal 2001; Strange 2001). 
Thus, it was deduced that people suffering from schizophrenia have excessive dopamine 
stimulation of dopamine D2 receptors. Post-mortem studies performed to investigate the 
hyperactivity of dopamine produced inconsistent results (Laruelle 2000). With the use of 
single-photon emission imaging, support the dopamine hypothesis now includes data that 
more directly reflects dopamine production and transmission in the brain of a 
schizophrenic patient. For the last couple decades, reports of imaging studies included 
data that support of the dopamine hypothesis. In 2000, Laruelle et al. reported increased 
dopamine transmission in schizophrenic patients in amphetamine-challenge imaging 
studies (Laruelle 2000). In 2000, Abi-Dargham et al. reported data that suggest increased 
D2 receptor stimulation in schizophrenia patients (Abi-Dargham, Rodenhiser et al. 2000). 
However, critics of the dopamine theory argue that the increase of dopamine activity is 
actually a response to long-term drug therapy (Toru, Kurumaji et al. 1994) . Lomeña et 
al. performed an imaging study between neuroleptic-naïve patients (those that have never 
taken neuroleptics) and neuroleptic-free schizophrenia patients (those that have 
previously taken neuroleptics) and found no difference in D2 receptor density. This 
suggests that drug therapy does not increase dopamine activity (Lomena, Catafau et al. 
2004). 
Although the dopamine hypothesis is the most popular theory to date, dopamine 
hyperactivity in the striata is mainly associated with the psychotic symptoms of 
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schizophrenia. Laruelle et al. reported findings that demonstrated a possible relationship 
between dopamine hyperactivity in the striata and the negative symptoms of 
schizophrenia. However, it is widely accepted that negative symptoms are not influenced 
by the hyperactivity of striatal dopamine. Thus, alone, the dopamine hypothesis is not a 
sufficient hypothesis; it does not address the schizophrenic patient sub-group that has 
psychotic symptoms and that does not respond to neuroleptic drug therapy. It also does 
not offer a pathological explanation for the manifestation of negative symptoms. A 
hypothesis has been proposed by several investigators to explain the pathology of both 
negative symptoms and positive symptoms (Weinberger, Berman et al. 1988; Davis, 
Kahn et al. 1991; O'Donnell and Grace 1998). Their hypothesis suggests the underlying 
cause of negative symptoms is dopamine hypo-activity in the prefrontal cortex. Positive 
symptoms are associated with dopamine hyperactivity in the striata (Laruelle 2000). 
 Treatment of schizophrenia is continuous and requires steady administration of 
medication. Currently, antipsychotic drugs are used commonly in the management of 
schizophrenia. These drugs are divided into the traditional and the atypical category. 
Traditional antipsychotic drugs block dopamine D2 receptors. A common traditional 
antipsychotic drug is haloperidol, commercially known as Haldol. Traditional 
antipsychotic drugs are most effective in suppressing positive or psychotic symptoms. 
However, traditional antipsychotic drugs produce tardive dyskinesia, a parkinsonism-like 
disorder, due to the blocking of D2 receptors. Not all schizophrenia patients respond to 
traditional neuroleptics. Atypical neuroleptics help about 50% of schizophrenic patients 
that do not respond well to traditional neuroleptics. Patients that express positive 
symptoms are more likely to respond to neuroleptics than patients that express negative 
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symptoms. Atypical antipsychotic drugs block primarily serotonin, nonrepinephrine, 
histamine, and other dopamine receptors. These drugs suppress negative symptoms as 
well as positive symptoms. A common atypical neuroleptic is clozapine. A common side 
effect of atypical neuroleptics is agranulocytosis, the significant loss of white blood cells. 
New atypical drugs that work similar to atypical drugs but have milder side effects are 
available. These drugs work by blocking D2 receptors and serotonin receptors. 
Risperidone and Olanzapine are new atypical antipsychotic drugs. 
 
2.4 Imaging the Striata 
 Critical to quantitative imaging studies is the selection and use of the appropriate 
radiopharmaceutical, especially for small tissue volumes, such as the striata. Selection of 
the right radiopharmaceutical is important because the properties of a 
radiopharmaceutical have a significant influence on the accuracy of measurements 
obtained using it. Imaging of the striata requires a radiopharmaceutical that participates in 
the physiological function of the nigrostriatal dopaminergic system without disruption. In 
addition, radiopharmaceuticals used to image the striatal dopaminergic system have a 
relatively high affinity for dopamine receptors or dopamine transporters, and have a low 
affinity for surrounding brain tissue (Halldin, Gulyas et al. 2001; Catafau 2003). These 
radiopharmaceuticals readily bind to the target area and unbind at a slow rate (low 
dissociation rate). This allows for adequate imaging time after equilibrium (steady-state 
condition) is reached to complete acceptable data acquisitions.  
To date, most radiopharmaceuticals used for single-photon emission imaging 
studies of dopaminergic neurotransmission have been labeled with the radioisotope 123I. 
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TRODAT, which is labeled with 99mTc, is the exception. Table 2.1 lists some 
radiopharmaceuticals used in dopaminergic investigations. The radiopharmaceuticals in 
bold print will be discussed in detail later in this chapter. Although 123I is rather 
expensive, it readily binds to several pharmaceutical agents that demonstrate high affinity 
to the dopaminergic system in the striata. It is because of this chemical reactivity that 123I 
is the principal radioisotope in striatal dopaminergic studies. 123I has the moderately short 
half-life of 13.2 hours. It has a primary photon emission of 159 keV at an abundance of 




Table 2.1. Radiopharmaceuticals used in single-photon emission imaging studies of 
dopaminergic neurotransmission in humans (Catafau 2003). 
Target Radioligand 













energies ranging from 248 to 783 keV. Figure 2.18 is a list of the energies and yields of 
the primary gamma emission and high-energy gamma emissions of 123I. Due to the high-
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energy emissions of 123I, special considerations need to be made, if radiopharmaceutical 
uptake in the striata is to be accurately assessed. High-energy emissions further 
complicate the problem of obtaining quantitative measurements as they have the potential 





















Figure 2.18. Percentage yield of I decays.123  The distribution of high-energy source 
emissions from the lungs and GI tract region was simulated according to the percentage 




through and/or scatter in the gamma camera’s collimator and interact in the scintillation 
crystal depositing energy in the photopeak. Such occurrences are referred to as 
downscatter. Downscatter degrades image quality, and more importantly, produces an 
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error in the estimation of the activity in the striata. The influence of downscatter from 
shielding and collimator penetration can be significant, when imaging patients suffering 
from Parkinsonism, in which the activity uptakes in the striata are small. The extent of 
contribution is dependent on several factors – shielding, scatter correction techniques 
employed, camera parameters, and radiopharmaceutical biodistribution. 
Approximately 85% of all imaging procedures in the United States are performed 
using a radiopharmaceutical labeled with 99mTc (Karesh 1996). As a result, nuclear 
medicine devices are designed to image 99mTc radiopharmaceuticals. Although 99mTc is 
the most common radioisotope used in nuclear medicine, it does not bind readily to 
presently used pharmaceutical agents exhibiting high affinity to the dopaminergic system. 
Consequently, most radiopharmaceuticals used in this context are not labeled with 99mTc. 
99mTc TRODAT is the exception. Pharmacological studies are currently being performed 
to investigate the chemical reactivity of 99mTc with other dopaminergic pharmaceuticals, 
because integration of a 99mTc radiopharmaceutical into a clinical setting is easier than the 
integration of an 123I labeled compound (Karesh 1996; Kung, Kung et al. 2003). 99mTc is 
readily available and relatively inexpensive. It has a half-life of 6 hours. Its principal 
photon emission is a 140 keV gamma with an abundance of 89%. 
 
2.4.1 Non-specific Binding 
In addition to striatal dopamine, non-neuronal dopamine can be found throughout 
the body as dopamine assists in regulation of gastrointestinal function, renal function, and 
respiratory function (Mezey, Eisenhofer et al. 1996; Pestana, Faria et al. 1997; Cabezas, 
Lezama et al. 2001; Cabezas, Israili et al. 2003; Tonini, Cipollina et al. 2004). 
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Consequently radiopharmaceutical uptake in the lungs, kidneys, gallbladder, and sections 
of the gastrointestinal tract is common. Radiopharmaceutical uptake in these organs is 
referred to as out-of- field of view (FOV) activity throughout the remainder of the 
dissertation. The degree of uptake depends on the specific radiopharmaceutical used. 
Out-of-FOV activity uptake of 123 I striatal radiopharmaceuticals poses as problem in 
quantitative studies because the higher energy photon emissions of 123I are sufficiently 
energetic to escape the body, scatter, and deposit energy into the photopeak window. The 
inclusion of these counts is especially problematic, when small FOV cameras are being 
used, such as a dedicated imaging system. Since the out-of-FOV activity is typically in 
the lungs and GI tract, the higher energy photons will most likely penetrate the gamma 
camera from the bottom. For clinical gamma cameras in which the FOV is larger, counts 
due to interactions of higher energy photons will be toward the bottom of the FOV away 
from the striatal and background ROIs used in modified conjugate imaging. But due to 
the smaller dimensions of small FOV gamma cameras, counts from higher energy 
photons are more likely to be included in the striatal ROI and background ROI.  
 
2.4.2 Pre- and Post-Synaptic Radiopharmaceuticals 
The radiopharmaceuticals used in the imaging of the dopaminergic system in the 
striata are categorized as pre-synaptic or post-synaptic. Pre-synaptic 
radiopharmaceuticals, also known as dopamine transporter (DAT) ligands, bind to the 
dopamine receptors located at the pre-synaptic terminal of the dopaminergic neuron. (The 
pre-synaptic terminal is the end of a neuron that projects from the substantia nigra pars 
compacta to the striatum. See section 2.3.) These radiopharmaceuticals are commonly 
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used to confirm the presence of Parkinsonism when clinical symptoms are ambiguous. 
Often patients with essential tremor or drug-induced Parkinson’s are diagnosed with 
some form of Parkinsonism because the symptoms are similar. Patients suffering from 
Parkinsonism, however, have fewer pre-synaptic dopaminergic nerve terminals due to 
degeneration of the dopaminergic neurons. Patients with essential tremor have normal 
amounts of pre-synaptic nerve terminals (Tatsch 2001). Thus, uptake of a dopaminergic 
radiopharmaceutical in a patient with Parkinsonism is considerably less than such uptake 
in a patient with essential tremor or drug-induced Parkinson’s. DAT ligands are also used 
for early and pre-clinical diagnosis of Parkinsonism. 
Post-synaptic radiopharmaceuticals bind to the D2 receptors located on the post-
synaptic terminal of a striatal neuron. These radiopharmaceuticals are used to distinguish 
between Parkinson’s disease and other Parkinsonism forms. Parkinson’s disease affects 
the pre-synaptic dopaminergic nerve terminals but does not affect the post-synaptic D2 
receptors. This is in contrast to what happens in other forms of Parkinsonism in which 
both the dopamine transporters and D2 receptors are affected (Tatsch 2001). Post- 
synaptic radiopharmaceuticals are also important in schizophrenia, as studies have found 
that some schizophrenic patients have excessive dopamine and D2 receptors. 
There are several pre- and post-synaptic ligands available for dopaminergic 
imaging in humans. See table 2.1. The biodistributions of four radiopharmaceuticals are 
used in the characterization and simulation of the modified conjugate imaging technique 
using a novel dedicated conjugate imaging system. The 123I radiopharmaceuticals, 123I β-
CIT, 123I FP-CIT, and 123I IBZM, are chosen based on commercial availability and type 
of radiopharmaceutical – pre- or post-synaptic.  Since 123I β-CIT, 123I FP-CIT, and 123I 
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IBZM are commercially available, European guidelines for nuclear medicine procedures 
exist (Tatsch, Asenbaum et al. 2002) . These guidelines are used in this study. 99mTc 
TRODAT is chosen due to its clinical promise and possible ease of integration into the 
clinic. 
 
2.4.2.1 Biodistribution of 123I β-CIT 
 Commercially known as DOPASCAN, 123I β-CIT has a high specific binding in 
the striatum (Seibyl, Wallace et al. 1994; Bourguignon, Pauwel et al. 1997; Messa, 
Volonte et al. 1998; Seibyl, Marek et al. 1998; Catafau 2003; Kung, Kung et al. 2003). 
Seibyl reports the striatal-to-occipital ratios for the right and left striatum to be 9.3 ±2.9 
and 10.3±3.5, respectively (Seibyl, Wallace et al. 1994).The European Association of 
Nuclear Medicine Procedure Guidelines recommends that image data acquisition occur 
18-24 hours post-injection. The recommended “standard” dose for an adult is 150-250 
MBq –  typically 185 MBq (5 mCi) (Tatsch, Asenbaum et al. 2002).The percent activity 
uptakes used in the simulation studies reported in this dissertation are taken from the 
biodistribution study performed by Seibyl et al (Seibyl, Wallace et al. 1994). The dose 
given in the study was 185 MBq within the recommended dose. The equilibrium time 
was taken to be approximately 21 hours, also within the recommended acquisition 
window. At the time of acquisition, the activity uptakes in the striata and brain are 2% 
and 10%, respectively of the initial activity administered. The percent uptake in the lungs, 
liver, and intestines is 21%, 25%, and 27%, respectively (Seibyl, Wallace et al. 1994). 
For the purposes of the simulation studies, the liver and small intestine uptakes are 
summed to get an overall activity uptake of 52%. 
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2.4.2.2 Biodistribution of 123I FP-CIT 
 123I FP-CIT, iodine-123-labelled N-ω-(fluoropropyl)-2β-carbomethoxy-3β-(4-
iodophenyl) tropane is an N-ω-(fluoropropyl) analogue of β-CIT. It is commercially 
known as DATSCAN. 123I FP-CIT has a relatively high specific binding in the striata 
(Booij, Sokole et al. 1998; Tissingh, Booij et al. 1998; Booij, Hemelaar et al. 1999; 
Benamer, Patterson et al. 2000; Booij, Speelman et al. 2001). Booij reports the ratios are 
2.24±0.32 (P<0.01) and 0.89±0.34 for healthy volunteers and Parkinson’s patients, 
respectively, when the ratios are computed three hours post-injection (Booij, Hemelaar et 
al. 1999). Although the specific binding of 123I FP-CIT is lower than that of 123I β-CIT, 
123I FP-CIT has faster kinetics, making one-day imaging protocols possible, which is 
advantageous for clinical settings (Seibyl, Marek et al. 1998; Tissingh, Booij et al. 1998; 
Booij, Hemelaar et al. 1999; Tatsch and Frey 2002). However, the smaller specific 
binding ratio and fast kinetics of 123I FP-CIT might decrease the accuracy in quantitative 
studies (Seibyl, Marek et al. 1998). The European Association of Nuclear Medicine 
Procedure Guidelines recommends that image data acquisition occurs 3-6 hours post-
injection. The recommended standard dose for an adult is 150-250 MBq – typically 185 
MBq (5 mCi) (Tatsch, Asenbaum et al. 2002). Figure 2.19 includes transaxial images of 
123I β-CIT and 123I FP-CIT uptake in the striata of a healthy individual and a Parkinson’s 
disease patient. 
The percent activity uptakes used in the simulation studies reported in this 
dissertation were taken from the 123I FP-CIT biodistribution study performed by Booij et 
al (Booij, Sokole et al. 1998). The simulated dose used is the recommended dose of 185 
MBq. The equilibrium time is taken to be approximately 3 hours. At the time of 
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equilibrium the activity uptakes in the striata and brain are 0.8% and 2.2%, respectively, 
of the initial activity administered. The percent uptakes in the lungs, liver, and intestines 






Figure 2.19. I β-CIT and I FP-CIT striatal activity uptake.123 123  SPECT axial images in 
healthy control subject and Parkinson’s disease patient. The same healthy subject and 
Parkinson’s disease patient were used for both radiopharmaceutical studies. For 123I β-
CIT study, 6 mCi of activity are given to both subjects. For the 123I FP-CIT study, 9 mCi 
of activity are given to both subjects. The striatal uptake for the Parkinson’s disease 
patients is markedly less than that of the healthy individuals. Reprinted by permission of 




studies, the liver and intestine uptakes were summed to get an overall activity uptake of 
36%. 
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2.4.2.3 Biodistribution of 99mTc TRODAT 
Technetium-99m TRODAT, technetium-99m 2-[[2-[[[[3-(4-chlorophenyl)-8-methyl-8-
azabicyclo[3,2,1]oct-2-yl]-methyl](2-mercapto-
ethyl)amino]ethyl]amino]ethanethiolato(3-)]-oxo-1R-(exo-exo)]-) is a relatively new pre-
synaptic (DAT) ligand. Animal and human studies have shown that TRODAT readily 
binds to the dopamine transporters in the striata (Kung, Kim et al. 1996,2001; Meegalla, 
Plossl et al. 1997; Mozley, Stubbs et al. 1998; Fang, Wu et al. 2000; Tzen, Chin-Song et 
al. 2001). Huang performed a study on healthy controls and Stage I and II Parkinson’s 
disease patients and reported specific uptake values in the striatum of 1.98±0.24, 
1.62±0.11, and 1.22±0.12, for the healthy controls and Stage I and II Parkinson’s disease 
patients, respectively. The transaxial slices in figure 2.20 represent specific uptakes in 
controls and Parkinson’s disease patients (Huang, Lin et al. 2001). Huang chose to use 
the occipital region as the reference region. The occipital region has low uptake of 
TRODAT. Occipital data can be easily compared to striatum data from the same slice. 
Imaging took place 165 to 195 minutes post-injection (Huang, Lin et al. 2001). The 
administered dose was 740 MBq (20mCi) (Mozley, Schneider et al. 2000; Huang, Lin et 
al. 2001). The critical organs in healthy men and women controls were the liver, kidney, 
and the upper large intestine (Kung, Kim et al. 1996; Mozley, Stubbs et al. 1998). 
Human biodistribution studies focus on reporting radiation dosimetry. Animal 
studies concentrate on absolute activity uptake in organs, as invasive procedures are 
required in obtaining uptake information. As a result, the activity uptake information used 
in this dissertation is from animal studies (Meegalla, Plossl et al. 1997; Fang, Wu et al. 
2000). Fang et al. reported striata uptake as percent uptake per gram and the brain uptake 
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as percent uptake per organ. The striata percent uptake used in the reported simulation 
studies was determined by multiplying the striata uptake and mass of the simulated 
striata. Assuming equilibrium is reached at about 60 minutes post injection, the percent 
uptakes of initial activity used in the reported simulation studies in the striata and brain 





Figure 2.20. Tc TRODAT-1 striatal activity uptake.99m  SPECT axial images of Tc99m -
TRODAT-1 uptake for healthy volunteer (A) and of patients with Hoehn and Yahr scale 
stage I (B) and stageII (C) Parkinson’s disease. The Hoehn and Yahr scale (HYS) is a 
clinical classification system used to asses Parkinson’s disease. The HYS divides 
Parkinson’s disease into 6 stages. Stages I and II are classified as mild disease. Stage I is 
characterized by unilateral involvement. Stage II is characterized by bilateral disease 
involvement. A decrease in activity is apparent for the Parkinson’s disease patients. 
Asymmetrical activity uptake is also apparent for the Parkinson’s disease patients. 






these studies because the photon emissions from these activity distributions are assumed 
to have negligible influence on the quantitative studies performed. The dose used in the 
studies was 740 MBq. 
 
2.4.2.4 Biodistribution of 123I IBZM 
 123I IBZM, iodine-123 ((S)-(-)-2-hydroxy-3iodo-6-methoxy-N [(1-ethyl-2-
pyrrolidinyl)methyl] benzamide), is used to study dopamine systems, specifically those in 
Parkinsonism and schizophrenia patients (Tatsch and Frey 2002). The specific uptake 
ratio in the striata is relatively high (Kung, Alvai et al. 1990; Seibyl, Woods et al. 1992; 
Knable, Jones et al. 1995; Leslie, Abrams et al. 1996; Schwarz, Oertel et al. 1996; 
Leenders 2003; Lomena, Catafau et al. 2004). IBZM accumulates readily in the striatum, 
brain, large intestine, liver, spleen, and bladder. The critical organs are the wall of the 
large intestine, the spleen, and the wall of the urinary bladder (Kung, Alvai et al. 1990). 
The European Association of Nuclear Medicine reports the critical organs to be the 
thyroid and the bladder wall. The European Association of Nuclear Medicine Procedure 
Guidelines state the “standard” dose for an adult is 150-250 MBq – typically 185 MBq 
(5mCi) (Tatsch, Asenbaum et al. 2002). It is recommended that data acquisition begin 
1.5-3 hours post-injection. Figure 2.20 is the image of 123I IBZM activity uptake in the 






Figure 2.21 I IBZM striatal activity uptake123 . Planar image of 123I IBZM uptake in the 
striata of a healthy subject two-hour post-injection. Striatum-to-frontal cortex uptake ratio 
was 1.73. Reprinted by permission of the Society of Nuclear Medicine from (Leslie, 




The activity uptakes used in this dissertation are taken from the biodistribution 
study reported by Kung et al (Kung, Alvai et al. 1990). The percent uptakes reported are 
for two hours post-injection. The activity uptakes in the brain, striata, lungs, liver, small 
intestine, and gall bladder are 2%, 1.7%, 8.1%, 9.6%, 14.2%, and 3.8%, respectively. For 
the purposes of the simulation studies, the liver, small intestine, and gall bladder uptakes 
are summed to get an overall activity uptake of 27.5%. Kung reports a brain activity 
uptake of 3.72% two hours post injection (Kung, Alvai et al. 1990). This brain activity 
uptake is for the whole brain, including the striatum. The striatum uptake is determined 
by volume analysis and volume estimates provided in the text of the biodistribution 
study.  
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Chapter 3  
 




As discussed in chapter 2, classic conjugate imaging has been successfully 
applied to the estimation of activity in a single source and to the estimation of the sum of 
activities in multiple sources embedded in an attenuating medium. This estimation of 
activity is independent of source depth. Thomas and Tsui expanded classic conjugate 
imaging techniques to the estimation of activity in multiple sources aligned and 
embedded in an attenuating medium (Thomas, Maxon et al.1976; Tsui, Chen et al. 1981). 
Their formulations, however, require a priori knowledge of activity ratios between the 
sources. Obtaining such activity ratios usually requires invasive procedures; a 
requirement that renders the technique clinically difficult at best. 
Presented in this chapter is a mathematical formulation for estimation of the 
activities in each of two aligned sources embedded in a uniformly attenuating medium. 
The formulation does not require knowledge of the activity ratio between the sources. 
However, it does require that the depth of each source be known. The requirement of 
depth measurements introduces new variables as well as complexity as compared to 
analysis of conjugate imaging. Nonetheless, data acquisition is the same as that for 
classic conjugate imaging; two emission, two transmission, and two camera sensitivity 
data sets. The motivation for development of this extension is quantification of specific 
activity uptake in the striata in Parkinsonism and schizophrenia studies. Thus, the 
physical model used to formulate this extension is based on the anatomy of the brain, the 
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striata, and the specific and non-specific binding of radiopharmaceuticals used in imaging 
the striata.  
 
3.1 Geometric Models 
3.1.1 A Model of Striata and Head 
Figure 3.1 is an illustration of a model representing activity uptake in the striata 
and in the surrounding brain tissue. The model consists of the skull, brain tissue, and the 
striata. The brain tissue has a total thickness T. The skull is represented by thicknesses t0 
and t6 with attenuation coefficients µ0 and µ6, respectively. The brain tissue is segmented 
into sections of thicknesses t1, t2, t3, t4, and t5 with attenuation coefficients of µ1, µ2, µ3, 
µ4, and µ5, respectively. The striata are represented by thicknesses t2 and t4. The 
nonspecific activities in the sections of brain tissue surrounding the striata are represented 
as A1, A3, and A5. The activities in the striatal regions are represented as A2 and A4. 
Activity A2 is the sum of the specific activity and the nonspecific activity in the relevant 
volume. Similarly, A4 is a sum of specific and nonspecific activity  
 
3.1.2 Simplified Model of Striata and Head 
To obtain a more tractable model of striata and head, several assumptions are 
made about the characteristics of the brain and the striata of the model illustrated in 
figure 3.1. Assuming that the nonspecific activity concentration is constant throughout 
the brain tissue, the nonspecific activities in the sections of brain tissue are proportional 






Camera L Camera R
t1t0 t6t2 t5t3 t4
A2,µ2 A3,µ3 A4,µ4µ0 µ6  
Figure 3.1. Seven-volume model of the head. Volumes 0 and 6 represent the skull. 
Regions 1, 3, and 5 represent the brain tissue excluding the striata. Regions 2 and 4 




The total nonspecific activity in the brain is the sum of A1, A3, A5, and the percentages of 
A2 and A4 representing the nonspecific activities in the striatal regions. The nonspecific 
activity in the brain tissue is referred to as background activity throughout the remainder 
of the dissertation.  
The self-attenuation correction factor of a source with a thickness of 3 cm that 
emits 140 keV photons has less than 1% effect. Since the thickness of each striatum in 
humans is on average 3 cm, the activity distributions in the striatal regions are treated, in 
this model, as if the activity was concentrated in the middle of each striatal region 
(Hokama, Shenton et al. 1995; Mintzer, Aarsvold et al. 2000). The brain consists of soft 
tissue regions with similar attenuation coefficients. As a result, it is assumed the brain 
tissue is a single attenuating medium with a constant attenuation coefficient.  
The application of these assumptions is illustrated in figure 3.2. The total brain 
thickness is denoted T. The skull is represented by thicknesses tL and tR; the subscripts L 
and R denote the left and right sides, respectively. The attenuation coefficient for skull is 
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denoted µb. The attenuation coefficient for the brain tissue is denoted µ. The uniformly 
distributed background activity in the brain tissue is denoted AB. The specifically bound 
activities in the striata are denoted A1 and A2. The depth of A1 is d1 as measured from the 
left edge of brain tissue. The depth of A2 is d2 as measured from the right edge of brain 
tissue. The distance between the striatal activities is denoted s. The brain model depicted 
in figure 3.2 is the basis for the work presented in the dissertation. It is used to formulate 












Figure 3.2. Simplified seven-region model. The activity in sections 1, 3, and 5 in figure 
3.1 represent non-specifically bound activity AB. This activity is referred to as 
background activity and is uniformly distributed throughout the brain. Activities A1 and 
A2 represent the sum of specifically bound activity in the striata and background activity. 
The specific activity distributions in the striata are planar as the thickness of the striata is 




3.2 Parameters Required 
Using conjugate imaging to estimate the activity in each of two aligned sources 
requires knowledge of the striatal depths d1 and d2, the brain thickness T, the skull 
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thicknesses tL and tR, and the attenuation coefficient of the skull µb. Computed 
tomography or magnetic resonance imaging can be used to determine a head thickness, 
depths of the striata, and skull thicknesses. The skull attenuation factors can be 
determined alternatively from skull thickness measurements and an empirically 
determined bone attenuation coefficient. The techniques employed to obtain 
measurements of these parameters are not the focus of this discussion and will not be 
discussed further. For this discussion, it is assumed that the striatal depths d1 and d2, the 
brain thickness T, the skull thicknesses tL and tR, and the attenuation coefficient of the 
skull µb have been determined. 
 
3.3 Pixel-based Computations and Analyses 
In conjugate-imaging data acquisition, each pixel in each emission, transmission, 
and flood projection represents the fraction of the imaged object that corresponds to the 
volume of the object from which the pixel records data. Thus, all activities, sensitivities, 
transmission factors and thicknesses are implicit functions of pixel location. The count 
data acquired from emission, transmission, and flood acquisitions are often referred to as 
maps. Conjugate imaging calculations are performed independently for each pixel within 
these maps. As a result, the conjugate imaging technique is implicitly pixel dependent. 
However, some desired quantities, e.g., total activity in each striatum, require that the 
values in a range of pixels delineated by regions of interest (ROIs) be summed or 
averaged. The ROIs used in the modified conjugate imaging technique are a striatal ROI 
and a background ROI. The striatal ROI is defined on an image or data set by delineating 
a region of inclusion of striatal pixels. The background ROI is a set of pixels defining 
brain tissue that does not include the striata.  
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All count maps are normalized and decay-corrected to yield count rate maps at a 
common time. The number of counts collected in a pixel between times t1 and t2, relative 









0 ,   (3.1) 
 
where N is the number of counts collected; C is the pixel sensitivity in counts per unit 
time per unit activity; Ao is the activity at time to; t1 and t2 are the start count acquisition 
time and end count acquisition time, respectively; and τ is the mean lifetime of the 
radioisotope. The normalized, decay corrected count rate at time to represented by 
measured count N is 
 










NCAN .  (3.2) 
 
The denominator in equation 3.2 is referred to as the normalization factor. This factor is 
determined using a reference time to. Each count map is divided by the appropriate 
normalization factor to obtain the corresponding decay-corrected count rate map.  
 
3.4 Conjugate Imaging of Two Aligned Sources 
 As with classic conjugate imaging, two emission, two transmission, and two flood 
count map data sets are acquired in the conjugate imaging of two aligned sources. 
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However, the data analysis used in determining the activity above background activity 
(the striatal specific activity minus the non-specific activity) in each of the two aligned 
sources is quite different from that used in classic conjugate imaging. In this section, the 
data analysis in conjugate imaging of two aligned sources is discussed.  
The emission data in conjugate imaging of two aligned sources, as in classic 
conjugate imaging, are measurements of the attenuated activity of the sources inside the 
object.  The emission data are used to determine the activity in the striata above the 
background activity. The emission count maps of the model in figure 3.2 in the striatal 
ROI are expressed as 
 
( )( )BeAeAkCE sddLLL ++= +−− 11 21 µµ   (3.3) 
( )( )BeAeAkCE dsdRRR ++= −+− 22 21 µµ , (3.4) 
where       (3.5) LtL ek
µ−=
     ,   (3.6) LtL ek
µ−=
 
EL and ER are the emission data from the left and right cameras, respectively; CL and CR 
are the camera sensitivities in the left and right cameras, respectively; kL and kR are the 
transmission factors through the left and right skull thicknesses, respectively; A1 and A2 
are the specific-uptake activities in the left and right striata, respectively; µ is the 
effective attenuation coefficient of the brain tissue; d1 and d2 are the depths of the left and 
right striata, respectively; s is the distance between the two striata; and B is the effective 
background activity.  










= ,   (3.7) 
 
where AB is the true background activity, fT is the self-attenuation correction factor of the 
brain, and e-µT/2 is the transmission factor through one half the brain thickness T.  
The measured activities from the left and right gamma cameras corrected for skull 





















µµ .  (3.9)  
 
The background activity in the striatal ROI is subtracted from the total activity in the 
striatal ROI to yield the sum of measured activities above background in each striatum. 
The specific activities as measured by the left and right gamma cameras within the 
striatal ROI, respectively, are thus defined as 
 
   ( ) ( )sdd
strLL
eAeABAA +−− +=−≡ 11 21
µµδ   (3.10) 
   ( ) ( ) 22 21 dsdstrRR eAeABAA µµδ −+− +=−≡ ,  (3.11) 
 
where <B>str  is the average background activity within the striatal ROI. Equations 3.10 





































= .   (3.13) 
 
These expressions represent the activity in each pixel in the striatal ROI. These activities 
are summed over the striatal ROI to yield the total activity in each striatum. The total 















22 ,    (3.15) 
 
where U1 and U2 are the total activity measured in each striatum; A1 and A2 are the 
activities of each striatum; and the summation indices i and j indicate pixel location.  
The background activity in the striatal ROI is determined from the background 
activity in a ROI defined in a region on the acquired data that contains only background 
activity. In a background-only ROI where A1 and A2 equal zero, the emission count maps 
are 
 
    BkCE LLL =     (3.16) 




where B is the effective background activity. Equation 3.7 describes effective background 
activity, taking into account self-attenuation. The measured background activities BL and 
BR in the background-only ROI as measured by the left and right gamma cameras, 









EB ≡ .    (3.19) 
 
The average background activity B for each pixel in the background-only ROI, is 
determined by taking the geometric mean of BL and BR 
 
( ) 21RL BBB = .    (3.20) 
 
The background activity values determined for the pixels in the background-only ROI are 
then averaged to yield an average measured background activity <B>bkgd.  From equation 













If the average brain tissue thickness imaged by the pixels in the striatal ROI is 
equal to that imaged by the pixels in the background-only ROI, the average measured 
background activity in the background-only ROI is equal to the averaged background 
activity in the striatal ROI.  If the average brain tissue thickness imaged by the pixels in 
the striatal ROI <T>striatal is different from that imaged by the pixels in the background 
ROI <T>bkgd, the average measured background activity in the striatal ROI is computed 
by scaling the average total background activity in the background ROI with the average 







AA = ,  (3.22) 
 
where <AB>str is the average background activity in the striatal ROI; <AB>bkgd is the 
average background activity in the background-only ROI; <T>str is the average brain 
tissue thickness within the striatal ROI; and <T>bkgd is the average brain tissue thickness 
imaged by the background-only ROI. The measured average background activity in the 
striatal ROI is then  







= .  (3.23) 
 
The two flood count maps are acquired to calculate the camera sensitivities of the 




FLL ACF =     (3.24) 
FRR ACF = ,    (3.25) 
 
where FL and FR are the flood counts from the left and right gamma cameras; CL and CR 
are the camera sensitivities for the left and right cameras, respectively; AF is the activity 
in the flood.  
The transmission data are acquired for use in the calculations of the effective 
attenuation coefficient of the brain. This differs from the classic conjugate technique in 
that a map of effective attenuation coefficient µeff is desired instead of a map of 
transmission factor e-µT of the object. During acquisition of transmission data, the camera 
is detecting photons from the flood that are attenuated by the skull thicknesses tL and tR 
and the brain thickness T. The transmission data are acquired after the injection of the 
radiopharmaceutical. As a result, the transmission images will include counts 
representing transmission and emission gammas. The emission data are subtracted from 




µ−=    (3.26) 
T
RLRR ekkFT
µ−= ,   (3.27) 
 
where TL and TR are the transmission counts acquired by the left and right cameras, 






µ−=     (3.28) 
Rbt
R ek
µ−= .    (3.29) 
Although not necessary, the following assumption is made to simplify some of the 
discussion. It is assumed 
 
bRL ttt == ,    (3.30) 
 
that is, it is assumed that the left and right skull thicknesses are equal. Calculation of the 











= − −⎜ ⎟
⎝ ⎠
.  (3.31) 
 
The skull transmission factors and the attenuation coefficient maps are then used in the 
emission data equations. 
The sum of the two specific uptake activities A1 and A2 can also be determined 
using the same sets of acquired data – emission, transmission, and flood. This 
corresponds to use of classic conjugate imaging for determination of the sum of activity 
of multiple aligned sources. 
As previously discussed in this section, the background activity in the striatal ROI 
<B>str is subtracted from the striatal and background activity emission data in the striatal 
ROI. The resulting emission data in the striatal ROI as measured by the left and right 




( )( )sddLLstrLLLL eAeAkCBkCEE +−− +=−≡ 11 21' µµ   (3.32) 
( )( )22 21' dsdRRcaudRRRR eAeAkCBkCEE µµ −+− +=−≡ ,  (3.33) 
 
where EL′ and ER′ are the left and right specific activities above background activity in 
the striatal ROI.  
The combination of Equations 3.32 and 3.33 leads to the expression of the sum of 




















































TTekk µ .    (3.35)  
 
Equation 3.34 is essentially the classic conjugate imaging equation with a source 
separation correction factor (the second factor on the right-hand side of the equation). 
The expression is similar to equation 2.9 in Chapter 2. If the distance between two 
aligned sources, denoted as s, is reduced to zero, equation 3.34 reduces to the classic 
conjugate imaging equation for a single source. The magnitude of source separation 
influences the accuracy of the estimation of total activity. A large source separation 
results in an overestimation of the total activity.  
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The total striatal activity is obtained by summing the values of the pixels in the 
striatal ROI, which were determined using equation 3.34. The total activity in the striatal 








21 ,    (3.36) 
 
where UT is the total activity; A1 and A2 are the specific activity uptakes in the striata; and 
the summation indices i and j indicate the pixel location. The total activity calculation 
does not require precise knowledge of the brain tissue attenuation coefficient µ or of the 
depths of the striata.  
 
3.5 Error Analysis 
Regardless of technique, quantitative analysis of radiotracer uptake is associated 
with sources of error. These errors are due to counting statistics, depth dependent 
blurring, partial-volume effects, detection of scattered radiation, and possible error in 
measurement of the standard and/or administered activities. The conjugate imaging 
method presented in this chapter requires the estimation of several parameters. In 
addition to usual sources of error associated with estimating radiotracer uptake, errors in 
these estimated parameters may propagate error and further limit accuracy. The 
parameters of concern are the skull attenuation coefficient µb, the skull thickness tb, the 
total brain-tissue thickness T, and the depths of the centers of striata, d1 and d2.  
Error in the estimation of µbtb affects the determination of the average effective 
brain-tissue attenuation coefficient µ and calculation of the left and right specific activity 
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maps δAL and δAR. Error in T also effects the determination of µ. Errors in µ, δAL, δAR, 
d1, and d2 result in error in the estimation of A1 and A2 and ultimately in the estimates of 
the total specific activity uptakes U1 and U2.  
The skull attenuation coefficient µb needs to be determined either by scaling the 
attenuation coefficient measured with tissue-equivalent material by a factor appropriate to 
the different compositions of tissue and skull matter or by actual experiments on samples 
of skull material. The thickness of the head, which is T+2tb, can be measured externally. 
A computed tomography scan of the head is required to estimate accurately the 
dimension of the skull thickness tb and the depths of the striata d1 and d2. A database of 
these dimensions as a function of externally accessible measurements for primates or 
humans could be used. However, using dimensions from such a database might increase 
uncertainties in these quantities. 
 
3.5.1 Uncertainty of Bone Attenuation Coefficient µb  
















−= .   (3.37) 
  
This equation is used to determine the effective attenuation coefficient of brain tissue. 
(Refer to equation 3.31.) The last term 2µbtb represents and removes the attenuation of 
the skull. To estimate the error in µ due to uncertainties in µbtb typical values for skull and 
brain thicknesses and an estimate of µb of primates and humans are used. The skull and 
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brain thicknesses are assumed to be 5 mm and 10 cm, respectively. Using attenuation 
measurements of 140 keV photons in water published by Thomas et al. the skull 
attenuation coefficient µb is determined to be approximately 1.3µ (Thomas, Maxon et al. 
1976).  The 2µbtb term results in about a 13% correction to µT using a 5 mm skull 
thickness, a 10 cm brain thickness, and a skull attenuation coefficient of 1.3µ. A 20% 
overestimate of µbtb would cause about a 2.5% underestimate of µT. Error in the 
measurement of brain thickness T would also affect the accuracy of the value for µ. 
However, assuming that the determination of T to within 1 or 2% is possible, the total 
uncertainty in µ can be kept less than 5%. 
 Uncertainties in the specific-uptake activity maps δAL and δAR due to errors in 
µbtb are estimated using the same values for the estimation of error in µ. A 20% 
overestimation of µbtb causes less than 2% underestimates of δAL and δAR. Due to this 
uncertainty, we expect estimation of µbtb, T, and µ to result in an error of less than 2% in 
U1 and U2. 
 
3.5.2 Uncertainty of A1-to-A2 Ratio 
The uncertainty in the activity in each striatum A1 and A2, due to errors in µ and 
errors in the depth measurements d1 and d2, can be expressed as a function of the ratio of 
































where A1 and A2 are the activity uptakes in the striata and δAL and δAR are the left and 
right measured specific-uptake activities in the striatal ROI, respectively. Assuming d1 
















1    (3.39) 








= ,    (3.40) 
 
where r is the ratio of measured specific activities in the striatal regions as detected by the 
left and right gamma cameras. Assuming the activities of the sources to be at least the 
background activity (A1 ≥ 0, A2 ≥ 0), the ratio of measured specific activities r is limited 
by the attenuation coefficient µ and distance between the two aligned source distributions 
s. The actual relationship is eµs ≥ r ≥ e-µs.  For the values of µ ≈ 0.14 cm-1 and s ≈ 2cm, r 
ranges from about 0.76 to 1.32. The ratio ranges from 0.8 to 1.2 for striatal uptake ratios 
of 1:5 to 5:1.  For values of µ ≈ 0.15 cm-1 and s ≈ 2 cm, r ranges from about 0.7 to 1.2 for 
activity ratios of 1:5 to 5:1. 
 
3.5.3 Uncertainty of Brain Tissue Attenuation Coefficient µ 











































where ∆A1/A1 is the fractional uncertainty; d is the depth of each striatum; s is the 
separation distance between the striata; r is the ratio of the left and right measured 
specific-uptake activities; and ∆µ is the uncertainty in µ. We have assumed that d1 and d2 
are equal and have a value d. Assuming T ≈ 10 cm, tb ≈ 5 mm, d ≈ 4 cm, s ≈ 2 cm, and µ 
≈ 0.142 cm-1, we find that a 2.5% underestimate in µ causes an underestimate of A1 from 
less than 1% to about 7% for the values of r corresponding to activity ratios of A1 to A2 
from 5:1 to 1:5.  
 Due to the symmetry of the problem, and thus of the expressions for A1 and A2, 
the uncertainty in A2 can be found by using the reciprocal value of r. The fractional 











































Assuming T ≈ 10 cm, tb ≈ 5 mm, d ≈ 4 cm, s ≈ 2 cm, and µ ≈ 0.142 cm-1, a 2.5% 
underestimate in µ causes an underestimate of A2 from about 7% to about 2% for the 
values of r corresponding to activity ratios of A1 and A2 from 5:1 to 1:5. For activity 
ratios not equal to one, larger percentage errors occur in estimates of the smaller of the 




3.5.4 Uncertainty of Position 
 This section discusses the uncertainty in A1 and A2 due to the errors in the 
measurements of s, the separation between the two striata, and the depths d1 and d2 of the 
striata. The total thickness of T is assumed to be constant and expressed as 
 
sddT ++= 21 .   (3.43) 
 
With T held constant, an error in one of the parameters will result in errors in one or both 
of the other parameters. The error analysis in this section exploits this relationship 
between s, d1, and d2. 






































1 , (3.44) 
 
where ∆A1/A1 is the fractional uncertainty; s is the separation distance between the striata; 
r is the ratio of the left and right measured specific-uptake activities; µ is the attenuation 
coefficient of the brain tissue; and ∆s is the uncertainty in s. A measurement of s with an 
error of plus or minus one millimeter (± 1 mm) results in an error in A1 of less than 0.5% 
to about 10% for the values of r corresponding to activity ratios from 5:1 to 1:5.  
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The uncertainty in A2 due to error in the measurement of separation distance s can 
be found by using the reciprocal value of r. The fractional uncertainty in A2 due to the 







































2 . (3.45) 
 
A measurement of s with an error of plus or minus one millimeter (± 1 mm) results in an 
error in A2 of less than 10% to about 0.5% for the values of r corresponding to activity 
ratios of A1 and A2 from 5:1 to 1:5.  
The fractional uncertainty in A1 due to an uncertainty in the d1 measurement is 
 

























,  (3.46) 
 
where ∆A1/A1 is the fractional uncertainty; s is the separation distance between the striata; 
µ is the attenuation coefficient of the brain tissue; and ∆d1 is the uncertainty in d1. The 
fractional uncertainty of A1 due to error in the estimation of the position of d1 is 
independent of r. A measurement of d1 with an error of plus or minus one millimeter (± 1 
mm) translates to approximately a 5% error in A1.  
The fractional uncertainty in A1 due to an uncertainty in the d2 measurement is 
 




























,  (3.47) 
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where ∆A1/A1 is the fractional uncertainty; s is the separation distance between the striata; 
r is the ratio of the left and right measured specific-uptake activities; µ is the attenuation 
coefficient of the brain tissue; and ∆d2 is the uncertainty in d2. A measurement of d2 with 
an error of plus or minus one millimeter (± 1 mm) results in an error in A1 of about 1% to 
about 5% for the values of r corresponding to activity ratios from 5:1 to 1:5. 
 Due to the symmetry of the problem, the fractional uncertainty in A2 due to 
measurement errors in d2 is expressed as 
 

























.  (3.48) 
 
The fractional uncertainty of A2 due to error in the estimation of the position of d2 is not 
dependent on the measured specific activities in the striatal regions, and thus, is 
independent of r. A measurement of d2 with an error of plus or minus one millimeter (± 1 
mm) results in about a 5% error in A2 for activity ratios of A1 and A2 from 5:1 to 1:5. 
Similarly, the fractional uncertainty in A2 due to measurement errors in d1 is 






























.  (3.49) 
 
The fractional uncertainty in A2 due to uncertainty in d1 is dependent on r. A 
measurement of d2 with an error of plus or minus one millimeter (± 1 mm) results in an 
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error in the A1 of about 5% to about 25% for the values of r corresponding to activity 
ratios of A1 and A2 from 5:1 to 1:5.  
 Assuming AL and AR do not vary greatly over the striatal ROI, these fractional 
uncertainties are estimates of the fractional uncertainties in U1 and U2. The fractional 
uncertainties in U1 and U2 due to positioning error are summarized for the values used 
throughout this error analysis section in table 3.1. For activity ratios not equal to one, the 
larger percentage error is associated with the estimation of the smaller of the two 
activities. 
The above error analysis indicates that reasonable accuracy can be achieved for 
the case of approximately equal uptakes. Estimates of the smaller of the two activities 
become increasingly less certain as the ratio between the two activity uptakes deviates 
from one. Table 3.2 lists all the sources of error discussed and gives estimates of the 




Table 3.1 Positioning Errors 
Type and magnitude of positioning error U1/U2 -  1
% Error in U1, U2
U1/U2 -  2 U1/U2 -  5
± 1mm error in separation s; d1, d2 constant   1.3%,  2.4% ± ±  0.1%,  0.1% ± ±   2.1%,  9.8% ± ±
± 1mm error in depth d1; d2 constant   5.1%,  4.9% ± ±
± 1mm error in depth d2; d1 constant   4.9%,  5.1% ± ±
  5.1%,  9.9% ± ±   5.1%,   25% ±  ±






Table 3.2 Summary of Errors 
Source of error Estimate of error U1/U2 -  1
% Error in U1, U2
U1/U2 -  2 U1/U2 -  5
estimation of µbtb ±20%
  2.5% in µ±
 ⇒
 ⇒
±  2.0% in δΑL,δΑL
  0.7%,  6.7% ± ±
measurement of T 
(± 2 mm) ±2.0% ⇒   2.0% in µ±
measurements of caudate positions, worst case 
error in depth d1, ± 1mm; d2 constant
  1.7%,  1.7% ± ±   1.1%,  3.0% ± ±
  0.6%,  5.3% ± ±  1.4%,  1.4% ± ±   0.9%,  2.4% ± ±
  2.0%,  2.0% ± ±
  5.1%,  4.9% ± ±   5.1%,  9.9% ± ±   5.1%,   25% ±  ±
Total uncertainty due to parameter measurement 
and estimation errors   10%,  10% ± ±   9.1%,  17% ± ±   8.4%,  39% ± ±  
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Chapter 4  
 




Phantom studies are conducted to characterize the accuracy of conjugate imaging 
applied to the estimation of two activities in two aligned sources, embedded within a 
uniformly attenuating medium. A quantitative SPECT study is also conducted to compare 
the accuracy of current clinical SPECT to that of the conjugate imaging technique. In 
addition, the sum of the two activities are calculated and compared to the sum of the 
activities calculated by standard conjugate imaging. The ratio of activity concentrations 
in each source and surrounding medium are varied to simulate the striatal activity uptake 
associated with Parkinson’s disease patients. The ratios of the activity uptake in the 
striata are 1:1, 2:1, and 5:1. The 1:1 ratio represents the activity uptake of a normal 
individual. The 2:1 ratio represents the activity uptake of a Parkinson’s disease patient 
presenting clinical symptoms. The 5:1 ratio represents the activity uptake of a severe 
Parkinson’s disease patient. Since the background activity concentration at the time of 
imaging is relatively low for the relevant radiopharmaceuticals (as discussed in chapter 
4), the ratio of striata activity concentration and background concentration is assumed 
and modeled to be 9:9:1 for the 1:1 striatal uptake ratio, 12:6:1 for the 2:1 striatal uptake 
ratio, and 15:3:1 for the 5:1 striatal uptake ratio. For these studies the source with the 
highest activity concentration is the left sphere and the source with the lower activity 
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concentration is the right sphere. A study is also performed with no background activity; 
the ratio of the two source activities is 5:1.  
Although most radiopharmaceuticals used in imaging the dopaminergic system 
are tagged with 123I, 99mTc pertechnetate is used in the studies. 99mTc pertechnetate is 
chosen because 99mTc photon emission spectrum is not as complex as that of 123I. The 
high-energy photon emissions of 123I complicate quantitative imaging calculations by 
introducing downscatter contributions to the photopeak of interest. Thus, foundational 
experimental assessment of the mathematical model presented in Chapter 3 is initiated 
with 99mTc. Although part of the motivation for the use of 99m Tc is its less complex 
photon emission spectrum, 99m Tc is clinically relevant for dopaminergic studies as 99m Tc 
TRODAT is used in the evaluation of striatal dopamine in Parkinson’s disease studies. 
 
4.1 Methods 
4.1.1 Conjugate Imaging 
4.1.1.1 Equipment 
Imaging System. A Marconi IRIX triple-head gamma camera system is used for 
image data acquisition. Heads II and III are used to acquire conjugate image data. Heads 
II and III are positioned 34 cm apart at 180º separation and are equipped with low-energy 
high-resolution (LEHR) collimators. A 15% energy window is placed symmetrically 
about the 140 keV 99m Tc photopeak. Images are acquired as 512 pixels x 512 pixels 
matrices with 1.18 mm x 1.18 mm pixels. 
Phantom. A cylindrical tank with two spherical inserts, representative of the brain 
with striata, is used. When radioactivity is placed in the spherical inserts and the tank in 
 104
 
quantities relative to the activity concentration ratios, this simple phantom models the 
specific activity uptake in the striata and background uptake in the brain. The phantom 
wall thickness is 0.635 cm (0.25”). The phantom inner height and inner diameter are 
30.48 cm (12”) and 20.32 cm (8.0”), respectively. The outer volume of each sphere is 
16.2 ml. The spheres were separated by 10.16 cm (4”). 
Flood/Transmission Source. A rectangular tank is used as the calibration flood 
and as the transmission source. Its inner dimensions are 58.75 cm x 43.0 cm x 2.54 cm. 
Self-attenuation of the flood source is accounted for by comparing the count rates of 
activity in a small syringe to the count rates of the same activity dispensed in the water-
filled flood. The small syringe represents a source with negligible self-attenuation. The 
count rates are normalized to an experiment start time and the acquired data were decay 
corrected. The count rates from the syringe and the flood are determined from 256 pixels 
x 256 pixels images.  Due to the fact that the physical dimensions of the flood image are 
larger than the 256 pixels x 256 pixels image, the activity imaged is a fraction of the total 
activity in the flood source. The pixel to flood size ratio is calculated and multiplied by 
the total number of pixels used (256 x 256) to determine the source fraction – the 
percentage of the flood activity in the 256 pixel x 256 pixel area.  The count rate from the 
syringe is divided into the flood count rate scaled by the source fraction. The flood source 
self-attenuation factor is thus measured to be 85.3%. 
 
4.1.1.2 Activity Concentrations 
A weighing technique is used in the dispensing of the 99mTc pertechnetate solution 
into the spheres and phantom to attain the desired ratios. A pre-weighed tuberculin 
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syringe is filled with Tc-99m pertechnetate solution (~1.0 ml). The total activity (~4.5 
mCi) is measured in a dose calibrator. Portions are dispensed by weight into the flood 
(~2.5 mCi), cylindrical tank (~1.0 mCi), and an additional volume of water (~25 ml). The 
further dilution of the solution is required to dispense more accurately much smaller 
amounts of activity (~5 to 30 µCi) into the spheres. After weighing the diluted activity, 
its activity concentration is calculated, and another syringe is weighed and filled. Portions 
of diluted solution are then dispensed by weight into the spheres. An analytic scale with 
better than 0.1 mg accuracy is used, resulting in better than 1% accuracy in this process 
of dividing the initial activity. Such accuracy is not achievable by separate dose-
calibrator measurements of each quantity dispensed; basic accuracy and linearity of dose 
calibrators is typically no better than 2% within a single range, and is worse between 
ranges. The measurement of activities in different volumes can also result in inaccuracies 
due to different self-absorption and source-detector geometries. 
 
4.1.1.3 Data Acquisition 
The flood data are acquired for 30 minutes. The left and right 
transmission/emission data are acquired for 15 minutes each and the emission data for 15 
minutes. Imaging times are adjusted to compensate approximately for decay; these 
adjustments ensured that all image data are approximately equivalent to that which would 
have resulted if all imaging had commenced at the same time.  
Each data set requires a different imaging geometry. For the collection of flood data, 
the flood source is positioned midway between the cameras. For emission data 
acquisition, the phantom is placed midway between the cameras. When transmission data 
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are acquired by camera head II, the flood source is placed between the phantom and 
camera head III. For transmission data acquisition by camera head III, the flood source is 
placed between the phantom and camera head II. Figure 4.1 illustrates the experimental 
set-ups. Figure 4.2 shows transmission image acquisition on head III. 
 
4.1.1.4 Data Processing 
Software is developed in MATLAB to perform calculations for conjugate imaging 
of two aligned volumes and standard conjugate imaging. The code processes the image 
data and calculates the effective attenuation coefficient µ, the background activity 
concentration B, the activities above background in each of the two volumes A1 and A2, 
and the sum of the activities above background AT. The data are decay-corrected and 
normalized for acquisition times and durations. This converts the data into count rates at 
a common calibration time. All images acquired with head II are flipped horizontally for 
processing so that corresponding pixels in the opposing views coincided. The camera 
sensitivities are then calculated from the flood images. Emission and transmission rates 
are corrected for cylinder wall attenuation using a measured wall attenuation coefficient, 
µb (~0.118 cm-1). The emission rates are subtracted from the transmission/emission rates 
to yield transmission rates. Due to the magnitude of the statistical fluctuations in the 
transmission data, the effective attenuation coefficient, µ, is determined using the 
fractional flood transmission averaged over a 37 pixel x 37 pixel source region of interest 
(ROI) centered on the source activities’ projections. The effective background activity is 
determined by averaging emissions over a 37 pixel x 37 pixel background ROI. The 
source activities above background are then calculated and summed over the source ROI.  
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Figure 4.1. Experimental set-up. The top figure illustrates the acquisition of flood data, 
which are used to determine the cameras’ sensitivities. The middle figure illustrates the 
acquisition of transmission data, which are used to determine the effective attenuation 
coefficient. The bottom figure illustrates acquisition of the emission data, which are used 
to determine the activity uptakes A1 and A2.
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Figure 4.2. The transmission data acquisition set-up. Shown are the cylinder-with-two-
spheres phantom, the flood/transmission source, and the gamma camera system used in 
the experiments. The configuration shown is specifically that used to obtain 
transmission/emission image data from head III; the transmission/emission left data are 
acquired similarly, except the flood is on the right side of the phantom rather than the left. 
Flood data are acquired with the cylindrical phantom removed and the flood/transmission 
source centered between the two cameras. The emission data are acquired with the 
cylindrical phantom centered between heads II and III.
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The background activity concentration is determined by correcting the effective 
background activity per pixel for self-attenuation and dividing by T and the pixel area. 
Figure 4.3 shows flood, transmission/emission and transmission image maps.  
The sum of the activities of the aligned volumes is estimated by summing the two 
estimates obtained from the above-outlined computations. The sum of the activities is 
also determined by applying a standard conjugate imaging analysis. In the case of two 
sources separated by a sufficiently large distance, the conjugate imaging calculations are 
modified to include a correction factor that accounts for the large distance. If the 
modifications are not made, the sum of the two activities would be overestimated. The 
correction factor depends on the product of the effective attenuation coefficient µeff and 
the distance between the volumes s and the ratio of the activities of the sources. Since the 
ratio is not known a priori, it is estimated by computing the ratio of the estimated source 
activities. 
 
4.1.2 Quantitative SPECT 
Two quantitative SPECT studies are performed. For the scope of this work, 
quantitative SPECT studies include attenuation correction and exclude scatter correction. 
This approach is used because most current clinical SPECT studies are not performed 
using scatter correction techniques. The two SPECT studies are performed with no 
background activity and a spheres activities ratio of 5:1. The results of these studies are 
compared to the conjugate imaging study performed with no background activity and a 
5:1 spheres activities ratio. 
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Figure 4.3. Examples of flood, transmission/emission, emission, and transmission activity 
maps for heads II and III. The maps shown represent a region that covers the entire 
phantom. The white squares are representative of the source and background ROIs used 
in the computations. Flood activity maps (upper left). Transmission/emission activity 




Imaging System. The Marconi IRIX triple-head gamma camera system is used for 
SPECT data acquisition. Heads I, II, and III are used. They are separated by 120º. Each 
camera head is equipped with a LEHR collimator. A 15 % energy window is placed 
symmetrically about the 140 keV 99mTc- photopeak. Images were acquired as 128 x128 
matrices with 4.72 mm x 4.72 mm pixels. 
Phantom. The phantom used in the conjugate imaging study is used in the 
quantitative SPECT study. The reader is referred to the section 4.1.1.1 for a detailed 
description of the phantom. 
 
4.1.2.2 Activity Concentrations 
 The weighing technique used in the conjugate imaging study to dispense the 
activity is used in the quantitative SPECT study as well. The reader is referred to section 
4.1.1.2 for a detailed description of the weighing technique. 
 
4.1.2.3 Data Acquisition 
 SPECT acquisition on the Marconi system involves a two-step process – emission 
and transmission acquisition. Transmission acquisition is performed for attenuation 
correction. The transmission scan is performed in two parts. The phantom is placed on 
the IRIX patient bed for the emission acquisition and for the first transmission 
acquisition. The phantom is removed from the field of view during a blank scan, the 
second transmission scan. The transmission and emission scans of the phantom also 
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includes the imaging of a point source of known activity, a calibration source for use in 
the quantitative analysis of the SPECT data. 
The emission data are acquired with a continuous circular orbit with 120 
projections per head over 360° at 1° per step and 8 seconds per stop. The Marconi IRIX 
system is equipped with BEACON attenuation-correction technology. This attenuation-
correction technology uses two10 mCi Ba-133 emission sources, with primary emission 
356 keV. The first transmission scan is performed with camera heads I and II and the Ba-
133 transmission sources. The data are acquired with a step-and-shoot circular orbit with 
180 projections per head over 360° at 1° per step and 6 seconds per stop. The second scan 
is a static, blank, calibration scan of 5-minute acquisition. Camera heads I and II are used. 
 
4.1.2.4 Data Processing 
 The collected SPECT data are processed into three data sets. These data sets are 
(1) filtered non-attenuation-corrected data (Filtered Non-AC), (2) filtered attenuation-
corrected data (Filtered AC), and (3) non-filtered attenuation-corrected data (Non-
Filtered AC). Filtered Non-AC data are reconstructed using ordered subsets maximum 
likelihood expectation maximization (OSEM) and post-filtered with the default 
smoothing filter. Attenuation correction is not applied. Filtered AC data are reconstructed 
using OSEM, corrected for attenuation, and post-filtered with the default smoothing 
filter. Non-Filtered AC data are reconstructed with OSEM and corrected for attenuation. 
No post-filtered is performed on Non-Filtered AC data. The activity in each sphere is 
determined by comparing the calibration source count information. ROIs are placed about 
the calibration source and the two spherical sources on image slices in which the sources 
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are visible. The size of the ROIs changes with each slice to account for the spherical 
volume of the sources. In other words, for each slice of the spherical volume, the circle 
representing a slice of the volume changes in size with the largest circle being defined 
halfway through the volume. The total counts for each sphere are determined by adding 
the counts in the ROIs from the slices. For the first SPECT study, a total of 15 projections 
are used for each sphere. For the second SPECT study, 16 projections are used for each 
sphere. The total counts from the calibration source are divided by the activity in the 
calibration sphere at the time of the study to estimate counts per unit activity. The total 
counts for each spherical source is divided by the counts per unit activity to determine the 
activity amount in each sphere.  
 
4.2 Results 
4.2.1 Conjugate Imaging 
As previously mentioned, the left sphere contained more activity than the right 
sphere for activity uptake ratios not equal to one. Tables 4.1, 4.2, and 4.3 display the 
calculated estimates and corresponding percent errors for the uptake ratio studies that 
included background activity. Table 4.1 displays the effective attenuation coefficient and 
the estimated background activity concentration for each experiment. Table 4.2 shows the 
estimated activities in the left and right spheres. The estimates in these two tables are 
determined using the conjugate imaging algorithm for two aligned sources. Table 4.3 
shows the sums of the estimated left and right activities listed in Table 4.2 and shows the 




Table 4.1. Effective Attenuation Coefficient and Background Activity Concentration 
Effective  %Error 
Nominal Ratio Attenuation Coefficient Background Activity Background Activity
µeff (cm -1) Concentration (µCi/cc)  Concentration
1:1 0.122 0.118 +   13.5
2:1 0.117 0.119 +   10.7
5:1 0.121 0.130 +   13.0




Table 4.2. Estimated Above Background Activity in Left and Right Spheres 
Left Sphere % Error Right Sphere % Error
Nominal Ratio Above-Background Left Sphere Above-Background Right Sphere 
Activity (µCi) Above -Background Activity Activity (µCi) Above -Background Activity
1:1  16.0  +  11.1 14.0 +     2.2
2:1 20.7  +    2.5     8.14 -   12.8
5:1 31.8  +    8.2      3.21 -   28.0




Table 4.3. Sum of Estimated Above Background Activities and Estimated Total Activity 
% Error
Left Sphere Left Sphere
Nominal Ratio Plus Plus  (Corrected) Classic Conjugate % Error
Right Sphere Right Sphere Total Activity (µCi) (Corrected) Classic Conjugate
Activity Activity Total Activity 
1:1 30.0 +   6.8 28.6 +   1.8
2:1 28.8 +   2.3 26.9 -   8.2
5:1 35.0 +   3.4 30.5 -   9.9




corrected for source separation. Standard conjugate imaging calculations, corrected for 
the separation of the two spheres, are used to estimate the sum of the two activities. The 
results of this computation are compared to the sum of the estimated source activities 
calculated from the modified conjugate technique. Corrected standard conjugate 
calculations yield total activity values within 10%. Total activities obtained by summing 
the estimates of source activities computed using modified conjugate calculations are 
within 11.1%. 
Tables 4.4, 4.5, and 4.6 display the calculated estimates and percent errors for the 
uptake ratio studies that did not include background activity. Table 4.4 displays the 
calculated effective attenuation coefficient and calculated background activity 
concentration. Table 4.5 shows the estimated above background activity in the left and 
right spheres and associated percent errors. Table 4.6 compares the total activity 
estimates calculated from summing the individual activity estimates and calculated from 
the classic conjugate imaging technique with separation correction. Also listed in table 




Table 4.4. No Background Activity Study: Estimates of Effective Attenuation Coefficient 
and Background Activity Concentration 
Effective
Nominal Ratio Attenuation Coefficient Background Activity 
µeff (cm -1) Concentration (µCi/cc)
5:1 * 0.127 0.003
5:1** 0.123 0.005  
* No ambient background subtraction 




Table 4.5. No Background Activity Study Estimated Above Background Activity 
 in Left and Right Spheres  
Left Sphere % Error Right Sphere % Error
Nominal Ratio Above-Background Left Sphere Above-Background Right Sphere 
Activity (µCi) Above -Background Activity Activity (µCi) Above -Background Activity
5:1 * 34.0 +   14.6 4.3 -   30.3
5:1** 33.3 +   12.2 3.6 -   42.1  
* No ambient background subtraction 




Table 4.6. No Background Activity Study 
Sum of Estimated Above Background Activities and Estimated Total Activity 
% Error
Left Sphere Left Sphere
Nominal Ratio Plus Plus  (Corrected) Classic Conjugate % Error
Right Sphere Right Sphere Total Activity (µCi) (Corrected) Classic Conjugate
Activity Activity Total Activity 
5:1 38.3 +   6.7 34.5 -   3.9
5:1 36.9 +   2.8 33.1 -   7.8  
* No ambient background subtraction 




4.2.2 Quantitative SPECT Study 
As with the conjugate imaging study, the left sphere contains more activity than 
the right sphere for activity uptake ratios not equal to one. The Filtered Non-AC SPECT 
data underestimate the activity in the left sphere by about 70% in both SPECT studies. 
The activity in the right sphere is underestimated by about 73% and 74% using Filtered 
Non-AC SPECT data in SPECT studies 1 and 2, respectively. In SPECT study 1, the 
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Filtered AC SPECT data overestimate the activity in each sphere by about 12%. In 
SPECT study 2, the Filtered AC SPECT data overestimate the activity in the left sphere 
by about 11% and overestimates the activity in the right sphere by 10%. In SPECT study 
1, the Non-Filtered AC SPECT data overestimate the activity in the left sphere by about 
12% and overestimate the activity in the right sphere by about 16%. In SPECT study 2, 
the Non-Filtered AC SPECT data overestimate the activity in the left sphere by about 
11% and overestimate the activity in the right sphere by about 14%. Tables 4.7 and 4.8 




Table 4.7. Percent Errors for quantitative SPECT Studies I  
Left Sphere % Error Right Sphere % Error
Technique Above-Background Left Sphere Above-Background Right Sphere
Activity (µCi) Above-Background Activity Activity (µCi) Above-Background Activity
Filtered Non-AC               6.3                   -70.1 1.2                   -72.7
Filtered AC 23.6 11.6 4.9 11.6












Table 4.8. Percent Errors for quantitative SPECT Studies II  
Left Sphere % Error Right Sphere % Error
Technique Above-Background Left Sphere Above-Background Right Sphere
Activity (µCi) Above-Background Activity Activity (µCi) Above-Background Activity
Filtered Non-AC             5.4                   -70.4 1.0                  -73.8
Filtered AC           20.2 10.8 4.2 9.7







This phantom study is conducted to evaluate the application of a conjugate 
imaging technique to the estimation of activity in each of two aligned sources. Four 
conjugate imaging experiments are conducted using three different source-to-source 
ratios (nominal ratio values were 1:1, 2:1, and 5:1). Estimates of the source activities and 
the sums of the two activities are determined. Tables 4.1 – 4.6 summarize the results. The 
values in the tables associated with the nominal ratio 1:5 are the result of an extension of 
the experiment involving the 5:1 ratio. 
The effective attenuation coefficient for each experiment is determined and used 
in estimation of the background concentration and the source activities. The estimates of 
the background concentrations are all overestimates (10.7% to 17.4%). Some statistical 
errors due to transmission maps with relatively low counts might be expected, but there 
may also be a systematic component to the error contributing to an overestimation of the 
effective attenuation coefficient. 
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Most of the estimates of the activities in the left and right spheres are within 13% 
of the known values. The 5:1 experiment resulted in a 28% underestimation of the 
smaller of the two sphere activities. An extension of this experiment is conducted to 
initiate investigation into the source of this error. The spheres used in the 5:1 experiment, 
together with their activities, are switched by rotating the base, upon which the spheres 
are mounted. The base is rotated until the right sphere is occupying the position of the left 
sphere and the left sphere is occupying the position of the right. Since the activity uptake 
ratios assume the sphere in the left position to be the reference source, the activity uptake 
ratio for this experiment is 1:5. The 1:5 experiment results in overestimates of the two 
activities that are less than 13% (3.6% and 12.2%). Throughout the computations, the 
source depths and separation distances are assumed known. A possible contributor to the 
large underestimation of the smaller activity in the 5:1 experiment may be a property of 
the phantom. The two spheres used as the sources are mounted on rods extending into the 
water in the cylinder. It is assumed the sources are separated by 10.1 cm, the separation 
of the mounting holes. It is possible that the rods, when attached to the cylinder cover, are 
not sufficiently perpendicular to the cover and thus the sphere positions with respect to 
the cylinder center are not the same as those of the mounting holes. If this is the case, the 
assumed values for the source depths and separation could have been incorrect for one or 
more experiments. Theoretical error analysis suggests that the conjugate imaging 
computations are sensitive to the accuracy of these values. A small mis-positioning of the 
larger-activity sphere could cause a significant fractional error in the estimation of the 
activity in the smaller-activity sphere. To corroborate the theoretical error analysis, the 
position of the left sphere used in the conjugate imaging calculations is moved in ±1 mm 
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increments from it original position. The percent errors in the left and right activity 
estimations are calculated using each new source location. Since a mis-positioning error 
in the left sphere results in a bias between the percent errors for left and right activity 
estimates that increases with increasing activity uptake ratio, the left sphere is moved 
until the percent errors are relatively equal for all three ratios. It is estimated that the left 
sphere is approximately +3.6 mm from the putative position.  
Most of the estimates computed using the data of the these experiments are very 
good estimates given that some of the raw data images are count limited and no scatter 
correction is performed. The phantom used is a cylinder with a relatively large diameter 
and not representative of typical human or primate head sizes. Imaging of a smaller 
phantom with less attenuation would be more realistic and result in higher count 
transmission/emission images and thus higher count transmission maps. All the data are 
collected at rates designed to keep camera dead time errors below 1%. This may not have 
been appropriate, as the reduced counts in the data may have produced errors greater than 
the errors that would have resulted if more dead time had been tolerated. The strength of 
the flood/transmission source is a parameter that needs additional investigation. 
The quantitative SPECT study is performed to compare the conjugate imaging 
calculations to clinically feasible techniques. As with the conjugate imaging studies, the 
SPECT study is performed with no scatter correction. Currently, scatter correction 
algorithms are not used widely in clinical settings. Filtered attenuation corrected SPECT 
provides the best estimates out of the three quantitative SPECT studies. The activity 
estimates in the left and right spheres are within 12% for both filtered attenuation 
corrected SPECT studies. The filtered attenuation corrected SPECT study and the 1:5 
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conjugate imaging study, where the mis-positioning error was minimized provided 
comparable results. This suggests that conjugate imaging of the two aligned sources is 
comparable in accuracy to current clinical capabilities and is a reasonable quantitative 
technique for estimating activity uptake in two aligned sources.
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Chapter 5  
 




This chapter presents the design and characterization of the shielding 
requirements for a novel dedicated mobile nuclear medicine system (Matthews, Mintzer 
et al. 1997 2000). The system is to perform modified conjugate imaging of 123I and 99mTc 
radiopharmaceuticals in the striata, and comprises two small field-of-view (FOV) gamma 
cameras mounted on a mobile gantry.  The FOV of each gamma camera, determined by 
the size of its scintillation crystal, is 10 cm x 10 cm. The conjugate imaging system is 
designed such that its two gamma cameras are positioned on opposite sides of a subject’s 
head. Figure 5.1 is a schematic of the system. Figure 5.2 is a photograph of the system 
gantry. The design of the gamma cameras, the amount of shielding, and the payload of 
the gantry are interdependent in the system development. Shielding optimization is an 
important part of the design and construction of any gamma camera system. A practical 
balance between the thickness and weight of the shielding is necessary. The shielding 
must sufficiently reduce the background counts in the scintillation crystal, and the weight 
of the shielding must be within the limits of the gantry payload. In addition, the shielding 
design must take into account the mobility of the system and the emission spectra of the 
radiopharmaceuticals to be used in studies conducted with the novel system.  
As discussed in chapter 2, most of the single-photon emitting 
radiopharmaceuticals used to image the dopaminergic system in the striata are labeled 









Figure 5.2. Photograph of conjugate imaging gantry. 
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the lung, liver, and certain organs in the gastrointestinal tract. This generates activity 
distributions outside the FOV of the camera. This out-of-FOV activity could reduce the 
accuracy in estimations of activity in the striata in quantitative studies using small FOV 
gamma cameras due to the high-energy photon emissions of 123I. Therefore, accurate 
quantification of focal uptake of 123I radiopharmaceuticals in the striata requires that 
downscatter contribute minimally to image data used for uptake estimation. Reduction of 
downscatter contribution can occur with sufficient detector shielding and/or data 
processing that compensates for these events. 
 In this chapter, we describe two Monte Carlo simulation studies performed to 
determine and characterize an appropriate shielding configuration for the small FOV 
gamma cameras comprising the novel system. The first simulation study is performed to 
determine a shielding design that adequately shields high-energy gamma emissions 
originating from outside the FOV and is within the weight limits for the mobile conjugate 
imaging system. The second simulation study is performed to characterize the 
distribution of events across the scintillation crystal due to high-energy gamma emissions 
that penetrate the selected shielding design and deposit energy in the 159 keV photopeak 
window.  
 
5.1 Monte Carlo Simulations 
The simulations are performed using Monte Carlo N-Particle Transport code, 
version 4c (MCNP-4c) (Briesmeister). The simulations are performed in MCNP’s photon 
transport mode. In this mode, only photons are transported and tracked. Electrons are 
generated but not transported. The thick target bremsstrahlung model (TTB) is used to 
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manage electron and bremsstrahlung generation and transport. In the TTB model, 
electrons are generated but are assumed to travel in the same direction as that of the 
incident photon and deposit their energy locally. Bremsstrahlung photons that are 
produced by the electrons were transported (Briesmeister 2000). The photon interactions 
that occurred during transport are modeled in MCNP’s detailed physics mode. In detailed 
physics mode, photoelectric absorption, Compton scattering, coherent scattering and pair 
production are modeled. Fluorescence photons are transported and photoelectrons are 
treated with the TTB model for photoelectric absorption. The binding energies of atomic 
electrons are accounted for in Compton scattering (incoherent scattering) (Briesmeister 
2000). 
The simulation set-up consists of a model primate and one small FOV camera 
with the face of its collimator located 1 cm from the primate’s head. Figure 5.3 is an 
illustration of the set-up used in the simulations. The activity placed in the striata 
represent in-FOV activity, and the activity in GI tract, liver, and lungs represent out-of- 
FOV activity. Simulations of activity in GI tract, liver and lungs omit the 159 keV 
gamma emission because its penetration of the shielding is negligible. The primary 
photon emission and the high-energy gammas are emitted from the appropriate sources in 
proportions corresponding to the relative yields of the decays of 123I. To achieve 
acceptable statistical accuracy over most of the spectrum, with reasonable execution 
times, 1×108 source photons and 5×108 source photons are simulated and the results are 










       10 cm Ø 
Figure 5.3. Configuration of idealized primate and camera used in the simulations. The 
primate was modeled using water-filled shapes as shown, representing tissue-equivalent 
material. The activity was uniformly distributed throughout the spherical volumes 
representing the GI tract, liver and lungs. The camera was positioned with the collimator 
face located 1 cm from the primate’s head.
127 
5.1.1 Primate Model 
The system is to be used to image primates as well as humans. Thus, a primate is 
modeled for the simulations. The primate is modeled with water-filled shapes to represent 
tissue equivalent material. The primate model is shown in Figure 5.3. The water is 
uniformly distributed in each shape. The head is a 10-cm diameter sphere; the neck a 5-
cm diameter, 3-cm long cylinder; and the torso a 20-cm diameter, 30-cm long cylinder. 
The striatal spheres have a 2 cm diameter and are symmetric about the vertical bisector of 
the head sphere. The centers of the spheres are 1 cm superior the center of the head and 
3.56 cm apart. The GI tract and the liver are represented by a 10-cm diameter sphere 
placed in the torso with the center of the sphere 20 cm from the top of the torso. For this 
study, the GI tract is assumed to include only the large and small intestines; the oral 
cavity, the pharynx, the esophagus, and the stomach were excluded. The lung is 
represented as a 10 cm diameter sphere located in the upper half of the torso with the 
center of the sphere 7 cm from the top of the torso. The modeled primate has no 
extremities. 
 
5.1.2 Camera Model 
The camera simulated consists of a lead collimator, a quartz light guide, photomultiplier 
tubes (PMTs), and a NaI scintillation crystal all encased in walls of tungsten, lead, and 
aluminum. The length of the camera is 26.27 cm. Figure 5.4 is a diagram of the simulated 
camera. The camera is modeled after the small gamma cameras in a novel conjugate -
system. Figure 5.5 is a photograph of such a gamma camera. Figure 5.6 is a schematic of 












































Figure 5.4. Detailed diagram of idealized camera components. Thicknesses of tungsten, 
lead, and aluminum wall components used in each simulation are listed. Lead distributed 
uniformly at 22% density within the collimator volume modeled a typical low-energy 
high-resolution collimator. The PMTs were modeled with SiO2 uniformly distributed at 
20% density within a 10 cm x 10 cm x 10 cm volume.
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 with hole size of 1.9 mm, septa thickness of 0.25 mm, hole length of 40 mm, and 
sensitivity of 250 cpm/µCi. However, to ensure reasonable simulation execution times, a 
4×10×10 cm 22%–density uniform lead distribution is used a small gamma camera. The 
gamma cameras have a high instead of a detailed collimator. The simulated NaI(Tl) 
scintillation crystal is 0.8 cm ×10 cm ×10 cm and positioned 0.2 cm behind the collimator 
to account for the presence of thin layers of material not modeled due to their low Z 
numbers. A 1.8-cm quartz light guide is placed 0.2 cm behind the NaI(Tl) crystal. The 
spacing is used to account for the presence of a thin layer of optical coupling compound 
between the light guide and crystal. The PMT glass envelopes are represented as a 10 cm 
×10cm ×10 cm volume of SiO2 with a uniform density of 0.6grams/cm3.  
Shielding for high-energy photons is composed usually of a highly dense material 
with a high atomic number (Z). The thickness of the shielding is inversely related to the 
material’s Z number and density. The higher the Z number and density, the less shielding 
required. For the shielding design of the gamma cameras, tungsten and lead are used. 
Tungsten is used in the front half of the camera to provide shielding of the crystal. The 
back half of the camera is shielded with lead. Tungsten walls extended 10 cm along the 
length of the camera starting at the collimator face. These tungsten walls are intended to 
provide maximum practical shielding of the NaI(Tl) crystal. The back plate of the camera 
is tungsten. The remaining lateral shielding is lead with structural walls of aluminum. 
Five different camera shielding configurations are simulated; each has different 




Figure 5.5. Small gamma camera for use in a novel dedicated conjugate imaging system. 












Figure 5.6. Cross-sectional schematic of small gamma camera for use in the dedicated 
conjugate imaging system. The collimator is shown in front of the 0.6” scintillation 




shown in figure 5.4. The thickness of tungsten is increased in increments of ¼”from ¼” 
to ¾”. Due to lead’s lack of hardness, the effect of including aluminum structural walls in 
the shielding design is investigated. Aluminum walls of 1/8” thickness are included for 
structural support in shielding designs two, four, and five. For shielding designs including 
aluminum walls, the thickness of lead is dictated by the thickness of the tungsten 
shielding and the aluminum walls. 
 
5.2 Shielding Determination 
To evaluate the count contribution from out-of-FOV activity as a function of 
shielding design, three simulation studies are performed. One simulation study models 
and investigates the detection of 159 keV photon emissions from the striatal sources. A 
second simulation study models and investigates the detection of downscatter from with 
activity in the GI tract and the liver. The third simulation study models and investigates 
the detection of downscatter from activity in the lungs. 
MCNP pulse-height tallies are collected to determine the event rates and the 
spectra of energy deposited in the NaI(Tl) crystal of the camera. The pulse-height tally 
results are fractions representing the number of energy-deposited events in each energy 
bin per source photon. Tallies are collected in 5 keV energy bins and a 20% energy 
window centered on 159 keV. These tallies are performed with and without MCNP’s 
detector Gaussian energy broadening (GEB). Tallies performed without GEB record the 
energy as if deposited in an ideal detector. Tallies performed with GEB record the energy 
as if deposited in a detector with finite energy resolution. The camera simulated has 12% 
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energy resolution at full width at half maximum (FWHM) at 159 keV. The energy 
resolution of the simulated camera is a function of E-1/2. 
 
5.2.1 Data Analysis 
The tallies collected in 5-keV bins are normalized by dividing by the bin size to 
yield plots of simulated pulse-height spectra. For ease of interpretation, the energy-
window tallies of striata, GI tract, and lung activities are converted to tallies with units of 
cps/mCi. For the GI tract and lung results, the conversions include multiplication by 
3.7×107 disintegrations/s/mCi and by 0.03 to reflect the fact that the emissions simulated 
represent only the 3% high-energy gamma emissions of 123I. The tally results from the 
striata simulations are multiplied by 3.7×107 disintegrations/s/mCi and by 83% to 
represent the yield of the primary photon emission. The cps/mCi of striatal activity and 
out-of-FOV activity is then multiplied by the corresponding fraction of activity uptake for 
each radiopharmaceutical to yield the counts per second of activity.  
Preliminary data analysis performed on the GI tract tally data assume the activity 
uptake in the GI tract and striata is 10 mCi and 10 µCi, respectively (Jangha, Mintzer et 
al. 2001). For each camera configuration, the counts per second recorded in the 159 keV, 
20% energy window as a result of the detection of scattered high-energy emissions from 
a 10mCi GI source is determined through simulation. The counts per second due to high-
energy emissions is compared to the counts per second due to striatal activity. The counts 
per second in the 159 keV 20% window from 10 µCi in the striata is not simulated, but is 
calculated to be 12.5 counts per second (Jangha, Mintzer et al. 2001) It is determined that 
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the out-of-FOV activity increase the striata count rate by 3% - 28% for shielding 
configurations 1-5, respectively. 
However, biodistribution studies have shown at the time of imaging, i.e. at 
biokinetic equilibrium, the total activity uptake in the lungs on average is 10 times greater 
than that in striata. The combined activity uptake in the liver and GI tract on average is 25 
times greater than that in the striata (Seibyl, Wallace et al. 1994). Subsequently, a more 
accurate simulation is performed using activity uptake values typical for 123I 
radiopharmaceuticals used in striatal imaging studies and simulating striatal activity 
uptake and detection. Data analysis is performed on both GI and lung pulse-height tally 
data using activity uptake values typical of 123I β-CIT, 123I FP-CIT, and 123I IBZM. The 
activity uptake values are based on the administration of 5 mCi doses to healthy 
individuals (controls). Table 5.1 shows the percent uptake of the striata, GI tract, and 
lungs for an injection dose of 5 mCi of 123I β-CIT, 123I FP-CIT, and 123I IBZM, 
respectively. The last two columns in Table 5.1 are the percent uptakes of initial doses 
used to represent patients in the early (2:1) and late stages (5:1) of Parkinson’s disease. 
These uptake ratios, which represent appropriate upper and lower bounds of ratios of 
activity uptake for Parkinson patients, are determined by subtracting the product of the 
percent dose for controls by the characteristic fractional loss of dopamine from the 
percent dose for controls. The reported fractional losses of dopamine in early- and late-
stage Parkinson’s disease patients are 50% and 75%, respectively (Marek, Seibly et al. 
1996; Seibyl 2003). It is assumed that there was a direct linear relationship between the 
percent loss and activity uptake. 
For each camera configuration, the counts per second recorded in the 159 keV, 
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Table 5.1 Percent Uptake of Initial Dose in Critical Organs  
Parkinson’s Patients 
Radiopharmaceutical Controls Early Stage Late Stage 
 striata lungs 
GI 
tract/liver striata striata 
123I β-CIT 2.0% 21.0% 52.0% 1.0% 0.5% 
123I FP-CIT 0.8% 9.0% 18.0% 0.4% 0.2% 




20% energy window due to the detection of scattered high-energy emissions from GI 
activity and lung activity is determined. The count rates resultant from the GI activity and 
lung activity are added to determine the total count rate for out-of-FOV activity. The 
striatal count rate is determined in the159 keV, 20% energy window. The percent 
increase in the striatal count rate is determined for each radiopharmaceutical. 
It is assumed that the counts in the 159 keV, 20% energy window collected from 
striatal activity are concentrated in the physical location of the striatal projection. Since 
each striatal source has a diameter of 2 cm, the projected lateral area of the spheres is 
approximately 3.14 cm2. Therefore, it is assumed that the projected striatal region can be 
encompassed by a square 4 cm2 ROI drawn on the image data. A 4 cm2 ROI is 4 % of the 
FOV of the gamma cameras. To determine the out-of-FOV contribution to the rate of 
emissions detected in a 4 cm2 region, the total count rate across the face of the crystal due 
to activity uptakes in the GI tract and lungs are multiplied by this area fraction. The 
percent increase in striatal counts due to these contributions is determined by dividing the 
 135
 
out of FOV counts by the striatal counts. The percent increase in striatal counts due to 
only GI tract activity and to only lung activity are also determined.  
 
5.2.2 Results 
The normalized pulse-height spectra without GEB pictured in figure 5.7 represent 
ideal detector resolution. The spectra with GEB pictured in figure 5.8 show the spectra of 
out-of-FOV shielding penetration events as would be detected by the small FOV gamma 
camera. The spectra show characteristic tungsten and lead fluorescence x-ray peaks. A 
broad backscatter peak around 180 keV due to scattered 529 keV gamma emissions can 
be seen. 
Figures 5.9 –5.11 show the percent increases due to out-of-FOV activity for 123I 
β-CIT, 123I FP-CIT, and 123I IBZM, respectively. Although the percent increase increases 
as the activity uptake ratio increased (total striatal activity decreased), the magnitude of 






















Figure 5.7. Pulse height spectrums as detected by ideal gamma camera. Pulse height 
spectrums from 123I high-energy photons emitted from the GI tract and liver as seen by an 
ideal gamma camera (gamma camera with perfect energy resolution). K-shell x-ray peaks 
for tungsten (~70 keV) and lead (~88 keV) are shown. The 173 keV backscatter peak due 

















Figure 5.8. Pulse height spectrums as detected by a gamma camera with finite resolution. 
Pulse height spectrums from I high-energy photons emitted from the GI tract and liver 
as seen by a gamma camera with energy resolution of 12% at 159 keV. The iodine and 
tungsten fluorescence escape peaks that are clearly seen in figure 10.9 are not as clearly 
depicted. The backscatter peak for the 529 keV photon is also shown but not as clearly 

















Figure 5.9. Comparison of percentage increase in striatal counts for 123I β-CIT activity 
uptakes in the striata of controls and early, stage, and late-stage Parkinson’s disease 
patients. The controls are considered to have normal striatal activity. It can be seen that as 
activity uptake in the striata decreases the significance of out-of-FOV count contribution 















Figure 5.10. Comparison of percentage increase in striatal counts for 123I FP-CIT activity 
uptake in the striata of controls and early, stage, and late-stage Parkinson’s disease 
patients. The controls are considered to have normal striatal activity. It can be seen that as 
activity uptake in the striata decreases the significance of out-of-FOV count contribution 
















Figure 5.11. Comparison of percentage increase in striatal counts for 123I IBZM activity 
uptake in the striata of controls and early, stage, and late-stage Parkinson’s disease 
patients. The controls are considered to have normal striatal activity. It can be seen that as 
activity uptake in the striata decreases the significance of out-of-FOV count contribution 
increases. 123I IBZM has the lowest percentage increase due to its low activity uptake in 





In order to perform accurate conjugate imaging of two aligned sources, the 
activity outside the FOV must be appropriately shielded and/or appropriately accounted 
for. Five shielding configurations of thicknesses from ¼ to ¾ inch are investigated using 
MCNP-4c simulations. It is determined that configuration 4 with ½ inch tungsten walls is 
a sufficient shielding design for the mobile conjugate imaging system. Although 
configuration 5 with ¾ inch tungsten walls shields better than configuration 4, 




The magnitude of the percent increase in striatal counts is dependent on the 
radiopharmaceutical used and the severity of the disease. The percent increase for 
patients in the late stages of Parkinson’s disease is about 3-4 times the percent increase of 
controls. The differences in percent increases among the radiopharmaceuticals are a 
function of the ratio of uptake in the striata and out-of-FOV activity, specifically the 
lungs. Although the activity uptake in the GI tract is significantly larger than the activity 
uptake in the lungs for all three radiopharmaceuticals, the activity uptake in the lungs 
contributes more counts to the striatal ROI than the activity in the GI tract. Since the 
lungs are closer to the gamma cameras, photon emissions have a shorter distance to travel 
to reach the gamma cameras. For example, for 123I IBZM, the activity uptake in the GI 
tract is much larger than the uptake in the lungs. As a result, the percent increase in the 
striatal counts due to 123I IBZM is not as large as the percent increase due to 123I β-CIT, 
which has a higher activity uptake in the lungs. However, the percent increase associated 
with 123I FP-CIT is due to the relatively low activity uptake in the striata. Thus, an 
increase in striatal counts due to out-of-FOV activity results in a larger percent increase.  
These studies assume that penetration events from the GI tract and lungs are 
uniformly distributed across the scintillation crystal. Under this assumption, background 
ROI subtraction used in the conjugate calculation of the striata activity uptake eliminate 
the penetration events due to GI tract and lung activity for all configurations simulated, 
with negligible additional statistical error. However, further analysis of the results reveals 
that the counts from the activity uptake in the GI tract and lungs are not uniformly 
distributed across the scintillation crystal. It is determined that there is approximately a 
4:1 variation in the rates of penetration events across the crystal. Simulations are 
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performed to investigate the significance of non-uniform count distribution across the 
crystal on background subtraction and on the limits of quantitative accuracy associated 
with the ½ inch shielding configuration. 
 
5.3 Shielding Characterization 
Monte Carlo simulations are performed to determine the spatial distribution of 
shielding penetration events across the scintillation crystal for the shielding design with 
½ inch tungsten walls. The code parameters, such as physics and mode, the simulation 
set-up, and the number and energy of photons as described in section 5.1 are used with 
the exception of collimator design. The collimator used in this study as well as in 
subsequent studies is hexagonal, with hole size 1.8 mm, septa thickness of 0.25 mm, hole 
length of 40 mm, and sensitivity of 250 cpm/ µCi. In addition, MCNP’s ptrac feature is 
used to track source photons, scattered photons, and fluorescent photons that interacted in 
the scintillation crystal and to output the location of interaction events and energy 
deposited per event.  
 
5.3.1 Data Analysis 
Images of out-of-FOV activity and in-FOV striatal activity are generated from 
MCNP-4c ptrac outputs. The MCNP ptrac feature is used to track source photons, 
scattered photons, and fluorescent photons that interact in the scintillation crystal and to 
output the event location and energy deposited at each event. A code is written in Matlab 
to parse the ptrac files and to generate energy-windowed images. The Matlab code 
provides ROI selection capabilities and event filtering options based on interaction 
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location with respect to the gamma camera. The energy windows used are a 20% window 
centered on 159 keV and two 20% windows one centered on 129 keV, the other on 195 
keV. The image size is 64 x 64 pixels, where the pixel size is 0.15625 cm. 
The simulated images are generated based on energy-weighted centroiding, a 
concept used in the generation of images from an ideal Anger camera. Energy-weighted 
centroiding is analogous to calculation of the center of mass. Photons may interact and 
deposit energy at more than one location in the scintillation crystal. Energy-weighted 
centroiding calculates the location at which the total energy deposited by a photon can be 
considered to be concentrated. This location is called the energy-weighted centroid. For 
this application the energy-weighted centroid is expressed in x and y coordinates. The 
energy-weighted centroid is expressed as 
 












x     (5.1) 












y     (5.2) 
 
where xE and yE  are the x and y coordinates of the energy-weighted centroid, 
respectively; index i represents the ith energy-depositing interaction; N is the total 
number of energy-depositing interactions; xi is the x coordinate for the ith interaction; yi 
is the y coordinate for the ith interaction; and Ei is the energy deposited by the ith 
interaction. If the total energy deposited by a photon is within the 159 keV, 20% energy-
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windowed image, a count is tallied in the pixel that corresponds to the location of the 
energy-weighted centroid. By using the energy-weighted centroid, cross-detection of an 
event by multiple photomultiplier tubes is ignored. 
To determine a more accurate percent increase in the striatal counts due to out-of-
FOV activity in the striatal region, a ROI with an area of 4.12 cm2 (13 by 13 pixels) is 
placed around the pixels that correspond to the physical location of the striata on the 
striatal, GI tract, and lung images. The counts in the pixels within the ROI are summed 
and converted into cps/mCi. For the GI tract and lung images, in which only high-energy 
photons are simulated, the total ROI counts are multiplied by 3.7x107 
disintegrations/s/mCi and by 0.03 to reflect the fact that the emissions simulated 
represent only 3% high-energy emissions of 123I and are divided by the total number of 
particles simulated to yield cps/mCi. The cps/mCi in each pixel within the ROI in GI tract 
image are added to the cps/mCi in the corresponding pixel in the lungs image to yield a 
total out-of-FOV activity count rate per mCi. For the striatal images, the total ROI counts 
are multiplied by the 3.7x107 disintegrations/s/mCi; divided by the total number of 
simulated photons; and by 0.83 to reflect the fact that the emissions simulated represent 
83% of 123I gamma emissions. The cps/mCi in each pixel within the ROI in one striatal 
image are added to the cps/mCi in the corresponding pixel in the second striatal image to 
yield a total striatal count rate per mCi.  
The calculated cps/mCi in each pixel in the striata, GI tract and lung images are 
multiplied by the percentage of 5 mCi of radiopharmaceutical taken up by the striata, GI 
tract and lung, respectively. The biodistributions of 123I β-CIT, 123I FP-CIT, and 123I 
IBZM are used. See table 5.1 for the percent uptakes in the striata, GI tract and lungs for 
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123I β-CIT, 123I FP-CIT, and 123I IBZM. Then the count rates in each pixel in the striata, 
GI tract, and lung images are multiplied by 900 seconds to represent typical 15 minute 
planar images of activity uptake in the striata, GI tract and lungs. Assuming Poisson 
statistics, the error in the calculated counts was determined by taking the square root of 
the counts. The percent increase was determined for each radiopharmaceutical by 
dividing the total out-of-FOV activity counts by the total striatal counts. 
It is noted that about 12% of counts due to striatal activity is displaced outside the 
4 cm2 (13 pixels x 13 pixels) ROI. As a result, the percent increase is determined for 
larger ROIs because the 4 cm2 ROI does not account for partial volumes effects. A 9 cm2 
(19 pixels x 19 pixels) ROI and a 16 cm2 (26 pixels x 26 pixels) ROI are also drawn 
around the striatal region to include displaced counts. To investigate the spatial 
distribution of counts due to out-of-FOV activity in non-striatal regions, background 
ROIs are drawn on the GI tract and lung count maps. However, the small FOV of the 
gamma camera limits the size of the background ROI. Thus, one background ROI is used 
in the investigations. The background ROI is about 3.125 cm by 2.03 cm (20 pixels x 13 
pixels). The background ROI is placed below the striatal ROI; the distance between the 
ROIs depends on the size of the striatal ROI. For the 4 cm2 striatal ROI, the background 
ROI is placed about 2.66 cm (17 pixels) from the bottom of the striatal ROI. For the 9 
cm2 striatal ROI, the background ROI is placed 2.34 cm (12 pixels) from the bottom of 
the striatal ROI. For the 16 cm2 striatal ROI, the background ROI is placed about 1.25 cm 
(8 pixels) from the bottom of the striatal ROI. The counts in each ROI are assumed to be 
uniformly distributed. The counts within the striatal ROI and background ROI due to GI 
tract and lung activity are compared. The counts in the striatal ROI and background ROI 
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for the GI tract and lung count maps are compared to the counts in the striatal ROI and 
background ROI of the striatal count maps. 
 
5.3.2 Results 
Figure 5.12 is an image of the count distribution across the scintillation crystal 
from activity in the GI sphere for ½ inch of shielding of tungsten, configuration 4. The 
white boxes represent the ROIs. The top ROI is the striatal ROI and the bottom ROI is 
the background ROI. There are more counts in the bottom half of the crystal. The counts 
in the background ROI due to activity in the GI tract are about 1.3 times larger than the 
counts in the striatal ROI due to activity in the GI tract. Figure 5.13 is an image of the 
count distribution across the scintillation crystal from activity in the lungs for ½ inch of 
shielding of tungsten, configuration 4. There are more counts in the upper half of the 
scintillation crystal. The counts in the background ROI are about 40% of the counts in the 
striatal ROI.  
Figure 5.14 shows the percent increases in counts in a 4 cm2  striatal ROI due to 
the out-of-FOV activity uptake from 5 mCi (185 MBq) of 123I β-CIT, 123I FP-CIT, and 
123I IBZM to control groups, patients in the early stages of Parkinson’s disease, and 
patients in the late stages of Parkinson’s disease. The percent increase due to out-of-FOV 
activity increases with the severity of Parkinson’s disease for all three 
radiopharmaceuticals. The percent increases due to 123I β-CIT are determined to be 
0.44%, 0.87%, and 1.75% for controls, early-stage Parkinson’s patients, and late-stage 
Parkinson’s patients, respectively. The percent increases due to 123I FP-CIT are 




Figure 5.12. Count distribution across the face of the scintillation crystal from activity 
uptake in the GI tract and liver for a 159 keV energy-windowed image. The square is the 
striatal ROI. The lower rectangle is the background ROI. There are more counts in the 




Figure 5.13. Count distribution across the face of the scintillation crystal from activity in 
the lungs for a 159 keV windowed image. The square is the striatal ROI. The lower 
rectangle is the background ROI. There are more counts in the upper half of the image. 
















Figure 5.14. Comparison of percentage increase in striatal counts in a 4 cm  ROI due to 
activity uptake of I β-CIT, I FP-CIT, and I IBZM.
2
123 123 123  Activity uptakes associated 
with control subjects, early and late stage Parkinson’s disease patients are compared. It is 
shown that the percent increases in striatal counts due to out-of-FOV activity from 123I 




and late-stage Parkinson’s patients, respectively. The percent increases due to 123I IBZM 
are determined to be 0.21%, 0.43%, and 0.86% for controls, early-stage Parkinson’s 
patients, and late-stage Parkinson’s patients, respectively. However, due to partial volume 
effects and blurring, striatal counts are spread outside the 4 cm2 area. As a result, larger 
ROIs are drawn around the stratial regions to include counts that are displaced. Figure 
5.15 shows the percent increases in striatal counts in a 9 cm2 ROI. The percent increase 
due to 123I β-CIT are determined to be 0.77%, 1.54%, and 3.08% for controls, early-stage 


















Figure 5.15. Comparison of percent increases in striatal counts for a 9 cm  ROI due to 
activity uptakes of I β-CIT, I FP-CIT, and I IBZM.
2
123 123 123  Activity uptakes associated 
with control subjects, early and late stage Parkinson’s disease patients are compared. The 




123I FP-CIT in the 9 cm2 are determined to be 0.80%, 1.60%, and 3.19% for controls, 
early-stage Parkinson’s patients, and late-stage Parkinson’s patients, respectively. The 
percent increases due to 123I IBZM are determined to be 0.38%, 0.75%, and 1.50% for 
controls, early-stage Parkinson’s patients, and late-stage Parkinson’s patients, 
respectively. Figure 5.16 shows the percent increases in striatal counts in a 16 cm2 ROI. 
The percent increases due to 123I β-CIT are determined to be 1.28%, 2.57%, and 5.13% 
for controls, early-stage Parkinson’s patients, and late-stage Parkinson’s patients, 

















Figure 5.16. Comparison of percent increases in striatal counts for a 16 cm  ROI due to 
activity uptakes of I β-CIT, I FP-CIT, and I IBZM.
2
123 123 123  Activity uptakes associated 
with control subjects, early and late stage Parkinson’s disease patients are compared. As 
seen with the smaller ROIs, the percent increase in striatal counts increases with decrease 
in activity uptake. The percent increases associated with the 16 cm2 ROI is larger than 




2.66%, and 5.32% for controls, early-stage Parkinson’s patients, and late-stage 
Parkinson’s patients, respectively. The percent increases due to 123I IBZM are determined 
to be 0.63%, 1.25%, and 2.50% for controls, early-stage Parkinson’s patients, and late-





In the context of conjugate imaging, subtraction of counts in a background region 
from counts in the striatal region is important.  Thus, characterization of the spatial 
distribution of counts is important, specifically in the striatal and background ROIs. 
Preliminary simulations revealed that the spatial distribution of counts from out-of-FOV 
activity uptake in the GI tract was not uniformly distributed across the scintillation 
crystal. This prompted a second Monte Carlo simulation study. The second study is 
conducted to characterize the distribution of out-of-FOV counts across the scintillation 
crystal. This study is conducted using the shielding design with ½ inch tungsten walls, as 
it was determined that this shielding design was the model of choice. In this second 
study, the percent increase in striatal counts is determined by using counts in a ROI 
placed around the projected striatal area. The percent increase determined using the 
counts encompassed in a ROI is larger than the percent increase determined under the 
assumption that out-of-FOV activity uniformly distributes counts across the scintillation 
crystal. The assumption of a uniform count distribution generates an underestimation of 
percent increase. The use of ROIs provides a more accurate estimation of percent 
increase in striatal counts due to out-of-FOV activity.  
The simulation studies performed show that a large percentage of gamma photons 
leave the lungs at angles that allow them to travel through the collimator bypassing the ½ 
inch thick tungsten shielding along the bottom of the camera and deposit energy in the 
upper portion of the scintillation crystal. The marked concentration of counts in the lower 
proportion of the scintillation crystal from activity uptake in the GI tract is due to the 
angle at which the photons escaped from the GI tract and impinge on the bottom of the 
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gamma camera. Although there is a significant difference in counts in the striatal ROI 
and the background ROI due to activity uptakes in the GI tract and lungs, the overall 
contributions of counts in the striatal ROI and background ROI due to out-of-FOV 
activity is negligible for 123I β-CIT, 123I FP-CIT, and 123I IBZM. However, the influence 
of the high-energy penetration counts increases as the striatal activity uptake decreases. 
The magnitude of this influence is also dependent on the ROI size; the larger the ROI the 
larger the influence. 
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Chapter 6  
 
EVALUATION AND CHARACTERIZATION OF THE MODIFIED 




 Monte Carlo simulations are performed to evaluate and characterize the modified 
conjugate imaging technique in the context of the novel dedicated imaging system. The 
biodistributions of radiopharmaceuticals are simulated and the photon emissions from the 
radiopharmaceuticals are detected using simulated gamma cameras. Estimates of the 
activity uptake in each of the striatum are determined using the modified conjugate 
imaging technique. To assess the range of the technique three activity uptake ratios, 
which represented three stages of Parkinsonism, are simulated.  
The simulated conjugate imaging is similar to practical conjugate imaging in that 
both require data acquisition and image array generation before conjugate imaging 
calculations can be performed. However, data acquisition for simulated conjugate 
imaging is obtained through Monte Carlo simulations. The generation of image data is an 
explicit process, which included converting the results from the Monte Carlo simulations 





6.1 Monte Carlo Simulations 
6.1.1 Data Acquisition 
Simulation studies are performed using photon emissions of 123I and 99m Tc using 
the primate/camera model discussed in chapter 5. To represent activity uptake of 123I and 
99m Tc radiopharmaceuticals, activity is uniformly distributed throughout the striata, head, 
lungs, and GI tract. The left striatum, right striatum, head, lungs, and GI tract simulations 
are performed separately. For 123I studies, two simulations are performed, one for 159 
keV primary emissions and one for high-energy emissions ranging from 248 to 783 keV. 
The 159 keV and high-energy photons are emitted from the sources in proportion to their 
relative yields from 123I. A simulation study using 140 keV photon emissions is 
performed for the 99mTc study. The 140 keV photons are emitted from the sources in 
proportion to their relative yields from 99mTc. The parameters used in the simulations are 
described in section 5.2.1. 
To represent acquired data from the second gamma camera Monte Carlo 
simulations are performed with the same geometry, but with a different random number 
sequence. This is done to ensure that the simulated photons used in generating data for 
the second camera does not undergo the same interactions as the photon used in 
generating the image data for the first gamma camera.  
 
6.1.2 Image Generation 
 Images are generated from the ptrac output produced by the MCNP simulations. 
This process is described in section 5.3.1. In chapter 5, the images are only of scattered 
high-energy photon emissions from 123I emitted from activity distributions in the lungs 
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and gastrointestinal tract. The images in this section are generated from the primary 
photon emissions and high-energy photon emissions, if applicable, from 123I and 99mTc 
radiopharmaceuticals in the striata, brain, and lungs and gastrointestinal tract. The 
biodistributions of these radiopharmaceuticals used in chapter 5 are also used for these 
studies. Table 6.1 lists the biodistributions, which include the activity uptake in brain. 
The activity uptake in the striata in table 6.1 is based on the activity uptake of a healthy 
individual. The activity in the striata is varied to simulate the various stages of 
Parkinson’s disease. As the severity of the disease increases, the activity uptake in the 
striata decreases. In this study, three striatal activity uptake ratios, 1:1, 2:1, and 5:1 are 





Table 6.1 Percent Uptake of Radiopharmaceuticals in Brain, Striata, and Critical Organs 
Radiopharmaceutical Striata Brain Lungs 
Gastrointestinal 
Tract 
123I β-CIT 2 10 21 52 
123I FP-CIT 0.8 2.2 9 18 
123I IBZM 1.7 2 8.1 27.5 
99mTc TRODAT 0.63 0.12 - - 
- Percent uptake in that organ or system not used in simulation study.   
123I radiopharmaceutical biodistribution based on 5mCi of administered activity 






Since the amount of activity that accumulates in the brain, the striata, and the 
critical organs differs, the pixel values in the image arrays for the head, the striata, and 
the out-of-FOV organs are scaled by the appropriate uptake fraction of administered 
activity. Once the primary and high-energy image arrays for each organ are scaled, the 
corresponding primary and high-energy image arrays are added together to generate data 
that reflect an emission image from an activity distribution in each organ. Then all the 
emission images from the organs are added together to simulate a complete emission 
image from all activity uptakes seen in actual patients. For the 123I studies, the total 
injected dose is assumed to be 5 mCi. For the 99mTc study the total injected dose is 
assumed to be 20 mCi. The 123I total dose is based on the recommendation of the 
European Association of Nuclear Medicine Procedure (Tatsch, Asenbaum et al. 2002). 
The 99mTc total dose is based on research studies (Meegalla, Plossl et al. 1997; Fang, Wu 
et al. 2000). The pixel values in the energy-windowed images are converted into counts 
per second per milliCurie (cps/mCi). A total imaging time of 15 minutes (900 seconds) is 
used to represent typical planar imaging protocols.  
 The photopeak window for the 123I studies is a 20% window centered on 159 keV. 
The photopeak window for the 99mTc studies is a 20% window centered on 140 
keV. Thus, the photopeak window used for the 123I studies is 142 keV-175 keV and that 
used for the 99mTc study was 126 keV-154 keV. The image size is 64 pixels x 64 pixels. 
The image data arrays computed from the MCNP data simulated with a different random 
number sequence are flipped from left to right to represent the mirrored view as would be 
seen by the second camera. Figures 6.1-6.5 show the images for the emissions from a 





Figure 6.1. Images of a calibration source in the 159 keV 20% energy window as seen by 
the left gamma camera. These images are from the 123I β-CIT study. The left image is 
generated from the 159 keV emissions only. The right image is generated from the high-




   
Figure 6.2. Images of brain activity in the 159 keV 20% energy window as seen as by the 
left gamma camera. These images are from the 123I β-CIT study. The left image is 
generated from the 159 keV emissions only. The right image is generated from the high-





   
Figure 6.3. Images of activity in the right striatum in the 159 keV 20% energy window as 
seen by the left gamma camera. These images are from the 123I β-CIT study. The left 
image is generated from the 159 keV emissions only. The right image is generated from 




   
Figure 6.4. Images of activity in the left striatum in the 159 keV 20% energy window as 
seen by the left gamma camera. These images are from the 123I β-CIT study. The left 
image is generated from the 159 keV emissions only. The right image is generated from 





   
Figure 6.5. Images of activity in the GI tract (left) and lungs (right) in the 159 keV 20% 
energy window as seen by the left gamma camera. These images are from the 123I β-CIT 





Figure 6.6. 123I β-CIT images 1:1 simulated data. These images are before conjugate 
imaging calculation. Image on the left is from the left simulated gamma camera. Image 




by the left gamma camera for the case of 123I β-CIT. Figure 6.6 is the sum of the 
calibration, brain activity uptake, striatal activity uptake, lungs activity uptake, and GI 
tract activity uptake image data. This represents a complete emission conjugate imaging 
images for the study. 
 
6.1.3 Conjugate Imaging 
The theoretical development of the conjugate imaging calculations for two 
aligned sources is discussed in chapter 3.  In summary, conjugate imaging requires three 
data sets, emission, transmission, and flood data sets. The transmission data are used to 
determine the effective attenuation coefficient. The flood data are used to determine the 
camera sensitivities. The emission data are used to estimate the activity in the left and 
right striata above background using the estimated attenuation coefficient and the 
estimated camera sensitivities. A relative striatal uptake study is also performed to 
compare the accuracy of conjugate imaging estimations of striatal uptake ratios. 
The conjugate imaging calculations performed in these studies require two 
regions of interest (ROIs), a striatal ROI and a background ROI. The conjugate imaging 
calculations are performed pixel by pixel within the striatal ROI. The background ROI is 
used to determine the background activity, the activity distributed in the brain. The 
activity in the background ROI is scaled by the ratio of average brain thickness in the 
striatal ROI and background ROI. The estimated background activity is subtracted from 
the estimated activity in the striatal ROI. The dimensions of these ROIs are determined in 
a ROI study. The ROI study is discussed in the following section. 
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Several deviations are made in order to simulate acceptable statistically accurate 
data within reasonable execution times. An effective attenuation coefficient, determined 
from transmission data, is not used in the conjugate imaging calculations. Instead, 
narrow-beam and broad-beam attenuation coefficients from published data are used. Use 
of a uniform attenuation coefficient is considered to be reasonable as Monte Carlo 
simulations have shown that transmission-based non-uniform attenuation correction is 
not crucial for brain studies (Van_Laere, Koole et al. 2000; Van_Laere, Koole et al. 
2001; Kim, Varrone et al. 2003). A constant attenuation coefficient used in quantitative 
brain studies produce reasonably accurate results (Tsui 1996; Van_Laere, Koole et al. 
2000; Van_Laere, Koole et al. 2001). The narrow-beam attenuation coefficients used are 
interpolated from the published data from the National Institute of Standards and 
Technology (NIST). The broad-beam attenuation coefficients used are from published 
striatal studies. For the 123I studies the narrow-beam attenuation coefficient and the 
broad-beam attenuation coefficient are 0.1481 cm-1 and 12 cm-1, respectively (NIST 2004 
and Soret et al. 2003). The broad-beam attenuation coefficient used for 123I is determined 
using a linear relationship between the narrow-beam and broad-beam attenuation 
coefficients of 123I and 99mTc (Soret et al. 2003). The narrow beam attenuation and broad-
beam attenuation coefficient used in the 99mTc studies are 0.1526 cm-1 and 0.12 cm-1, 
respectively (NIST 2004)(Harris, Greer et al. 1984; Zaidi and Montandom 2002). The 
narrow-beam attenuation coefficient is used to represent a situation in which scatter 
photon detection is not taken into account. The broad-beam attenuation coefficient 
represented a situation in which scatter photon detection is taken into account. 
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A point source is used instead of a flood source to determine the sensitivity of the 
gamma cameras. The counts detected across the entire scintillation crystal are used to 
determine camera sensitivity. The simulated camera sensitivity data are generated into 
image data array using the same technique for organ-simulated data, excluding scaling 
the data for fractional activity uptake. Figure 6.1 shows an image of the calibration source 
emission. For the 123I sensitivity studies, a total of 200 million photons are simulated 
from the point source, 100 million 159 keV photons and 100 million high-energy 
photons. A total of 100 million 140 keV photons are simulated for the 99mTc sensitivity 
studies. The values in the data arrays are converted into counts/decay and then summed 
over the entire face of the camera to yield the camera sensitivities. 
Due to lack of counts, the background activity is averaged over the background 
ROI. After background subtraction, negative pixel values occur within the striatal ROI. 
To handle the negative pixel values a short iterative algorithm is used to sum all the 
negative pixel values. The sum of the negative pixel values is divided by the number of 
pixels with positive values. This value is subtracted from all positive value pixels and the 
negative values are replaced with zero. This process is repeated until no negative values 
were within the striatal ROI. 
 
6.1.4 ROI Study 
Although a crude ROI study is performed and described in chapter 5 for the 
shielding characterization, a MCNP study is performed to determine the best striatal and 
background ROI dimensions. Choosing an appropriate ROI size is of concern because 
counts from the striatal activity uptake are displaced due to blurring. An appropriate ROI 
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will include most of the counts from both striatum. The percent of counts contained in the 
ROIs depends on the proximity of the striatum to the gamma camera. Counts from the 
striatum nearest the gamma camera are consolidated to a smaller region than the counts 
from the far striatum.  
The simulation set-up consists of a gamma camera and a sphere representing a 
striatum. The gamma camera has the same specifications described in the camera model 
section 5.1.2. The striatal sphere has a 2 cm diameter. To represent the left striatum, the 
near striatum, the striatal sphere is placed 4.22 cm from the gamma camera and 1 cm 
superior the gamma camera horizontal midline. To represent the right striatum, the far 
striatum, the striatal sphere is placed 6.0 cm from the gamma camera and 1 cm superior 
the gamma camera horizontal midline. For 123I, 159 keV photons are emitted from the left 
and right striatum separately and detected by the both gamma cameras. For 99m Tc 140 
keV photons are similarly emitted and detected. The total counts in various ROIs are 
compared to the total image counts. Square ROIs are used. The ROI sizes used in this 
study are 13 pixels x 13 pixels, 15 pixels x 15 pixels, 17 pixels x 17 pixels, 19 pixels x 19 
pixels, 26 pixels x 26 pixels, and 32 pixels x 32 pixels. The dimensions of a pixel are 
0.15625 cm x 0.15625 cm. The 13 pixels x 13 pixels ROI is 2.03 cm x 2.03 cm; the side 
of the ROI is approximately the diameter of the striatal sphere. The ROI with13 pixels 
x13 pixels contain 89% of the total counts for the near striatum study and approximately 
77% of the total counts for the far striatum study. Approximately 96% of the total counts 
from the near striatum study are within the ROI with 19 pixels x19 pixels Approximately 
86% of the total counts from the far striatum study are within the 19 pixels x19 pixels 
ROI. Although the percentage of total counts increases as the ROI increases, the 19 pixels 
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x19 pixels ROI is considered to be the best ROI size due to the small FOV of the gamma 
cameras. Larger ROIs increase cross talk between the striatum ROI and the background 
ROI, which is located below the striatal ROI. It should be noted that these count percents 
are determined in the absence of head attenuation and scatter.  
The location of the background ROI is limited by the size of the small FOV 
gamma camera. As a result, background ROIs cannot be drawn too far from the striatal 
ROI. However, background ROIs too close to the striatal region might include counts 
from the activity uptake in the striata resulting in a possible overestimation of 
background activity. This overestimation of background activity reduces the amount of 
estimated activity in the striata. To determine the location of the background ROI, a 
background ROI is placed at different distances from the striatal ROI and the amount of 
background activity is estimated from the counts in the ROI. The counts in the ROI 
placed 4 pixels (0.625 cm) from the bottom edge of the gamma camera produce the 
background activity estimate closest to the known background activity. The background 
activity estimation using background ROIs ranging from 13 pixels x 13 pixels to 32 
pixels x 32 pixels does not vary significantly. As result the size of the background ROI is 
kept at 13 pixels x 13 pixels ROI. 
 
6.2 Results 
6.2.1 Absolute Activity Estimation 
6.2.1.1 13 pixels x 13 pixels ROI
Although it is determined in the ROI study that the 13 pixels x 13 pixels ROI does 
not contain adequate counts, conjugate imaging studies are performed using a 13 pixels x 
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13 pixels ROI for comparative purposes. Conjugate imaging studies for all ROI sizes are 
in Appendix A. Two conjugate imaging studies are performed for each 
radiopharmaceutical. The first study uses a narrow-beam attenuation coefficient and the 
second uses a broad-beam attenuation coefficient. Table 6.2 lists the percent error for the 
estimates of background activity per cm2 for each activity uptake study. The percent error 
for the estimates of background activity, the brain activity uptake, for 123I β-CIT study 
increases as the activity uptake increases. The percent errors for background activity 
estimates for the other radiopharmaceuticals decreases as the activity uptake increases. 
Table 6.3 lists the percent errors for the activity estimates of the left and right striata for 
the 1:1, 2:1, and 5:1 uptake ratios using the 13 pixels x 13 pixels ROI and the narrow-
beam attenuation coefficients. For the 123I radiopharmaceutical studies, the percent errors 
for right and left striata activity estimates for the 1:1 uptake ratio are relatively equal. 
However, as the activity uptake ratio increases, the difference between the percent errors 
increases. The percent error in the activity estimate for the left striatum remains relatively 
stable as the percent error associated with the activity estimate of the right striatum 
increases significantly. For the 99mTc TRODAT study, the difference between the percent 
errors also increases. While the percent error for the left striatum increases, the percent 
error for the right striatum decreases. The magnitude and direction of the percent errors 
for the left and right striatum in the 99mTc TRODAT study are considerably smaller than 
those for the 123I radiopharmaceutical studies. The difference between the percent errors 
for the left and right striata is also smaller than the difference for the 123I 
radiopharmaceutical studies. Table 6.4 lists the percent error in the activity estimation of 
the left and right striata for the 1:1, 2:1, and 5:1 uptake ratio using the 13 pixels x 13 
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Table 6.3. Percent Errors for Activity Estimates for Narrow-beam Attenuation Study 
 




Table 6.4. Percent Errors for Activity Estimates for Broad-beam Attenuation Study 




pixels ROI and the broad-beam attenuation coefficients. The percent errors in this study 
are larger than the corresponding percent errors in the narrow-beam attenuation 
coefficient study. The activity estimates are underestimated for all radiopharmaceuticals. 
Similar to the narrow-beam attenuation coefficient study, the differences between the 
percent errors for the left and right striatal activity estimates increase as the activity 
uptakes increase. However, the magnitudes of the differences are considerably larger than 
the corresponding magnitudes in the broad-beam attenuation coefficient study. The 
percent errors in the activity estimates for the left striatum decrease as the percent errors 
associated with the activity estimates of the right striatum increase significantly for all 
radiopharmaceuticals. 
 
6.2.1.2 19 pixels x 19 pixels ROI
 The 19 pixels x 19 pixels ROI is chosen as the best ROI size because of the size 
of the conjugate imaging system FOV and adequate counts from both striata are 
contained in this ROI. The estimates of the background activity per cm2 for the activity 
uptake studies are listed in Table 6.5. Similar to the 13 pixels x 13 pixels ROI study, the 
percent errors associated with the background activity estimates for the 123I β-CIT study 
increase as the activity uptake ratios increase. The magnitudes of the percent errors are 
larger for the 19 pixels x 19 pixels ROI. The percent errors in the other 
radiopharmaceutical studies are smaller than the percent errors in the 13 pixels x 13 
pixels ROI study and decrease as the activity uptake ratios increase. Table 6.6 lists the 
percent error for the estimates of activities in the left and right striata for the 1:1, 2:1, and 
5:1 activity uptake ratios using the 19 pixels x 19 pixels ROI and the narrow-beam 
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Table 6.6. Percent Errors for Activity Estimates for Narrow-beam Attenuation Study 
 




attenuation coefficient. The percent errors associated with the left and right striata for the 
123I radiopharmaceutical studies are within ±11% for all three uptake ratios. As the 
activity ratios increase, the activity estimates for the left striatum slightly decrease and 
the activity estimates for the right striata increase. Table 6.7 lists the percent errors for the 
estimates of activities in the left and right striata for the 1:1, 2:1, and 5:1 striatal uptake 
ratios using the 19 pixels by 19 pixels ROI and the broad-beam attenuation coefficient. In 
the 123I radiopharmaceutical studies, the activity estimates for all activity uptake ratios are  
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Table 6.7 Percent Errors for Activity Estimates for Broad-beam Attenuation Study 
 




underestimated. As the activity uptake ratios increase, the percent errors for the left 
striatum decrease and the percent errors for the right striatum increase. The percent errors 
for the right striatum are similar for all 123I radiopharmaceutical studies. For the 99mTc 
TRODAT study, the percent errors for activity estimates for left striatum and right 
striatum increase as the activity uptake ratios increase. The percent errors for the 99mTc 
TRODAT are considerably smaller than the percent errors for the 123I studies. 
 
6.2.2 Relative Activity Estimation 
Relative activity uptake ratios are also calculated using the activity estimates 
calculated from the 13 pixels x 13 pixels ROI and narrow-beam attenuation coefficient 
study and the 19 pixels x 19 pixels ROI and narrow-beam attenuation coefficient study 
described above. These studies are chosen because the activity estimates determined in 
these studies have relatively small percent errors. Figure 6.7 is a graph of the percent 
errors for the calculated relative uptake ratios using the 13 pixels x 13 pixels ROI and 
narrow-beam attenuation coefficient. The percent errors associated with the estimated  
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Figure 6.7. Relative uptake ratio for 13 pixels x 13 pixels ROI. Percent error in activity 
ratio between left and right striatum using the 13 pixels x 13 pixels ROI and a narrow-




activity ratios for the 1:1 and 2:1 ratios are less than 10% for all radiopharmaceutical 
studies.  The percent error for the estimated activity ratio for the 5:1 ratio varies widely 
among the radiopharmaceuticals. The 123I β-CIT study generates the worst percent error 
(36.5%) and 99m Tc TRODAT generates the best percent error (1.9%). 
Figure 6.8 is a graph of the percent errors for relative uptake ratios calculated 
using the 19 pixels x 19 pixels ROI and narrow-beam attenuation coefficient. The percent 
errors associated with the estimated activity ratios for the 1:1 and 2:1 activity uptake ratio 
are less than -9% for all radiopharmaceutical studies. Unlike the 13 pixels x 13 pixels  
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Figure 6.8. Relative uptake ratio for 19 pixels x 19 pixels ROI. Percent error in activity 
ratio between left and right striatum using the 19 pixels x 19 pixels ROI and a narrow-




ROI study, the differences between percent errors among the radiopharmaceuticals are 
relatively small. The 99m Tc TRODAT study generates the worst percent error of -16.2% 
and the 123I IBZM study generates the best percent error of -12.6% 
 
6.3 Discussion 
Simulation studies are performed to assess the accuracy of activity estimates for 
each of the striata determined using the modified conjugate imaging technique and a 
proposed dedicated conjugate imaging system. The accuracies of the activity uptake 
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ratios between the left and right striata are also determined using the technique and 
imaging system. The biodistributions of four radiopharmaceuticals are used in the studies 
to evaluate the influence of biodistribution on the accuracy of estimation of activities in 
left and right striata and estimation of activity uptake ratios. The agents used are chosen 
because of their clinical viability. The activity uptake in the right sphere representing the 
right striata is varied to simulate unequal activity uptake in the left and right striata 
characteristic in Parkinson’s disease. 
The accuracy of the activity estimate for each striatum is influenced by ROI size, 
attenuation coefficient, and biodistribution of the radiopharmaceutical. ROI size and 
attenuation coefficient are correlated in their influence on accuracy. The activity 
estimates determined from the counts in the 13 pixels x 13 pixels ROI are on average 
smaller than activity estimates determined from counts in the 19 pixels x 19 pixels ROI 
due to the lack of counts. The extent of this underestimation of activity is dependent on 
the attenuation coefficient applied. The application of the broad-beam attenuation 
coefficient results in large underestimations of the activity uptakes for the 13 pixels x 13 
pixels and 19 pixels x 19 pixels ROI. This indicates that the broad-beam attenuation 
coefficient chosen is too broad, overestimating the detection of scattered photons. The 
modified conjugate imaging technique uses a measured effective attenuation coefficient 
to account for attenuation and the inclusion of scattered photons. It is determined through 
error analysis of the modified technique that -2.5% error in the attenuation coefficient of 
the brain results in 1-7% underestimation errors in the activity estimates. Although the 
use of constant attenuation coefficients is warranted, the large percent errors for the 
activity estimates suggest that the broad-beam attenuation coefficient used is 
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underestimated by more than 2.5%. A measured effective attenuation coefficient might 
produce more accurate results, as the effects of geometry might thus be better modeled. 
The studies are performed without skull effects. Modeling of a skull will increase 
attenuation and scatter. An effective attenuation coefficient would include these effects. 
However, use of a transmission-based attenuation coefficient could introduce statistical 
error and might require an averaging technique as did the background activity 
estimations. 
The differences in biodistribution influence the accuracies of the background and 
striatal activity estimates. When the percent uptake for the striata was larger or 
comparable to the percent uptake of brain, the percent errors for background activities are 
significantly overestimated. Scatter from the striatal region contribute counts to the 
background ROI, which result in an overestimation of background activity. Due to the 
large difference in volumes between the striata and the brain, comparable percent uptakes 
indicate that activity concentration in the brain is significantly smaller than that of the 
striata. As a result, a small amount of scatter contribution into the background ROI 
translates to a larger fractional increase. The magnitudes of the percent errors for the 
striatal estimates are also associated with the differences between the percent uptake of 
the striata and brain. Larger differences between the percent uptakes of striata and brain 
result in larger percent errors in activity estimates. The differences in magnitudes for the 
123I radiopharmaceuticals are less apparent for the broad-beam attenuation coefficient 
studies.  
The 99mTc radiopharmaceutical studies usually results in an overestimation of 
activity, especially when the narrow-beam attenuation coefficient is applied. This is 
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contrary to the 123I studies, which usually result in an underestimation of activity. This 
difference can be attributed to the difference in emission spectra between 99mTc and 123I, 
which influences the detection and inclusion of scattered photons in calculations. The 
inclusion of counts from scattered photons decreases the estimated camera sensitivity by 
increasing the number of counts detected per known activity amount. Although the 
inclusion of counts from scattered photons also increases the estimates of activity, the 
influence of scattered photons in the calculation of camera sensitivity is greater.  The 
relationship between the detection of scattered photons and camera sensitivity is 
dependent on the attenuation coefficient used. The relationship between the detection of 
scattered photons and activity estimates is also dependent on the attenuation coefficient 
used. This dependence is significant, when the attenuation coefficient used is not 
measured. Since the camera sensitivity for 123I studies is determined using the primary 
and high-energy photon emissions of 123I, the camera sensitivity is underestimated. This 
underestimation results in the underestimation of the activity estimates. This suggests that 
the underestimation of camera sensitivity has more influence than the inclusion of 
scattered photons in the estimation of activity estimates. This is supported by preliminary 
studies that show activity estimates determined using only the primary emission of 123I 
are overestimated, when using narrow-beam attenuation coefficient. This is because 
narrow-beam attenuation coefficients do not account for the detection of scattered 
photons. As a result, the detected scattered photons are treated as primary photons. The 
influence of scatter is apparent in these simulation results. Accordingly, scatter correction 
is applied to this simulated data. The method and results of scatter correction are 
discussed in chapter 7. 
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6.4 Clinical Relevance 
The clinical application of modified conjugate imaging using the dedicated 
conjugate imaging system is striatal imaging with specific application to the diagnosis 
and management of Parkinsonism and schizophrenia. Several simulation studies are 
performed where the ROI size and attenuation coefficient are changed. The 19 pixels x 
19 pixels ROI is deemed more clinically applicable as the ROIs drawn in clinical settings 
are more likely to be drawn larger than the physical dimensions of the striata due to 
limited spatial resolution. Although the broad-beam attenuation coefficient would be 
considered a better representative of attenuation coefficients determined from 
transmission data, the broad-beam attenuation coefficient chosen was considered too 
broad. Thus, the 19 pixels x 19 pixels ROI study using the narrow-beam attenuation 
coefficient is used to determine the technique’s efficacy. For absolute activity estimation, 
the modified conjugate imaging technique could be used to diagnosis early- and late-
stage Parkinson’s disease patients with an accuracy of ±11%. This is limited to 123I 
radiopharmaceuticals. 99mTc TRODAT could be used to diagnosis and differentiate 
between healthy and early-stage Parkinson’s disease patients using the broad-beam 
attenuation coefficient with an accuracy of ±8%. Relative uptake ratio estimations are 
useful in monitoring the progression of Parkinson’s disease and schizophrenia. The 
modified conjugate imaging could monitor the onset of disease, which is often presented 









 Approximately 20%-40% of all counts detected are from scattered photon 
interactions, primarily Compton scattering events (Jaszczak, Greer et al. 1984; Rosenthal, 
Cullom et al. 1995). The detection of these scattered events degrades spatial resolution 
and inflates counts. For quantitative single-photon emission studies this count inflation 
leads to an overestimation of activity. Thus, an accurate quantitative emission study has 
to correct for scatter detection in addition to effects of attenuation. Conjugate imaging, 
classic or the new modified technique presented in this dissertation, accounts for 
attenuation by using transmission data. Classic conjugate imaging corrects for attenuation 
by using the transmission data to estimate e-µt where t is the thickness of the patient or 
some part of the patient. Modified conjugate imaging accounts for attenuation by using 
the transmission data to estimate an effective attenuation coefficient. However, conjugate 
imaging does not correct for the effects of scatter detection. In chapter 6, Monte Carlo 
simulations using the modified conjugate imaging and a model of a dedicated conjugate 
imaging system are performed to evaluate the accuracy of activity estimates in each 
striatum. In the MCNP model, the striata are modeled as left and right spheres. Following 
the initial simulation, a scatter correction technique was applied to selected data sets from 
the simulation studies presented in chapter 6. This is done to improve the quantitative 
accuracy of the activity estimates in the left and right striata. The triple energy window 
(TEW) technique is the scatter correction technique used in this simulation study. The 
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results from this study are evaluated and compared with the simulated results reported in 
the previous chapter.  This chapter discusses the triple energy window technique and 
reports the results of application of the technique in this setting. This chapter concludes 
with a discussion section that evaluates the accuracy of activity estimations determined 
using scatter-corrected data and of the clinical value of the combination of the TEW 
technique and conjugate imaging of two aligned sources. 
 
7.1 Triple Energy Window 
 The triple energy window (TEW) technique was introduced in 1991 by Ogawa et. 
al. as a practical SPECT scatter technique (Ogawa, Harata et al. 1991). The TEW 
technique is an energy-distribution-based scatter correction technique. Energy-
distribution-based scatter correction techniques use the number of counts in various 
energy windows to determine the amount of scatter in the photopeak window. TEW uses 
counts in two narrow energy windows adjacent to the photopeak window to estimate 
scatter in the photopeak window. Figure 7.1 illustrates example locations of the three 
energy windows used in TEW. TEW has become a popular scatter correction technique 
for SPECT studies using radiopharmaceuticals with secondary higher-energy photon 
emissions. TEW can account for downscatter in the photopeak from these higher-energy 
photons emissions, as well as scatter from primary photon emissions. The scatter estimate 














C +=     (7.1) 
 
where Clower is the number of counts in the lower-energy window; Cupper is the number of 
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Figure 7.1. Locations of the energy windows used in standard TEW. Clower are the counts 
in the lower energy window with a width of ws. The counts in the lower window are from 
scattered photons with initial energy of that of the primary photon emissions or high-
energy photon emissions. Cupper is the counts in the upper energy window with a width of 
ws. The counts in the upper window are from downscattered high-energy photon 




















counts in the upper-energy window; ws is the width of the sub-windows; wm is the width 
of the photopeak window, and Cscat is the number of counts in the photopeak window that 
represent scattered photons. The scatter estimate is referred to as a trapezoidal 
approximation because the equation of the scatter estimate is that of the area of a 
trapezoid. The estimated scatter counts are then subtracted from the photopeak window to 
yield the primary photons  
 
scattotalprim CCC −=    (7.2) 
 
where Cprim is the counts of primary photons in the photopeak window (non-scattered 
photons) and Ctotal is the counts of primary and scattered photons in the photopeak 
window (primary and scattered photons). The estimation and subtraction of scatter is 
performed for each pixel in each SPECT projection. 
For radiopharmaceutical studies with primary and secondary higher-energy 
photon emissions, such as 123I imaging studies, the counts in the lower-energy window 
are from scattering of primary photons and scattered higher-energy photons. The upper-
energy window contains counts from scattered high-energy photons. For 99mTc imaging 
studies, the higher-energy sub-window is set to zero, as 99m Tc does not emit high-energy 















This scatter estimate is known as a triangular approximation as the number of scattered 
counts in the photopeak window is estimated by the area of a triangle. 
 The TEW technique is not object or imaging system dependent.  It does not 
require object and imaging system calibration to remove the scatter component 
adequately. The triple energy window method is emission spectrum dependent. The 
effectiveness of the TEW scatter compensation technique has been reported in 
quantitative imaging studies using 123 I and 99m Tc activity distributions (King, Long et al. 
1991; Ogawa, Harata et al. 1991; Buvat, Benali et al. 1994; Buvat, Rodriguea-Villafuerte 
et al. 1995; Haynor, Kaplan et al. 1995; Narita, Eberl et al. 1996; Pollard, Lewellen et al. 
1996; Hashimoto, Sasaki et al. 1999; Leong, O' Connor et al. 1999; Buvat, Soret et al. 
2001; Moore, Kijewski et al. 2001; Soret, Koulibaly et al. 2003; Vines, Ichise et al. 
2003). Since TEW can be applied as a post-processing technique and can be applied 
directly to projections, it has been used for planar studies. (Ichihara, Ogawa et al. 1993; 
Okada, Imal et al. 1999; Deplon, Ferrer et al. 2003). TEW can be performed before an 
attenuation correction technique is applied (Ichihara, Ogawa et al. 1993). 
 
7.2 Monte Carlo Simulations 
 Chapter 6 describes and presents results from simulated conjugate imaging 
studies. Estimated activity uptakes for the left and right striatal spheres are determined 
using several combinations of ROI sizes and attenuation coefficients. The best estimates 
are determined when the 13 pixels x 13 pixels ROI and narrow-beam attenuation 
coefficient and the 19 pixels x 19 pixels ROI and broad-beam attenuation coefficient are 
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used. Accordingly, the scatter correction studies presented in this chapter report results, 
which are determined using these parameters. 
Similar to chapter 6 methods, simulation of data acquisition requires two steps. 
The first step is to perform MCNP simulations. The second acquisition step is processing 
the Monte Carlo output into image array data.  Once the image data arrays are generated, 
the image data were scatter-corrected using the TEW technique. Then the activities in the 
left and right striata are estimated from the scatter-corrected image data using the 
modified conjugate imaging technique. Data acquisition, the simulated geometry, and the 
application of the modified conjugate imaging technique are discussed in the methods 
section in chapter 6. The application of TEW to the simulated data sets is described in the 
following section. Two simulation studies are performed using 123I and 99m Tc 
radiopharmaceuticals. The radiopharmaceuticals used are 123I β-CIT, 123I FP-CIT, 123I 
IBZM, and 99mTc TRODAT. The percent uptakes of the administered 
radiopharmaceutical used in these studies are listed in Table 6.1. Narrow-beam and 
broad-beam attenuation coefficients are used in the 123I and 99mTc studies. The selection 
of the attenuation coefficients is discussed in chapter 6. Two striatal ROI sizes are used in 
these studies. The first set of studies use a 13 pixels x 13 pixels ROI and a narrow-beam 
attenuation coefficient and the second use a 19 pixels x 19 pixels ROI and a broad-beam 
attenuation coefficient. 
 
7.2.1 TEW Scatter Correction 
Scatter correction is performed before conjugate imaging calculations are 
performed. Two scatter correction studies are performed. In the first study only the 
 183
 
emission data is scattered corrected. In the second study the camera sensitivity data and 
the emission data are scattered corrected. Typically, the lower and upper energy windows 
are narrow and abut the photopeak window to ensure that the scatter distribution in these 
side windows closely approximates the scatter distribution in the photopeak window. 
Unfortunately, narrow windows translate to low counts, which result in noisy scatter 
estimations (King and Farncombe 2003). In the 123I studies, five sets of energy windows 
are investigated. Table 7.1 lists the upper and lower energy windows used in the 123I 
studies. In study one, larger lower window of 12 keV lower energy window and a 5 keV 
upper energy window are used. Study 2 uses energy windows based on Monte Carlo 
spectral studies. Monte Carlo studies are performed to analyze the 159 keV primary 
component and the high-energy component of the 123I spectrum. Study 3 uses a 5 keV 
and a 5 keV upper energy window. Study 4 uses overlapping energy windows. Study 5 




Table 7.1. Scatter energy windows for 123I studies. 
Study Lower Energy Window Upper Energy Window 
1 130-142 175-180 
2 130-140 185-190 
3 137-142 175-180 
4 139-144 173-178 





Figure 7.2 is the emission spectral data generated from the MCNP simulations of the 123I 
emissions.  The primary and high-energy components are graphed individually. The 
backscatter peak for the 529 keV photon emissions smears into the upper bound of 
photopeak window. (A backscattered 529 photon has a energy of 173 keV. The upper 
bound of the photopeak in this analysis is the 170-175 keV bin as the energy of the 
spectrum was binned into 5 keV bins.) The backscatter peak is relatively symmetric with 
a peak at 180-185 keV. As a result, the counts in the 170-175 keV window from the high 
energy emissions are equal to the total counts in the 185-190 keV window, which are 
from high energy emissions. Thus, the 185-190 keV window is considered to be a good 
representation of the high-energy scatter contribution in the 170-175 keV. To investigate 
the significance of the upper energy window, the last energy window set contains only an 
abutting lower energy window that is 13 keV wide. 
For the 99m Tc studies the upper energy window is omitted. The lower energy 
window is based on MCNP spectral data study of 140 keV photon emission of 99m Tc in 
water.  The width and placement of the lower energy window is varied. Figure 7.3 is the 
spectral data generated from the MCNP simulations of the 99m Tc emissions. Table 7.2 
lists the windows used in the 99m Tc study. The lower energy window 121-126 keV used 
is based on previous studies (Zaidi 1996). An abutting energy window of 114-126 and an 























Figure 7.2. 123I emission spectrum in water. 123I emission spectrum in water as detected 
by a gamma camera from the conjugate imaging system simulated using MCNP 4c. The 
gamma camera was simulated with an energy resolution of 12% full width half maximum 
at 159 keV. The curve entitled Total represents the complete 123I spectrum. The 159 keV 
photon emissions are represented by the Primary curve. The high-energy photon 
emissions are represented by the High curve. It is apparent from the graph that the high-
energy photon emissions are responsible for the counts in the upper region of the Total 
spectrum. There is a symmetric curve about 180 keV in the high-energy photon spectrum. 
This curve is due to the backscattering of the 529 keV photon emissions. The selection of 
185-190 keV scatter window was based on this backscatter curve. Due to the symmetric 
nature of the curve, the counts in the 185-190 window closely approximates the scatter 
























Figure 7.3. 99mTc photon emissions in water. 99mTc photon emissions in water as detected 
by a gamma camera from the conjugate imaging system simulated using MCNP 4c. The 




Table 7.2. Scatter energy windows for 99mTc studies. 
Study Lower Energy Window Upper Energy Window 
1 121-126 none 
2 114-126 none 





7.3.1 123I Radiopharmaceutical Studies 
 The results presented in the following sections are determined using TEW scatter 
energy windows listed in tables 7.2 and 7.3 for the 123I and 99mTc studies, respectively. 
The ROI and attenuation coefficient combination used are 13 pixels x 13 pixels ROI and 
narrow-beam attenuation coefficient and 19 pixels x 19 pixels ROI and broad-beam 
attenuation coefficients. Results from simulation studies performed with different 
combinations of ROI sizes and attenuation coefficients can be found in the Appendix B. 
 
7.3.1.1 Scatter-Corrected Emission Only Study 
Tables 7.3-7.12 lists the percent errors associated with the conjugate imaging 
calculations using TEW scatter corrected emission data from selected 123I 
radiopharmaceuticals. The application of TEW to the emission data results in the 
underestimation of activity estimates for the left and right striatum. Tables 7.3-7.7 list 
percent errors from studies that used a 13 pixels x 13 pixels ROI and narrow-beam 
attenuation coefficient. The percent errors for the activity estimates in the left and right 
striata are approximately equal for each activity uptake ratio and each scatter 
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Table 7.3. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper:175-180 
 




Table 7.4. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 185-190 
 




Table 7.5. Percent Error in Striatal Activity Estimates; Lower:137-142, Upper:175-180 
 
Narrow-beam attenuation coefficient used: 0.1481 cm-1
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Table 7.6. Percent Error in Striatal Activity Estimates; Lower:139-144, Upper: 173-178 
 




Table 7.7. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 000-000 
 




correction study. Although the percent errors for the left and right activity estimates are 
close in magnitude, the percent errors do vary. The largest relative difference between 
percent errors for the left and right activity estimates is observed in the 5:1 uptake ratio. 
The percent errors for the left striatum increase with an increase in the activity uptake 
ratio (1:1 – 5:1). The changes in magnitude in the percent error for the right activity 
estimate are dependent on the radiopharmaceutical and scatter energy windows used. For 
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the studies using the 1) 130-142 keV and 175-180 keV, 2) 137-142 keV and 175-180 keV 
and 3) 139-144 keV and 173-178 keV scatter energy windows, the percent errors for the 
activity estimates in the right striatuu decrease. The studies using the 1) 130-142 keV and 
185-190 keV and 2) 130-142 keV and 000-000 keV scatter energy window produce 
similar percent errors, where the percent errors for the right activity estimates increase 
with the exception of 123I IBZM and scatter energy windows of 130-142 keV and 185-
190 keV. The most accurate activity estimates, defined by magnitude of percent error and 
relative difference between the percent error for the left and right activity estimates, are 
produced from the study using lower energy window 130-142 keV and high-energy 
window of 185-190 keV. The least accurate activity estimates are produced from the 
study using lower energy window of 139-144 keV and upper energy window of 173-178 
keV. 
Tables 7.8-7.12 list the percent errors from studies using a 19 pixels x 19 pixels 
ROI and a broad-beam attenuation coefficient 0.12 cm-1. The percent errors in this study 
are larger than the 13 pixelss x 13 pixelss ROI study, with the exception of the percent 
errors associated with the123I β−CIT 5:1 uptake ratio. The differences in percent errors 
with respect to the radiopharmaceuticals in a given scatter energy window set are larger 
in this study. The percent errors for the left striatum decrease as the activity uptake ratios 
increase for all radiopharmaceuticals and all scatter energy window studies. The changes 
in direction (increase or decrease) and magnitudes of percent errors for the right striatum 
are dependent on the radiopharmaceutical and scatter energy window study. The 




Table 7.8. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper:175-180 
 




Table 7.9. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 185-190 
 




Table 7.10. Percent Error in Striatal Activity Estimates; Lower:137-142, Upper:175-180 
 
Broad-beam attenuation coefficient used: 0.12 cm-1
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Table 7.11. Percent Error in Striatal Activity Estimates; Lower:139-144, Upper: 173-178 
 




Table 7.12. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 000-000 
 




striatum are significantly larger than the changes in the percent errors for the activity 
estimate in left striatum. Similar to the 13 pixels x 13 pixels ROI study, the largest 
differences in percent errors between the left and right striata are for the 5:1 activity 
uptake ratio. The percent errors from studies using the scatter energy windows 139-144 
keV and 173-178 keV are on average larger than the percent errors from the other energy 
window studies. Studies using the 130-142 keV and 185-190 keV energy windows 
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produce the most accurate activity estimates as a whole. It is important to note that the 
percent errors from both ROI studies are on the same magnitude. 
 
7.3.1.2 Scatter-Corrected Emission and Camera Sensitivity Study
 Tables 7.13-7.22 list percent errors associated with activity estimates determined 
using scattered corrected emission and camera sensitivity data. Tables 7.13-7.17 list the 
percent errors from studies that used the 13 pixels x13 pixels ROI and narrow-beam 
attenuation coefficient 0.1481 cm-1. The percent errors for the uptake ratios are 
significantly smaller than the corresponding scatter correction study using the same 
energy windows but applied only to the emission data. Although the percent errors are 
smaller, the differences in percent errors among the radiopharmaceuticals and scatter 
energy window sets are larger. The percent errors for the left striatum increase for all 
scatter energy windows except the scatter energy window study using the lower energy 
window 130-142 keV only. The percent errors for the activity estimate for the right 
striatum do not follow a trend but instead are dependent on the radiopharmaceutical and 
scatter energy windows. The study using the lower energy window of 130-142 keV only 
produces the worst percent errors. The most accurate activity estimates, defined by the 
magnitude of percent error and relative difference between the percent error for the left 
and right activity estimates, are produced from the study using lower energy window 






Table 7.13. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 175-180 
 




Table 7.14. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 185-190 
 




Table 7.15. Percent Error in Striatal Activity Estimates Lower:137-142, Upper: 175-180 
 
Narrow-beam attenuation coefficient: 0.1481cm-1
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Table 7.16. Percent Error in Striatal Activity Estimates; Lower:139-144, Upper: 173-178 
 




Table 7.17. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 000-000 
 




Tables 7.18 -7.22 list the percent errors from studies that used the 19 pixels x19 pixels 
ROI and broad-beam attenuation coefficient 0.12 cm-1. The percent errors in this study 






Table 7.18. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 175-180 
 




Table 7.19. Percent Error of Striatal Uptakes; Lower:130-142, Upper: 185-190 
 




Table 7.20. Percent Error in Striatal Activity Estimates; Lower:137-142, Upper: 175-180 
 
Broad-beam attenuation coefficient: 0.12cm-1
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Table 7.21. Percent Error in Striatal Activity Estimates; Lower:139-144, Upper: 173-178 
 




Table 7.22. Percent Error in Striatal Activity Estimates; Lower:130-142, Upper: 000-000 
 




corrected. The percent errors for the left striatum decrease, while percent errors for the 
right striatum increase as the activity uptake ratios increase for all radiopharmaceuticals 
and scatter energy windows. The magnitudes of the percent errors in the 19 pixels x 19 
pixels ROI study are higher than the percent errors in the 13 pixels x 13 pixels ROI study. 
The study using only a lower scatter energy window of 130-142 keV produces the least 
accurate activity estimates for all radiopharmaceuticals. There is no one scatter energy 
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window set that produces the best results for all three activity uptake ratios and for all 
radiopharmaceuticals. Reasonable estimates for the 1:1 and 2:1 activity uptake ratios are 
determined for all scatter energy window sets. For the 5:1 activity uptake ratio, the 
accuracy of the activity estimates is dependent on the scatter energy window set. The 
study with scatter energy windows 137-142 keV and 175-180 keV produces the most 
accurate activity estimates for 123I β-CIT uptake. The study with scatter energy windows 
139-144 keV and 173-178 keV produce the most accurate activity estimates for 123I FP-
CIT and 123I IBZM uptake. 
 
7.3.2 99mTc Radiopharmaceutical Study 
7.3.2.1 Scatter-Corrected Emission Only Study 
Tables 7.23-7.24 list the percent errors from studies using scatter-corrected 
emission data only. Table 7.23 lists the percent errors associated with activity estimates 
determined using 13 pixels x 13 pixels ROI and narrow-beam attenuation coefficient 
0.1526 cm-1. Percent errors for the left striatum decreas, while the percent errors for the 
right striatum increase, as the activity uptake ratios increase. The study using the lower 
scatter energy window of 114-126 keV produces the most accurate activity estimates for 
both striata. The magnitude of increases in the percent errors for the right striatum is 
larger than the magnitude of decrease in the percent errors for the left striatum.  
Table 7.24 lists the percent errors for studies using the 19 pixels x 19 pixels ROI 
and broad-beam attenuation coefficient of 0.12 cm-1. Similar to the 13 pixels x 13 pixels 
ROI study, the percent errors for the activity estimates in the left striatum decrease, while 
the percent errors for the right striatum increase, as the activity ratio uptakes increase. 
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Table 7.23. 99mTc TRODAT Percent Error in Striatal Activity Estimates 
 




Table 7.24. 99mTc TRODAT Percent Error in Striatal Activity Estimates 
 




However, the magnitudes of the percent errors are significantly larger in the 19 pixels x 
19 pixels ROI study. The most accurate activity estimates are determined using the 114-




7.3.2.2 Scatter-Corrected Emission and Camera Sensitivity Study 
Tables 7.25-7.26 list the percent errors from studies using scatter-corrected 
emission and camera sensitivity data. Table 7.25 lists the percent errors associated with 
activity estimates determined using 13 pixels x 13 pixels ROI and narrow-beam 
attenuation coefficient 0.1526 cm-1. The activity estimates in this study are more accurate 
than the activity estimates determined using scatter-corrected emission data only. The 
exception is the study using the scatter energy window 123-128 keV for activity uptake 
ratios 1:1 and 2:1. For the studies using the scatter energy windows 121-126 keV, percent 
errors for the left and right striata increase as the activity uptake ratios increase. For the 
study using the scatter energy window 114-126 keV, the percent errors for the left 
striatum increase, while the percent error for the right striatum decrease for activity ratios 
1:1 and 2:1. For the study using the scatter energy window 123-128 keV, the percent 
errors for the left striatum increase, while the percent errors for the right striatum 
decrease as the activity uptake ratios increase. The magnitudes of change in the percent 
errors for the right striatum are larger than those of the left striatum, especially for 123I 
IBZM. The differences in the percent errors among the three studies are not as great as 
the differences in the studies using only scatter-corrected emission data. The study using 
the scatter energy window of 114-126 keV produces the most accurate activity estimates. 
Table 7.26 lists the percent errors for studies using the 19 pixels x 19 pixels ROI 
and broad-beam attenuation coefficient of 0.12 cm-1. The magnitudes of percent errors 
are less in this 19 pixels x 19 pixels ROI study than in the corresponding study using 
scatter corrected emission data only. The percent errors for the activity estimates in the 
left striatum decrease and the percent errors for the right striatum increase as the activity  
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Table 7.25. 99mTc TRODAT Percent Error in Striatal Activity Estimates 




Table 7.26. 99mTc TRODAT Percent Error in Striatal Activity Estimates 
 




uptake ratios increase. The most accurate activity estimates for the 1:1 and 2:1 uptake 
ratios are determined using the 114-126 keV scatter energy window. The most accurate 






The triple energy window (TEW) technique is the scatter correction technique 
used to scatter correct data used in the modified conjugate imaging studies. It is chosen 
because of its applicability to planar images, its treatment of high-energy photon 
emission downscatter and easy implementation into the clinic. Conventional lower and 
upper scatter energy windows have been narrow and abut the photopeak window 
(Ogawa, Harata et al. 1991; Ichihara, Ogawa et al. 1993; Rosenthal, Cullom et al. 1995; 
Narita, Eberl et al. 1996; Okada, Imal et al. 1999; Deplon, Ferrer et al. 2003; King and 
Farncombe 2003; Soret, Koulibaly et al. 2003). In addition to the standard scatter energy 
windows, a couple of unconventional scatter energy window sets are used in these 
studies. These are not equal in width and not adjacent to the photopeak window. A total 
of five energy window sets are used to scatter correct the image data in the 123I studies. 
Three energy windows were used in the 99mTc study. Scatter correction techniques are 
usually applied to emission data only. In these studies, two scatter correction studies are 
compared; one in which scatter correction is applied only to the emission data and the 
second study in which scatter correction is applied to on the emission data and the camera 
sensitivity data. The effects of scatter correction on the conjugate imaging calculations 
are evaluated. Conjugate imaging calculations are performed with a 13 pixels x 13 pixels 
ROI and a narrow-beam attenuation coefficient and a 19 pixels x 19 pixels ROI and 
broad-beam attenuation coefficient were used for the 123I and 99mTc studies.  
It was anticipated that the application of scatter correction would further improve 
the accuracy of the estimations of activity in the left and right striatum. However, the 
magnitude of improvement is dependent on 1) which data sets scatter correction are 
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applied; 2) which scatter energy windows are used; 3) the size of the ROI; and 4) the 
radiopharmaceutical. Activity estimates determined using scatter-corrected emission and 
scatter-corrected camera sensitivity data are more accurate than activity estimates 
determined with scatter-corrected emission data only. Scatter correcting the emission data 
decreases the activity estimates, while scatter correcting the camera sensitivity counters 
this decrease by increasing activity estimates due to the increased camera sensitivity. 
Scattered corrected camera sensitivity increases activity estimates because a smaller 
number of counts now represent the known amount of activity, which translated into 
larger activity estimates. 
Although the scatter-corrected emission and camera sensitivity data provide more 
accurate activity estimates, the scatter energy windows do influence the degree of 
accuracy. The scatter energy window selection is influenced by the ROI size and 
biodistribution of the radiopharmaceuticals. The accuracy of the activity estimates 
changes with ROI size because of the inclusion of more scatter. For 
radiopharmaceuticals, like 123I β-CIT, with large brain to striatal activity concentration 
ratio, the activity estimates in the 19 pixels x 19 pixels ROI are, in general, not as 
underestimated as activity estimates determined using radiopharmaceuticals with small 
head to striatal activity concentration ratio, like 123I FP-CIT, 123I IBZM, and 99mTc 
TRODAT. For larger brain to striatal activity concentration ratios, a large fraction of 
counts due to scattered photons are from brain activity. Scatter correction removes these 
counts. However, for smaller brain to striatal activity concentration ratio, the fraction of 
counts from scattered photons from brain activity is small. As a result, scatter correction 
removes more primary counts. This is especially apparent in the 2:1 and 5:1 uptake ratios 
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where the overall activity amount is less. This is most likely compounded by the use of a 
too broad attenuation coefficient, which removes too large a fraction of counts.  
Several studies are performed with various parameters. The best scatter correction 
results are produced when the 13 pixels x 13 pixels ROI, narrow-beam attenuation 
coefficient, and scatter corrected emission and camera sensitivity data are used. Although 
all scatter energy windows produce reasonable percent errors, the best scatter energy 
windows are 130-142 keV and 185-190 keV for uptake ratios 1:1 and 2:1. This is based 
on magnitude and relative difference of percent error between the left and right activity 
estimates. The larger lower scatter energy window of 130-142 keV provides a better 
scatter estimate because it introduces less noise due to the larger number of counts. The 
upper energy window of 185-190 keV is a better estimation of the high-energy scatter 
because unlike the 175-180 keV energy window it contains only scattered counts. The 
best scatter energy window for the 5:1 uptake ratio is the scatter energy windows 139-144 
keV and 173-178 keV. For the 99m Tc studies, the wider lower energy window 114-121 
keV provides the most accurate activity estimates. In the wider window of 114-126 keV, 
the signal to noise ratio is smaller than 121-126 keV window providing for better 
estimation of scatter.  
However, the use of the 13 pixels x 13 pixels ROI and narrow-beam attenuation 
coefficient does not model adequately the clinical setup. The ROI drawn in the clinic will 
most likely be drawn around the striatum highlighted from radiopharmaceutical. Due to 
blurring the striatum projected on the image will be larger than it physical size. This 
indicates that the ROI will not have the dimensions of the physical size of the striatum. 
The attenuation coefficient determined from the flood data will most likely be closer to 
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the value of the broad-beam attenuation coefficient even with scatter correction. Thus, the 
results determined from the 19 pixels x 19 pixels ROI and broad-beam attenuation 
coefficient most accurately model the clinical setting. The broad attenuation coefficient 
used in these studies overcompensates by removing too many counts. The activity 
estimates determined using these parameters are less accurate than the 13 pixels x 13 
pixels ROI study, particularly for the striatum containing less activity (right striatum). 
Although the activities are less accurate, the percent errors are reasonable for the 1:1 and 
2:1 uptake ratio for all radiopharmaceuticals and most scatter energy window sets. The 
percent errors for the activity estimates for both striata for the 5:1 uptake ratio are within 
10% for the 123I β-CIT and 123I FP-CIT for most scatter energy windows. 
 
7.5 Clinical Relevance 
The application of TEW on emission data and camera sensitivity data improves the 
accuracy of the activity estimates for the left and right striata. The percent errors 
associated with the activity estimates for the left and right striata in the 123Ι β-CIT and 123I 
FP-CIT studies for the 1:1, 2:1, and 5:1 uptake ratios suggest that the modified conjugate 
imaging in conjunction with TEW is a feasible quantitative estimation technique for early 
to late Parkinson’s disease striatal studies. 123I IBZM and 99mTc TRODAT provide 










In this dissertation, the development and characterization of conjugate imaging of 
two aligned activity distributions embedded in an attenuating medium, with specific 
application to the quantification of activity uptake in the striata, were reported. The 
actualization of this research involved the completion of six tasks.  Tasks one two and 
three involved the model and general application of the technique. Tasks four, five and 
six were related to the specific application of striatal imaging and neurodegenerative 
diseases.  
The development and assessment of conjugate imaging of the two aligned activity 
distributions with respect to the techniques general applicability were addressed by tasks 
one, two, and three. Task one was the derivation of a tractable mathematical model for 
conjugate imaging of two aligned activity distributions. Other extensions of conjugate 
imaging have been developed, but none have provided a practical means of estimating 
accurately two distinct aligned distributions. Task two was an error analysis of the 
mathematical model. The error analysis demonstrated the model was sensitive to the 
accuracy of the measured input parameters and the activity uptake ratio between the two 
activity distributions. The theoretic error was larger for a 5:1 activity uptake ratio than for 
a 1:1 ratio. Task three entailed the completion of a series of phantom studies to evaluate 
the practical application of the developed model. Software was developed to apply the 
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model to image data acquired using a phantom and a commercially available gamma 
camera system. The activity estimates obtained had accuracy consistent with that 
predicted by the mathematical model. The activity estimates were also comparable to 
activity estimates determined from quantitative analysis of attenuation-corrected SPECT. 
The results from the first three tasks indicated that the modified conjugate imaging 
technique presented can be used to estimate activity accurately in each of two aligned 
activity distributions with a diameter of 3cm or less separated by a distance s. 
Tasks four, five, and six involved the specific application of conjugate imaging of 
activity uptake in the striata of a primate using a novel dedicated small field-of-view 
(FOV) imaging system and 123I and 99mTc- labeled radiopharmaceuticals. These last three 
tasks utilized a Monte Carlo simulation model developed to simulate conjugate imaging 
of activity uptake in the striata of a primate using two small FOV gamma cameras. Task 
four was the designing and characterization of an appropriate shielding design for the 
small FOV gamma cameras comprising the dedicated conjugate imaging system. Task 
five was the use of the simulation model to assess the accuracy of the activity estimates in 
each striatum. To represent healthy, early-stage Parkinson’s, and late-stage Parkinson’s 
patients, three activity uptake ratios were investigated. In addition, four 
radiopharmaceuticals, two attenuation coefficients, and 2 regions of interest (ROIs) were 
investigated. The activity estimates obtained had accuracies consistent with the theoretic 
error analysis. However, the theoretic error analysis did not incorporate the influence of 
ROI size variability and the emission spectrum and biodistribution of 
radiopharmaceuticals. It was apparent from the differences in accuracies of activity 
estimates determined using different ROI sizes and different radiopharmaceuticals that 
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ROI size and choice of radiopharmaceuticals influence the accuracy of the activity 
estimates. Although the accuracies were consistent with the trends predicted by the 
theoretic error analysis, the influence of ROI size and properties of the 
radiopharmaceuticals introduced new correlations, which warrant further investigation. 
Task six was the investigation of the application of scatter correction to data acquired 
from conjugate imaging of two aligned activity distributions. The triple energy window 
(TEW) scatter correction technique was applied to the data obtained from the Monte 
Carlo simulations. It was determined that TEW scatter correction must be applied to 
emission and transmission data to improve accuracies of activity estimates. Even though, 
the scatter correction investigation was specific to the conjugate imaging of primate 
striata, it is probable key aspects of the investigation extrapolate to the general 
application of conjugate imaging of two aligned activity distributions. The results from 
tasks four through six indicated the viability of the modified conjugate imaging technique 
as a tool to evaluate striatal activity uptake. 
 
8.2 Future Work 
The modified conjugate imaging technique presented in this dissertation is a 
viable quantitative imaging technique to evaluate activity uptake in the striata. Its 
accuracy is comparable to that of diagnostic quantitative emission techniques currently 
used in clinical settings. A novel dedicated conjugate imaging system is capable of 
acquiring the data required for modified conjugate imaging of striatal uptake. A next step 




The Monte Carlo simulations were performed with modifications. The attenuation 
coefficients and camera sensitivity were determined for one pixel and applied to all pixels 
instead of on a pixel-by-pixel basis. Future research could include performing Monte 
Carlo simulations using flood data to determine the effective attenuation coefficients and 
camera sensitivity for each pixel. An anthropomorphic phantom could be used in the 
Monte Carlo simulations to account for skull effects. Furthermore, the application of 
alternative scatter correction techniques that are applicable to planar data should be 
pursued. 
Another research direction would include an investigation and clarification of the 
origins of the errors associated with the activity estimates. Error analysis of the modified 
conjugate imaging technique indicated that the accuracy of the activity estimates was 
sensitive to error in depth measurements. This sensitivity is exacerbated when the activity 
uptake ratio is not one to one.  However, there was still a noticeable difference in the 
percent errors between the large and small activity striatum in the simulated studies, 
where the depth of each striatum was accurately known. A thorough investigation could 







 Listed below are the activity uptake estimates determined using the modified 
conjugate imaging technique for various ROI sizes and two attenuation coefficients. This 
data represent the complete set of data generated from the simulations. 
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 Listed below are the activity uptake estimates determined using the modified 
conjugate imaging technique and triple energy window scatter correction for various ROI 
sizes and two attenuation coefficients. This data represents the complete set of data 
generated from the scatter-corrected emission only and scattered-corrected emission and 
camera sensitivity simulations. Tables B.1 - B.55 list the data from the study using 
scatter-corrected emission data only. Tables B.56 - B.109 list the data from the study 
using scatter-corrected emission and camera sensitivity data. The activity estimates listed 




Table B.1. 123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.2. 123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.3. 123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.4. 123I FP -CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.5. 123I FP -CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.6. 123I FP -CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.7. 123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.8. 123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.9. I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 






Table B.10. 123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.11. 123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.12. 123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.13.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.14.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.15.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.16.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.17.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.18.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.19.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.20.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.21.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.22.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.23.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.24.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.25.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.26.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.27.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.28.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.29.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.30. I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 





Table B.31.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.32.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.33.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.34.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.35.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.36.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.37.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.38.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.39.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.40.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.41.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.42.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.43.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.44.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.45.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.46.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data Only; 




Table B.47.99mTc TRODAT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.48.99mTc TRODAT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.49.99mTc TRODAT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.50.99mTc TRODAT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.51.99mTc TRODAT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.52.99mTc TRODAT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.53.99mTc TRODAT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.54.99mTc TRODAT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.55.99mTc TRODAT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission Data 




Table B.56.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.57.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.58.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.59.123I FP-CIT, 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.60.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.61.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.62.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.63.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.64.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.65.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.66.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.67.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.68.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.69.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.70.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.71.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.72.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.73.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.74.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.75.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.76.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.77.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.78.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.79.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.80.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.81.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.82.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.83.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.84.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.85.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.86.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.87.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.88.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.89.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.90.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.91.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.92.123I β-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.93.123I β-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.94.123I β-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.95.123I FP-CIT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.96.123I FP-CIT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.97.123I FP-CIT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.98.123I IBZM 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.99.123I IBZM 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and Camera 




Table B.100.123I IBZM 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.101.99mI TRODAT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.102.99mI TRODAT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.103.99mI TRODAT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.104.99mI TRODAT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.105.99mI TRODAT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.106.99mI TRODAT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.107.99mI TRODAT 1:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.108.99mI TRODAT 2:1 Activity Uptake Ratio, Scatter-Corrected Emission and 




Table B.109.99mI TRODAT 5:1 Activity Uptake Ratio, Scatter-Corrected Emission and 
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